WO2010081692A1 - Oxadiazole derivatives as slpl receptor agonists - Google Patents

Oxadiazole derivatives as slpl receptor agonists Download PDF

Info

Publication number
WO2010081692A1
WO2010081692A1 PCT/EP2010/000158 EP2010000158W WO2010081692A1 WO 2010081692 A1 WO2010081692 A1 WO 2010081692A1 EP 2010000158 W EP2010000158 W EP 2010000158W WO 2010081692 A1 WO2010081692 A1 WO 2010081692A1
Authority
WO
WIPO (PCT)
Prior art keywords
groups
group
tetrahydroisoquinolin
oxadiazol
dimethyl
Prior art date
Application number
PCT/EP2010/000158
Other languages
French (fr)
Inventor
Nuria Aguilar Izquierdo
Marta Carrascal Riera
Julio Cesar Castro Palomino Laria
Montserrat Erra Sola
Original Assignee
Almirall, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BRPI1005153A priority Critical patent/BRPI1005153A2/en
Priority to EP10700383A priority patent/EP2387571A1/en
Priority to MX2011007455A priority patent/MX2011007455A/en
Priority to AU2010205825A priority patent/AU2010205825A1/en
Priority to JP2011545678A priority patent/JP2012515182A/en
Priority to SG2011048329A priority patent/SG172452A1/en
Application filed by Almirall, S.A. filed Critical Almirall, S.A.
Priority to CA2748394A priority patent/CA2748394A1/en
Priority to CN2010800049696A priority patent/CN102282144A/en
Priority to US13/144,377 priority patent/US20110274657A1/en
Priority to EA201101089A priority patent/EA201101089A1/en
Publication of WO2010081692A1 publication Critical patent/WO2010081692A1/en
Priority to IL213630A priority patent/IL213630A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Definitions

  • the present invention relates to new compounds, in particular new tetrahidroisoquinolyl derivatives, to processes for their preparation and to pharmaceutical compositions containing them.
  • These compounds are potent agonists of S1 P1 receptors and thus, they are useful in the treatment, prevention or suppression of diseases and disorders known to be susceptible to improvement by sphingosine-1 -phosphate receptors agonists (S1 P1 ), such as autoimmune diseases, chronic immune and inflammatory diseases, transplant rejection, malignant neoplastic diseases, angiogenic-related disorders, pain, neurological diseases, viral and infectious diseases.
  • S1 P1 sphingosine-1 -phosphate receptors agonists
  • Sphingosine -1 phosphate is a pleiotropic lipid mediator that exhibits a broad spectrum of biological activities, including cell proliferation, survival, lymphocyte trafficking, cytoskeletal organization, and morphogenesis.
  • S1 P is generated from endogenous sphingosine through phosphorylation by specific kinases, named sphingosine kinases 1 and 2.
  • the levels of S1 P in biological fluids and tissues are tightly regulated by the balance between its synthesis by sphingosine kinases and its degradation by S1 P lyase. This tight control is important since an excessive production of S1 P has been associated to various pathological conditions, such as angiogenesis and vascular permeability changes in cancer, inflammation, myocardial infarction or transplant rejection.
  • S1 P1 to S1 P5 G-protein coupled receptor subtypes
  • S1 P1 to S1 P5 G-protein coupled receptor subtypes
  • the interest on this family of receptors increased following the discovery that they were the pharmacological target of FTY720.
  • This compound a synthetic analog of a natural product derived from the fungus lsaria sinclairii, exhibited a peculiar immunomodulatory potential in vivo. When administered in vivo, it caused lymphopenia, due to the sequestration of lymphocytes from the blood into the lymph nodes and Peyer ' s patches.
  • FTY720P phosphorylated FTY720 in vivo
  • FTY720 is currently in phase III trials for the treatment of relapsing-remitting multiple sclerosis. The drug is presumed to act by causing the retention of pathogenic lymphocytes in lymph nodes, thus preventing them to infiltrate the central nervous system (CNS).
  • CNS central nervous system
  • S1 P1 agonists have been recently disclosed for the treatment or prevention of autoimmune diseases, such as multiple sclerosis (WO2008000419, WO2008021532), rheumatoid arthritis or Crohn ' s disease (WO2007091501 ), chronic immune and inflammatory diseases such as asthma, transplant rejection (WO199400943), cancer (WO2003097028), lymphoid malignancies (WO2007143081), angiogenic-related disorders, pain (WO2004110421 , WO2007089715) neurological diseases such as neurodegeneration (WO2005025553) or dementia (WO2005058295), cardiovascular diseases (WO2004010987),.
  • autoimmune diseases such as multiple sclerosis (WO2008000419, WO2008021532), rheumatoid arthritis or Crohn ' s disease (WO2007091501 ), chronic immune and inflammatory diseases such as asthma, transplant rejection (WO199400943), cancer (WO2003097028), lymphoid malignancies (WO2007143081),
  • Autoimmune diseases include but are not limited to rheumatoid arthritis, multiple sclerosis, inflammatory bowel diseases such as Crohn's diseases and ulcerative colitis, psoriatic arthritis, thyroiditis such as Hashimoto's thyroiditis, type I diabetes; systemic lupus erythematosis and Sj ⁇ gm's syndrome.
  • Transplant rejections include but are not limited to rejections of kidney, liver, heart, lung, pancreas, cornea and skin transplants and graft-versus-host disease brought about by stem cell transplantation.
  • Immune and inflammatory diseases which may be prevented or treated include but are not limited to asthma, COPD, respiratory distress syndrome, acute or chronic pancreatitis and hepatitis; chronic sarcoidosis, contact dermatitis, atopic dermatitis, allergic rhinitis, allergic conjunctivitis, Behcet syndrome, inflammatory eye conditions such as conjunctivitis and uveitis.
  • Malignant neoplastic diseases that may be prevented or treated include but are not limited to solid cancer, tumor metastasis and lymphoid malignancies.
  • Angiogenesis-related disorders that may be prevented or treated include but are not limited to hemangiomas, ocular neovascularization, macular degeneration or diabetic retinopathy.
  • Pain, including neuropathic pain, that may be prevented or treated includes but is not limited to prophylaxis or treatment of chronic pain, wherein chronic pain is selected from chronic muscular diseases such as back pain, pain during menstruation, pain during osteoarthritis, pain during rheumatoid arthritis, pain during gastrointestinal inflammation, pain during inflammation of the heart muscle, pain during multiple sclerosis, pain during neuritis, pain during AIDS, pain during chemotherapy, tumor pain, neuropathic pain e. g. after amputation, trigeminal neuralgia, migraine or post herpetic neuralgia.
  • Cardiovascular diseases which may be prevented or treated include but are not limited to chronic heart failure, congestive heart failure, arrhythmia or tachyarrythmia, unstable angina, acute myocardial infarction and complications from cardiac surgery. Cardiovascular diseases may also refer to improving heart energy efficiency or cardiac output.
  • Neurological diseases including neurodegeneration, dementia or brain degeneration that may be prevented or treated include but are not limited to neurological disorders including Parkinson's desease, Parkinsonian disorders, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, spinal ischemia, ischemic stroke, spinal cord injury, cancer-related brain injury, and cancer-related spinal cord injury, Shy-Drager syndrome, progressive supranuclear palsy, Lewy body disease, stroke, cerebral infarction, multi-infarct dementia, and geriatric dementia,
  • neurological disorders including Parkinson's desease, Parkinsonian disorders, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, spinal ischemia, ischemic stroke, spinal cord injury, cancer-related brain injury, and cancer-related spinal cord injury, Shy-Drager syndrome, progressive supranuclear palsy, Lewy body disease, stroke, cerebral infarction, multi-infarct dementia, and geriatric dementia,
  • Viral diseases which may be prevented or treated include but are not limited to HIV infection, hepatitis C and cytomegalovirus infection.
  • Infectious diseases which may be prevented or treated include but are not limited to pathogenic fungal diseases.
  • tetrahidroisoquinolyls derivatives are novel and potent agonists of S1P1 and can therefore be used in the treatment or prevention of these diseases.
  • the present invention is directed to new tetrahidroisoquinolyls derivatives of formula (I) or pharmaceutically acceptable salts or N-oxides thereof
  • A is selected from the group consisting of -N-, -O- and -S-;
  • B and C independently are selected from the group consisting of -N- and -O-, with the proviso that at least two of A 1 B and C are nitrogen atoms;
  • G 1 is selected from the group consisting of nitrogen atoms and -CR C - groups, wherein R c represents a hydrogen atom, a halogen atom, a Ci -4 alkyl group or a Ci -4 alkoxy group;
  • R 1 is selected from the group consisting of hydrogen atoms, Ci -4 alkyl groups, C 1 ⁇ alkoxy groups, C 3-4 cycloalkyl groups, and -NR d R e groups wherein R d and R e are independently selected from hydrogen atoms and C 1-4 alkyl groups;
  • R 2 and R 3 are independently selected from the group consisting of hydrogen atoms and C 1-4 alkyl groups
  • R 4 , R 5 and R 7 are independently selected from the group consisting of hydrogen atoms, halogen atoms, C 1-4 alkyl groups, Ci -4 alkoxy groups and haloalkyl groups;
  • R 6 represents a C 1-4 alkyl group or a C 1-4 hydroxyalkyl group; or R 6 is selected from the group consisting of -S(O) 2 -NR a R b groups, groups, -(CH 2 ) n -NR a R b groups, -O-(CH 2 ) n -NR a R b groups, -(CH 2 J n -COOH groups, -(CH 2 ) n -NR a - CO-R b' groups, -(CH 2 ) n -NR a -(CH 2 ) p -(NH) q -SO-CH 3 groups and -(CH 2 ) n -CO-NR a R b groups, wherein
  • n, p, x and y are each independently integers from 0 to 3; q is 0 or 1 ;
  • R f , R 9 , R h , R', R J and R k independently represent hydrogen atoms or halogen atoms
  • R b is selected from the group consisting of methylsulphonyl groups, C 1-4 alkyl groups, Ci -4 hydroxyalkyl groups, C 1-4 carboxyalkyl groups, and C 1-4 haloalkyl groups;
  • R a and R b are independently selected from the group consisting of hydrogen atoms, methylsulphonyl groups, C 1-4 alkyl groups, C 1 ⁇ hydroxyalkyl groups, C 1-4 carboxyalkyl groups, and C 1-4 haloalkyl groups, or
  • R a and R b or R a and R b together with the nitrogen atom to which they are attached form a 4 to 6 membered, saturated heterocyclic group, which contains, as heteroatoms, one or two nitrogen atoms and which is substituted by a carboxyl group or a C 1-4 carboxyalkyl group; or
  • R c together with R 6 form a C 5-8 carbocyclic ring optionally substituted by -NHR' wherein R' represents a hydrogen atom or a C 1-4 carboxyalkyl group.
  • Further objectives of the present invention are to provide a method for preparing said compounds; pharmaceutical compositions comprising an effective amount of said compounds; the use of the compounds in the manufacture of a medicament for the treatment of pathological conditions or diseases susceptible to improvement by sphingosine-1 -phosphate receptors agonists (S1 P1 ), wherein the pathological condition or disease is selected from autoimmune diseases, chronic immune and inflammatory diseases, transplant rejection, malignant neoplastic diseases, angiogenic- related disorders, pain, neurological diseases.viral and infectious diseases, and methods of treatment of pathological conditions or diseases susceptible to amelioration by sphingosine-1 -phosphate receptors agonists (S1 P1 ), wherein the pathological condition or disease is selected from autoimmune diseases, chronic immune and inflammatory diseases, transplant rejection, malignant neoplastic diseases, angiogenic- related disorders, pain, neurological diseases.viral and infectious diseases comprising the administration of a therapeutically effective amount of the compounds of the invention to a subject in need of such treatment.
  • C 1-4 alkyl embraces optionally substituted, linear or branched hydrocarbon radicals having 1 to 4 carbon atoms.
  • Preferred substituents on the alkyl groups are halogen atoms and hydroxy groups, and are more preferably halogen atoms. Examples include methyl, ethyl, ⁇ -propyl, /-propyl, n-butyl, /-butyl, sec-butyl and te/f-butyl radicals.
  • C 1-4 haloalkyl group is an alkyl group, for example a C 1-4 or C 1- 2 alkyl group, which is attached to 1 , 2 or 3 halogen atoms.
  • said C 1-4 haloakyl group is chosen from -C(-)CI-, -CHCI-, -CCI 2 -, -CHCI 2 , -CCI 3 , -C(-)F-, -CHF-, -CF 2 -, -CHF 2 , -CF 3 and -CH 2 CHF 2 .
  • said C 1 ⁇ haloalkyl group is chosen from -CH 2 CI, -CHCI 2 , -CCI 3 , -CH 2 F, -CHF 2 , -CF 3 and -CH 2 CHF 2 , most preferably - CH 2 CHF 2 .
  • C 1-4 hydroxyalkyl embraces linear or branched alkyl radicals having 1 to 4 carbon atoms, any one of which may be substituted with one or more hydroxyl radicals.
  • examples of such radicals include hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, dihydroxyethyl, 1 ,3-dihydroxypropyl, 2,3-dihydroxypropyl, 1 ,3-dihydroxy isopropyl, 2,3-dihydroxybutyl and 3,4-dihydroxybutyl radicals.
  • C 1-4 alkoxy (or alkyloxy) embraces optionally substituted, linear or branched oxy-containing radicals each having alkyl portions of 1 to 4 carbon atoms. More preferred alkoxy radicals are alkoxy radicals having 1 to 2 carbon atoms.
  • An alkoxy group is typically unsubstituted or substituted with 1 , 2 or 3 substituents which may be the same or different.
  • the substituents are preferably selected from halogen atoms, preferably chlorine or fluorine atoms and hydroxy groups. Typically, the substituents on an alkoxy group are themselves unsubstituted.
  • Preferred alkoxy radicals include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, sec-butoxy, t-butoxy, trifluoromethoxy, difluoromethoxy, hydroxymethoxy, 2-hydroxyethoxy and 2- hydroxypropoxy.
  • carboxyl embraces a -COOH group.
  • C 1-4 carboxyalkyl group embraces optionally substituted, linear or branched carboxyl-containing radicals having 1 to 4 carbon atoms. Preferred substituents on the alkyl group of the carboxyalkyl groups are halogen atoms and hydroxy groups.
  • cycloalkyl embraces saturated carbocyclic radicals and, unless otherwise specified, a cycloalkyl radical typically has from 3 to 6 carbon atoms, preferably from 3 to 4 carbon atoms. Examples include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
  • a cycloalkyl radical When a cycloalkyl radical carries 2 or more substituents, the substituents may be the same or different.
  • Preferred substituents on the cycloalkyl groups are halogen atoms and hydroxy groups, and are more preferably halogen atoms.
  • heterocyclic group embraces typically a non-aromatic, saturated or unsaturated 4 to 6 membered ring system, in which one or more, for example 1 , 2, or 3 of the carbon atoms preferably 1 or 2 of the carbon atoms are replaced by nitrogen. Saturated heterocyclyl radicals are preferred.
  • a heterocyclic radical may be a single ring or two or more fused rings wherein at least one ring contains a heteroatom. When a heterocyclyl radical carries 2 or more substituents, the substituents may be the same or different.
  • a said optionally substituted heterocyclic group is typically unsubstituted or substituted with 1 or 2 substituents which may be the same or different.
  • the substituents are preferably a carboxyl group or a C 1-4 carboxyalkyl group.
  • the substituents on a heterocyclyl group are themselves unsubstituted.
  • the heterocyclic group carries 2 or more substituents, the substituents may be the same or different.
  • heterocyclic radicals include azetidyl, piperidyl, pyrrolidyl, pyrrolinyl, piperazinyl, pyrazolinyl and pyrazolidinyl. Azetidyl and piperazinyl are preferred.
  • atoms, radicals, moieties, chains or cycles present in the general structures of the invention are "optionally substituted".
  • substituents can be either unsubstituted or substituted in any position by one or more, for example 1 , 2, 3 or 4, substituents, whereby the hydrogen atoms bound to the unsubstituted atoms, radicals, moieties, chains or cycles are replaced by chemically acceptable atoms, radicals, moieties, chains or cycles.
  • substituents may be the same or different.
  • halogen atom embraces chlorine, fluorine, bromine or iodine atoms typically a fluorine, chlorine or bromine atom, most preferably chlorine or fluorine.
  • halo when used as a prefix has the same meaning.
  • the term pharmaceutically acceptable salt embraces salts with a pharmaceutically acceptable acid or base.
  • Pharmaceutically acceptable acids include both inorganic acids, for example hydrochloric, sulphuric, phosphoric, diphosphoric, hydrobromic, hydroiodic and nitric acid and organic acids, for example citric, fumaric, maleic, malic, mandelic, ascorbic, oxalic, succinic, tartaric, benzoic, acetic, methanesulphonic, ethanesulphonic, benzenesulphonic or p-toluenesulphonic acid.
  • Pharmaceutically acceptable bases include alkali metal (e.g. sodium or potassium) and alkali earth metal (e.g. calcium or magnesium) hydroxides and organic bases, for example alkyl amines, arylalkyl amines and heterocyclic amines.
  • X- may be an anion of various mineral acids such as, for example, chloride, bromide, iodide, sulphate, nitrate, phosphate, or an anion of an organic acid such as, for example, acetate, maleate, fumarate, citrate, oxalate, succinate, tartrate, malate, mandelate, trifluoroacetate, methanesulphonate and p-toluenesulphonate.
  • mineral acids such as, for example, chloride, bromide, iodide, sulphate, nitrate, phosphate
  • organic acid such as, for example, acetate, maleate, fumarate, citrate, oxalate, succinate, tartrate, malate, mandelate, trifluoroacetate, methanesulphonate and p-toluenesulphonate.
  • X- is preferably an anion selected from chloride, bromide, iodide, sulphate, nitrate, acetate, maleate, oxalate, succinate or trifluoroacetate. More preferably X- is chloride, bromide, trifluoroacetate or methanesulphonate.
  • an N-oxide is formed from the tertiary basic amines or imines present in the molecule, using a convenient oxidising agent.
  • R a and R b together with the nitrogen atom to which they are attached do not form a 4 to 6 membered, saturated heterocyclic group, which contains, as heteroatoms, one or two nitrogen atoms and which is substituted by a carboxyl group or a Ci -4 carboxyalkyl group
  • R a and R b are independently selected from the group consisting of hydrogen atoms, methylsulphonyl groups, Ci -4 alkyl groups, C ⁇ hydroxyalkyl groups, and C 1-4 carboxyalkyl groups
  • R a and R b each independently represents a C 1-4 alkyl group or a Ci -4 haloalkyl group.
  • A is selected from the group consisting of -N- and -O-.
  • A represents -N-.
  • the dotted line in the ring containing A, B and C denotes that the ring may be saturated, unsaturated or aromatic.
  • the ring is aromatic, i.e. is represented by the formula
  • R a and R b are not simultaneously methylsulphonyl groups.
  • R a is hydrogen and R b is selected from the group consisting of hydrogen atoms, methylsulphonyl groups, C 1-4 alkyl groups, C 1-4 hydroxyalkyl groups, C 1-4 carboxyalkyl groups, and C 1 ⁇ haloalkyl groups, or R a and R b together with the nitrogen atom to which they are attached form a 4 to 6 membered, saturated heterocyclic group, which contains, as heteroatoms, one or two nitrogen atoms and which is substitute
  • R a is hydrogen and R b is selected from the group consisting of hydrogen atoms, methylsulphonyl groups, C 1-4 alkyl groups, C 1-4 carboxyalkyl groups, and C 1-4 haloalkyl groups, or R a and R b together with the nitrogen atom to which they are attached form a 4 to 6 membered, saturated heterocyclic group, which contains, as heteroatoms, one or two nitrogen atoms and which is substituted by a carboxyl group
  • R a is hydrogen and R b is selected from the group consisting of hydrogen atoms, methylsulphonyl groups, C 1-2 carboxyalkyl groups, and C 1-2 haloalkyl groups, or R a and R b together with the nitrogen atom to which they are attached form an azetidine or piperazine group which groups are substituted by a carboxyl group or a C ⁇ 2 carboxyalkyl group.
  • G 1 represents a -CR C - group, wherein R c represents a hydrogen atom, chlorine atom, fluorine atom or a C 1 ⁇ alkyl group.
  • G 1 represents a -CR C - group, wherein R c represents a hydrogen atom or a methyl group.
  • R 1 represents a hydrogen atom, a C 1-4 alkyl group or a C 3-4 cycloalkyl group.
  • R 1 is selected from the group consisting of hydrogen atoms, ethyl groups and C 3-4 cycloalkyl groups.
  • R 2 represents a hydrogen atom or a C 1-4 alkyl group, preferably R 2 represents a hydrogen atom or a methyl group. More typically R 2 represents a C 1-4 alkyl group.
  • R 3 represents a hydrogen atom or a C 1-4 alkyl group, preferably R 3 represents a hydrogen atom or a methyl group. More typically R 3 represents a C 1-4 alkyl group.
  • R 4 represents a hydrogen atom, a C 1-4 alkyl group or a -CF 3 group, preferably a hydrogen atom or a methyl group, more preferably a hydrogen atom.
  • R 5 represents a hydrogen atom, a C 1-4 alkyl group or a -CF 3 group, preferably a hydrogen atom or a C 1-4 alkyl group, more preferably a hydrogen atom or a methyl group, being the most preferred a methyl group.
  • R 7 represents a hydrogen atom, a C 1-4 alkyl group or a -CF 3 group, preferably a hydrogen atom or a methyl group, more preferably a hydrogen atom.
  • R 4 , R 5 and R 7 is a hydrogen atom. More typically, 1 or 2 of R 4 , R 5 and R 7 are hydrogen atoms. Preferably, two of R 4 , R 5 and R 7 are hydrogen atoms. More preferably, two of R 4 , R 5 and R 7 are hydrogen atoms and the other is methyl. Even more preferably, R 4 , and R 7 are hydrogen atoms and R 5 is methyl.
  • R 6 represents a C 1 ⁇ , alkyl group, or a C 1-4 hydroxyalkyl group; or R 6 is selected from the group consisting of -(CH 2 ) n -NR a R b groups, -(CH 2 XrCOOH groups, -(CH 2 ) n -NR a -(CH 2 ) p -(NH) q -SO-CH 3 groups and -(CH 2 ) n -C0-NR a R b groups, wherein
  • n and p are each independently integers from 0 to 3
  • R a and R b are independently selected from the group consisting of hydrogen atoms, methylsulphonyl groups, C 1-4 carboxyalkyl groups, C 1-4 alkyl groups and C 1 ⁇ haloalkyl groups, or
  • R a and R b together with the nitrogen atom to which they are attached form a 4 to 6 membered, saturated heterocyclic group, which contains, as heteroatoms, one or two nitrogen atoms and which is substituted by a carboxyl group or a C 1-4 carboxyalkyl group.
  • A represents -N-
  • G 1 represents a -CR C - group, wherein R c represents a hydrogen atom or C 1-4 alkyl group;
  • R 2 and R 3 independently represent C 1-4 alkyl groups
  • R 4 , R 5 and R 7 are independently selected from the group consisting of hydrogen atoms and C 1-4 alkyl groups;
  • R 6 represents a C 1-4 alkyl group or a C 1-4 hydroxyalkyl group, or R 6 is selected from the group consisting of -S(O) 2 -NR a R b groups, -(CH 2 ) n -NR a R b groups, -(CH 2 ) n -COOH groups, -(CH 2 ) n -NR a -(CH 2 ) p -(NH) q -SO-CH 3 groups and -(CH 2 ) n -CO-NR a R b groups, wherein
  • n and p are each independently integers from 0 to 3
  • R a and R b independently are selected from the group consisting of hydrogen atoms, methylsulphonyl groups, Ci -4 carboxyalkyl groups, C 1 ⁇ , alkyl groups and Ci -4 haloalkyl groups, or
  • R a and R b together with the nitrogen atom to which they are attached form a 4 to 6 membered, saturated heterocyclic group, which contains, as heteroatoms, one or two nitrogen atoms and which is substituted by a carboxyl group or a C 1-4 carboxyalkyl group; or
  • R c together with R 6 form a C 5-8 carbocyclic ring optionally substituted by -NHR' wherein R' represents a hydrogen atom or a C 1-4 carboxyalkyl group.
  • compounds of the present invention are compounds of formula (I 1 ), or a pharmaceutically acceptable salts or N-oxides thereof,
  • G 1 is selected from the group consisting of nitrogen atoms and -CR C - groups, wherein R c represents a hydrogen atom, a chlorine atom, or a Ci -2 alkyl group;
  • R 1 is selected from the group consisting of hydrogen atoms, Ci -2 alkyl groups, cyclopropyl groups, -NH 2 groups, -NHMe, and -NMe 2 groups;
  • R 4 , R 5 and R 7 are independently selected from the group consisting of hydrogen atoms, chlorine atoms, C 1-2 alkyl groups;
  • R 6 represents a Ci. 2 alkyl group or a C 1-4 hydroxyalkyl group; or R 6 is selected from the group consisting of -S(O) 2 -NHR 6 groups, -(CH 2 ) n -NHR b groups, -(CH 2 ) n -COOH groups, -(CH 2 ) n -CO-NHR b groups, and -O-(CH 2 ) n -NHR b groups wherein n is 2 or 3,
  • R b is selected from the group consisting of hydrogen atoms, methylsulphonyl groups, C 1-2 carboxyalkyl groups, and C 1-2 haloalkyl groups, or
  • R a and R b together with the nitrogen atom to which they are attached form an azetidine or piperazine group which groups are substituted by a carboxyl group or a C 1-2 carboxyalkyl group; or
  • R c together with R 6 form a C6 carbocyclic ring substituted by -NHR' wherein R' represents a hydrogen atom or a C 1-2 carboxyalkyl group.
  • compounds of the present invention are compounds of formula (I 1 ), or pharmaceutically acceptable salts or N-oxides thereof,
  • G 1 is selected from the group consisting of nitrogen atoms and -CR C - groups, wherein R c represents a hydrogen atom, a chlorine atom, or a C 1-2 alkyl group;
  • R 1 is selected from the group consisting of hydrogen atoms, C 1-2 alkyl groups, cyclopropyl groups, and -NH 2 groups;
  • R 4 , R 5 and R 7 are independently selected from the group consisting of hydrogen atoms, chlorine atoms, Ci -2 alkyl groups;
  • R 6 represents a C 1-2 alkyl group or a C 1-4 hydroxyalkyl group; or R 6 is selected from the group consisting of -S(O) 2 -NHR" groups, -(CH 2 ) n -NHR b groups, -(CH 2 ) n -COOH groups, and -(CH 2 ) n -CO-NHR b groups, wherein n is 2 or 3,
  • R b is selected from the group consisting of hydrogen atoms, methylsulphonyl groups, C 1-2 carboxyalkyl groups, and C 1-2 haloalkyl groups, or
  • R a and R b together with the nitrogen atom to which they are attached form an azetidine or piperazine group which groups are substituted by a carboxyl group or a C 1-2 carboxyalkyl group; or
  • R c together with R 6 form a C6 carbocyclic ring substituted by -NHR' wherein R' represents a hydrogen atom or a C 1-2 carboxyalkyl group.
  • R 6 represents a C 1-4 alkyl group, or a C 1-4 hydroxyalkyl group, or
  • R 6 is selected from the group consisting of -S(O) 2 -NR a R b groups, -(CH 2 ) n -NR a R b groups, -(CH 2 XrCOOH groups, and -(CH 2 ) n -C0-NR a R b groups, wherein,
  • n is an integer from 0 to 3
  • R a and R b are independently selected from the group consisting of hydrogen atoms, methylsulphonyl groups and C 1-4 carboxyalkyl groups, C 1-4 alkyl groups and C 1-4 haloalkyl groups, or
  • R a and R b together with the nitrogen atom to which they are attached form a 4 to 6 membered, saturated heterocyclic group, which contains, as heteroatoms, one or two nitrogen atoms and which is substituted by a carboxyl group or a C 1 ⁇ , carboxyalkyl group; or
  • R c together with R 6 form a C 5-8 carbocyclic ring optionally substituted by -NHR' wherein R' represents a hydrogen atom or a C 1-4 carboxyalkyl group.
  • both A and B represent -N- and C represents -O-, G 1 represents a -CR C - group wherein R c represents a C 1-4 alkyl group,
  • R 1 represents a -NR d R e group, wherein R d and R e are independently selected from hydrogen atom and C 1-4 alkyl group, Both R 2 and R 3 represent a methyl group, Both R 4 and R 7 represent a hydrogen atom, R 5 represents a C 1-4 alkyl group, and
  • R 6 represents a C 1-4 hydroxyalkyl group, -O-(CH 2 ) n -NR a R b or -(CH 2 ) n -NR a R b , wherein R a and R b independently represent a hydrogen atom or a C 1-4 alkyl group.
  • Particular individual compounds of the invention include:
  • compounds of general formula (I) may be prepared by reacting a compound of general formula (II) wherein X can be OH or Cl, with a compound of structure (III) in a one pot reaction in solvent such as DMF, THF, etc., optionally in the presence of one or more coupling agents such as 2-(1 H-benzotriazole-1-yl)-1 ,2,3,3-tetramethyluronium tetrafluoroborate (TBTU), N-(3-dimethylaminopropyl)-N'-ethyl-carbodiimide (EDC), dicyclohexyl carbodiimide (DCC), 1-hydroxybenzotriazole (HOBt), O-(benzotriazol-1- yl)-N,N,N',N'-tetramethyluroniium hexafluorophosphate (HBTU), carbonyl diimidazole (CDI), etc.
  • solvent such as DMF, THF, etc.
  • An alternative method could be following a two steps synthesis by a first coupling as described before and a subsequent cyclization in a solvent such as xylene, toluene, benzene, pyridine, DMF, dichloromethane, acetic acid, trifluoroacetic acid, etc. at rt or elevated temperatures optionally in the presence of auxiliaries such as acid (e.g.
  • trifluoroacetic acid acetic acid, hydrochloric acid, etc.
  • bases e.g., sodium hydride, sodium acetate, sodium carbonate, potassium carbonate, triethylamine, etc.
  • tetralkylammonium salts or water removing agents such as oxalyl chloride, a carboxylic acid anhydride, phosphoryl trichloride (POCI 3 ), tetrabutylammonium fluoride (TBAF), molecular sieves, etc.
  • POCI 3 phosphoryl trichloride
  • TBAF tetrabutylammonium fluoride
  • Intermediates of formula (III) and (IV) may be obtained from the corresponding intermediates of formula (Vl) and (VII) wherein Y is CN, COOH, COCI or COOR' by reacting with hydroxylamine or hydrazine or one of its salts in a solvent such as THF, methanol, ethanol, pyridine, etc., optionally in the presence of a base such as sodium bicarbonate, sodium carbonate, potassium carbonate, triethylamine, sodium ethoxide etc. and at a temperature from room temperature to the boiling point of the solvent.
  • a solvent such as THF, methanol, ethanol, pyridine, etc.
  • a base such as sodium bicarbonate, sodium carbonate, potassium carbonate, triethylamine, sodium ethoxide etc.
  • the reaction can be carried out in the presence of a coupling agent such as 2-(1 H-benzotriazole-1-yl)-1 ,2,3,3-tetramethyluronium tetrafluoroborate, N-(3- dimethylaminopropyl)-N'-ethyl-carbodiimide, dicyclohexyl carbodiimide, 1- hydroxybenzotriazole, etc.
  • a coupling agent such as 2-(1 H-benzotriazole-1-yl)-1 ,2,3,3-tetramethyluronium tetrafluoroborate, N-(3- dimethylaminopropyl)-N'-ethyl-carbodiimide, dicyclohexyl carbodiimide, 1- hydroxybenzotriazole, etc.
  • a coupling agent such as 2-(1 H-benzotriazole-1-yl)-1 ,2,3,3-tetramethyluronium tetrafluoroborate
  • the oxadiazole compounds of general formula (Ia) may be prepared by the condensation of the tetrahidroisoquinoline-4-carboxylic acid (Ma) with the corresponding carboximidamide (Ilia) following the synthetic procedures described above.
  • the intermediates of general formula (IX) may be prepared by the reaction of the corresponding commercial ketone (VIII) with diethylcarbonate in a basic media such as sodium hydride and in an aprotic solvent such as THF or DMF and at a temperature between 0 and the boiling point of the solvent.
  • the intermediates of general formula (X) may be prepared by the condensation of the intermediates of formula (IX) with 2-cyanoacetamide in basic media such as KOH or NaOH and in a protic solvent such as methanol or ethanol at a temperature between 2O 0 C and the boiling point of the solvent.
  • the intermediates of general formula (Xl) may be prepared by the reaction of the intermediates of formula (X) with POCI 3 or a mixture of POCI 3 and PCI 5 with or without a solvent such as toluene in a high pressure reactor and at high temperature.
  • the intermediates of general formula (XII) may be obtained by the coupling of the intermediates of formula (Xl) with the corresponding alkyl boronic acid or boronate under the conditions of a Suzuki reaction (Miyaura, N.; Suzuki, A. Chem. Rev. 1995, 95, 2457).
  • This reaction may be catalyzed by a palladium catalyst like [1 ,1'- bis(diphenylphosphino)-ferrocene] dichloropalladium (II) complex with dichloromethane (1 :1 ), tetrakis(triphenylphosphine)-palladium(0), bis(triphenylphosphine)palladium(ll) chloride or tris(dibenzylideneacetone)-dipalladium(0) in an aprotic organic solvent such as dioxane, toluene, DMF or DME and in the presence of a base such as cesium carbonate, sodium carbonate, potassium carbonate or potassium phosphate at a temperature from 8O 0 C to 14O 0 C.
  • a palladium catalyst like [1 ,1'- bis(diphenylphosphino)-ferrocene] dichloropalladium (II) complex with dichloromethane (1 :1 ), t
  • the intermediates of formula (XII) can be obtained by the reaction of the intermediates of formula (Xl) with an excess of the corresponding amine or alcohol with an extra base such as NaH, triethylamine, etc. in a solvent such as MeOH, EtOH or
  • the intermediates of general formula (XVI) may be prepared by the reaction of the corresponding commercial ketone (XIV) with the corresponding acyl chloride of formula (XV) in a basic media such as lithiumdiisopropylamide (LDA) and in an aprotic solvent such as THF and at a temperature between -78 0 C and room temperature.
  • a basic media such as lithiumdiisopropylamide (LDA) and in an aprotic solvent such as THF and at a temperature between -78 0 C and room temperature.
  • the intermediates of general formula (XVII) may be prepared by the condensation of the intermediates of formula (XVI) with 2-cyanoacetamide in basic media such as triethylamine, KOH or NaOH and in a protic solvent such as methanol or ethanol at a temperature between 20 0 C and the boiling point of the solvent.
  • Intermediates of formula (Ilia) may be obtained by the reaction of hydroxylamine or one of its salts with the corresponding nitrile (XIX) in a solvent such as THF, methanol, ethanol, pyridine, etc. optionally in the presence of a base such as sodium bicarbonate, sodium carbonate, potassium carbonate, triethylamine, etc. and at a temperature from 40 to 100 0 C.
  • a solvent such as THF, methanol, ethanol, pyridine, etc.
  • a base such as sodium bicarbonate, sodium carbonate, potassium carbonate, triethylamine, etc.
  • a precursor can be the corresponding bromoaryl derivative of formula (XVIII) which react with a source of cyanide such as copper (I) cyanide, in a high boiling point solvent such as NMP, DMF or DMSO at a temperature between 150-200 0 C to yield the corresponding nitrile of general formula (XIV).
  • a source of cyanide such as copper (I) cyanide
  • a high boiling point solvent such as NMP, DMF or DMSO
  • dicyanozinc can be also used as a source of cyanide, with a Pd catalyst such as tetrakis(triphenylphosphine)-palladium(0) in a high boiling point solvent, in a standard reactor or a microwave reactor.
  • these functionalities may require temporary protection.
  • protecting groups include e.g a tert-butyl or ethyl or methyl to protect an acid, a tert- butyloxycarbonyl (BOC) to protect an amine, etc.
  • BOC tert- butyloxycarbonyl
  • protecting groups may be employed according to standard methodology (e.g. T.W. Greene, P. G. M. Wuts, Protective Groups in Organic Synthesis, 3 rd Edition, Wiley New York, 1991).
  • the compounds of general formula (Ic) wherein R 6 is a -(CH 2 ) n -CO-NR a R b group can be prepared from the corresponding acid of general formula (Ib) by reacting with ammonia, an amine or an aminoacid of general formula HNR a R b in the presence of an activating agent such as N-(3-dimethylaminopropyl)-N'-ethyl-carbodiimide (EDC), dicyclohexyl carbodiimide (DCC), 1-hydroxybenzotriazole (HOBt), (benzotriazol-1- yloxy)-tris-(dimethylamino)-phosphonium hexafluorophosphate (BOP), bis-(2-oxo-3- oxazolidinyl)-phosphonic acid chloride (BOP-CI) 1 etc. in a solvent such as THF, dioxane, DMF, dichloromethane, acetonitrile
  • primary amines of general formula (Ie) can be prepared by Curtius rearrangement of the acids of general formula (Ib) using an azide such as sodium azide, diphenylphosphoryl azide (DPPA), etc, in acidic media such as sulphuric acid or basic media such as triethylamine, in solvent such as toluene, chloroform, THF, etc. or in a protic solvent such as terf-butanol or benzyl alcohol to yield the te/t-butylcarbonyl (BOC) or benzyloxycarbonyl (CBZ or Z) protected amine and subsequent deprotection as known in the art yield the final compounds of formula (Ie).
  • an azide such as sodium azide, diphenylphosphoryl azide (DPPA), etc
  • acidic media such as sulphuric acid or basic media such as triethylamine
  • solvent such as toluene, chloroform, THF, etc.
  • the compounds of general formula (Ig) may be prepared by the reductive amination of the aldehyde derivatives of general formula (XXIV) with the corresponding amine or aminoacid of formula HNR a R b in acidic media such as acetic acid, in a protic solvent such as methanol or ethanol and with a reductive agent such as sodium borohydride or sodium cyanoborohydride at a temperature from O 0 C to the boiling point of the solvent.
  • Intermediates of formula (XXIV) may be obtained by oxidation of diols of general formula (If) with an oxidative reagent such as NaIO 4 , NaCIO 4 , KIO 4 , etc. in a solvent such as methanol, ethanol, THF, dioxane, ether, etc. with the presence or absence of water.
  • an oxidative reagent such as NaIO 4 , NaCIO 4 , KIO 4 , etc. in a solvent such as methanol, ethanol, THF, dioxane, ether, etc. with the presence or absence of water.
  • Compounds of general formula (If) may be prepared by oxidation of the allyl intermediates of general formula (XXIII) using an oxidative reagent such as N-methyl- morpholine-N-oxide, sodium periodate, sodium perchlorate, potassium periodate, etc. in the presence of a catalyst such us sodium tetraoxide solid or a solution in water or tert-butanol, in a solvent such as methanol, ethanol, THF, dioxane, ether, acetone, etc. with the presence or absence of water.
  • an oxidative reagent such as N-methyl- morpholine-N-oxide, sodium periodate, sodium perchlorate, potassium periodate, etc.
  • a catalyst such us sodium tetraoxide solid or a solution in water or tert-butanol, in a solvent such as methanol, ethanol, THF, dioxane, ether, acetone, etc. with the presence or absence of water.
  • Allyl intermediates of general formula (XXIII) may be prepared by the condensation of the corresponding carboximidamide of formula (IHc) with the corresponding acid of general formula (Ma) as described above.
  • a catalyst such as tetrakis(triphenylphosphine)-palladium(0), palladium acetate, bis(triphenylphosphine)palladium(ll) chloride or tris(dibenzylideneacetone)- dipalladium(O)
  • the compounds of formula (Ih) may be obtained by the reaction of compounds of general formula (XXVII) with the corresponding alkylating agent in basic media such as sodium hydride in a solvent such as THF or DMF at a temperature from 0 to 15O 0 C.
  • basic media such as sodium hydride in a solvent such as THF or DMF
  • the phenolic functionality of (XXVII) may be coupled to suitable alcohol derivatives using a Mitsunobu coupling procedure (Mitsunobu, O., Synthesis 1 (1981 )).
  • Preferred coupling conditions include the use of a thalkylphosphine or triarylphosphine, such as tri-n-butylphosphine or triphenylphosphine, in a suitable solvent, such as tetrahydrofuran or dichloromethane, and an azodicarbonyl reagent, such as diethyl azodicarboxylate or 1 ,1'-(azodicarbonyl)dipipehdine.
  • a suitable solvent such as tetrahydrofuran or dichloromethane
  • an azodicarbonyl reagent such as diethyl azodicarboxylate or 1 ,1'-(azodicarbonyl)dipipehdine.
  • the compounds of general formula (XXVII) may be prepared by demethylation of the corresponding compound of general formula (XXVI) using BBr 3 or AIBr 3 or BF 3 or iodotrimethylsilane as demethylating agent in a solvent such as dichloromethane or 1 ,2-dichloroethane, chloroform at a temperature between 0 and the 6O 0 C.
  • a solvent such as dichloromethane or 1 ,2-dichloroethane, chloroform at a temperature between 0 and the 6O 0 C.
  • compounds of general formula (XXVII) may be prepared by demethylation using HBr in acetic acid as a solvent.
  • the mobile phase was formic acid (0.4 ml_), ammonia (0.1 ml_), methanol (500 tnL) and acetonitrile (500 ml.) (B) and formic acid (0.46 ml_), ammonia (0.115 ml.) and water (1000 ml.) (A), the gradients are specified in the following table for each methode used.
  • the reequilibration time between two injections was 1 min.
  • the flow rate was 0.8 mL ⁇ nin for method A and 0.4 mL/min for method B and C.
  • the injection volume was 5 microliter for method A and B and 3 microliter for method C. Diode array chromatograms were collected at 210 nM.
  • the solid was dissolved in DMSO/MeOH, injected into a Biotage C18 silica column (4OM, 25M or 25S according to the crude amount) and eluted on the SP1® automated purification system from Biotage.
  • the gradient used was H2O/Acetonitrile/MeOH (1 :1 ) (0.1% v/v HCOONH4 both phases) from 0% to 100% acetonitrile/MeOH (1 :1 ) in 80 column volumes.
  • the appropriate fractions were collected and the organic solvent evaporated under reduced pressure or liofilized.
  • Preparation 20 (1.1g, 4.43mmol) was dissolved in methanol (35ml_) and sodium acetate (0.55g, 6.70mmol) was added. Finally palladium chloride (0.16g, 0.90mmol) was added and the mixture hydrogenated at 15 psi for 5h. The catalyst was filtered off and the filtrate concentrated. The residue was redissolved in DCM and washed with water. The organic layer was dried over magnesium sulphate and concentrated to yield an oil (82% yield) as the desired compound.
  • Example 9 A mixture of Example 9 (100mg, 0.25mmol), tert-butyl 2-aminoacetate hydrochloride (62mg, 0.37mmol), HATU (94mg, 0.25mmol) and DIEA (130 ⁇ l, 0.75mmol) in DMF (3mL) was stirred overnight at r.t. The mixture was poured over ice/water and stirred for 15min. The solid formed was filtered off, washed with water and dried in the vacuum oven and used without further purification.
  • 6-bromo-1 ,2,3,4-tetrahydronaphthalen-2-amine To a solution of the 6-bromo 2-tetralone (2g, 8.89mmol) and NH 4 OAc (5.52g,
  • Example 18 A mixture of Example 18 (172mg, 0.46mmol), ethyl 2-oxoacetate (146Dl, 0.74mmol) and AcOH (239 ⁇ l, 4.18mmol) in methanol (5ml_) was stirred at room temperature for 1 h. Then NaBH 3 CN (20mg, 0.32mmol) was added and the reaction mixture stirred at r.t. overnight. Solvent was concentrated and the residue dissolved in ethyl acetate, washed with water and brine, dried over magnesium sulphate, filtered and concentrated. The crude obtained was purified according the General purification method to give the desired compound (50% yield).
  • Example 21 To a solution of Example 21 (75mg, 0.19mmol) in DCM (1OmL) was added triethylamine (94 ⁇ L 3.51 mmol) and the mixture stirred for 5 min. Then methanesulfonyl chloride (17 ⁇ L, 0.22mol) was added and the reaction mixture stirred at room temperature for 6h. Ethyl acetate was added and washed twice with water and once with brine. This organic layer was dried over magnesium sulphate and concentrated to give a white solid which was washed with diisopropyl ether and dried in the vacuum oven (66% yield).
  • the effect of the compounds was measured using a 35S-GTPyS binding assay. Briefly, membranes were incubated in a buffer containing 2OmM HEPES pH 7.4, 10OmM NaCI, 1OmM MgCI2, 10 ⁇ M GDP, 50 ⁇ g/mL saponin and 0.2% fatty acid-free BSA at various concentrations (0.1 nM-10 ⁇ M) and 0.1 nM 35S-GTPyS. 10 ⁇ M S1 P was used as 100% maximum efficacy. The assay was incubated for 90 min at room temperature with gentle mixing, and terminated by filtrating the reaction mixture through GF/C filter plates using the Manifold Filtration System. The filters were immediately washed with sodium phosphate pH 7.4 buffer. After drying the filter plates scintillant liquid were added to each well and 35S-GTPyS binding was measured on a Trilux Scintillation Counter.
  • the tetrahidroisoquinolyl derivatives of the invention may also be combined with other active compounds in the treatment of diseases known to be susceptible to improvement by treatment with a sphingosine-1 -phosphate receptor agonist (S1 P1 ).
  • S1 P1 sphingosine-1 -phosphate receptor agonist
  • the combinations of the invention can optionally comprise one or more additional active substances which are known to be useful in the treatment of autoimmune diseases, chronic immune and inflammatory diseases, transplant rejection, malignant neoplastic diseases, angiogenic-related disorders, pain, neurological diseases.
  • viral and infectious diseases such as (a) beta interferons such as Betaseron, Avonex or Rebif, (b), immunomodulators such as glatiramer acetate, (c) inhibitors of DNA synthesis and repair, such as Mitoxantrone, (d) anti-alpha 4 integrin antibodies, such as Natalizumab (Tysabri), (e) alpha 4 integrin antagonists such as R-1295 , TBC-4746, CDP-323, ELND-002, Firategrast and TMC-2003, (f), dyhydrofolate reductase inhibitors, such as Methotrexate or CH-1504, (g) glucocorticoids such as prednisone or methylpredn
  • the combinations of the invention may be used in the treatment of disorders which are susceptible to amelioration by sphingosine-1 -phosphate receptors agonists (S1 P1 ).
  • S1 P1 sphingosine-1 -phosphate receptors agonists
  • Preferred examples of such disorders are multiple sclerosis, transplant rejection, systemic lupus erythematosus, asthma, psoriasis, rheumatoid arthritis, psoriatic arthritis and Crohn's disease, more preferably multiple sclerosis, transplant rejection, asthma and rheumatoid arthritis, and most preferably multiple sclerosis.
  • the active compounds in the combinations of the invention may be administered by any suitable route, depending on the nature of the disorder to be treated, e.g. orally (as syrups, tablets, capsules, lozenges, controlled-release preparations, fast-dissolving preparations, etc); topically (as creams, ointments, lotions, nasal sprays or aerosols, etc); by injection (subcutaneous, intradermic, intramuscular, intravenous, etc.) or by inhalation (as a dry powder, a solution, a dispersion, etc).
  • suitable route e.g. orally (as syrups, tablets, capsules, lozenges, controlled-release preparations, fast-dissolving preparations, etc); topically (as creams, ointments, lotions, nasal sprays or aerosols, etc); by injection (subcutaneous, intradermic, intramuscular, intravenous, etc.) or by inhalation (as a dry powder, a solution, a dispersion,
  • the active compounds in the combination i.e. the sphingosine-1 -phosphate agonist of the invention, and the other optional active compounds may be administered together in the same pharmaceutical composition or in different compositions intended for separate, simultaneous, concomitant or sequential administration by the same or a different route.
  • One execution of the present invention consists of a kit of parts comprising a sphingosine-1 -phosphate agonist of the invention together with instructions for simultaneous, concurrent, separate or sequential use in combination with another active compound useful in the treatment of multiple sclerosis, transplant rejection, systemic lupus erythematosus, asthma, psoriasis, rheumatoid arthritis, psoriatic arthritis and Crohn's disease,
  • Another execution of the present invention consists of a package comprising a sphingosine-1 -phosphate agonist of formula (I) and another active compound useful in the treatment of multiple sclerosis, transplant rejection, systemic lupus erythematosus, asthma, psoriasis, rheumatoid arthritis, psoriatic arthritis and Crohn's disease,
  • compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy.
  • Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil- in-water liquid emulsion or a water-in-oil liquid emulsion.
  • the active ingredient may also be presented as a bolus, electuary or paste.
  • a syrup formulation will generally consist of a suspension or solution of the compound or salt in a liquid carrier for example, ethanol, peanut oil, olive oil, glycerine or water with flavouring or colouring agent.
  • a liquid carrier for example, ethanol, peanut oil, olive oil, glycerine or water with flavouring or colouring agent.
  • composition is in the form of a tablet
  • any pharmaceutical carrier routinely used for preparing solid formulations may be used.
  • examples of such carriers include magnesium stearate, talc, gelatine, acacia, stearic acid, starch, lactose and sucrose.
  • a tablet may be made by compression or moulding, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, lubricating, surface active or dispersing agent.
  • Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
  • the tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein.
  • composition is in the form of a capsule
  • any routine encapsulation is suitable, for example using the aforementioned carriers in a hard gelatine capsule.
  • composition is in the form of a soft gelatine capsule
  • any pharmaceutical carrier routinely used for preparing dispersions or suspensions may be considered, for example aqueous gums, celluloses, silicates or oils, and are incorporated in a soft gelatine capsule.
  • Dry powder compositions for topical delivery to the lung by inhalation may, for example, be presented in capsules and cartridges of for example gelatine or blisters of for example laminated aluminium foil, for use in an inhaler or insufflator.
  • Formulations generally contain a powder mix for inhalation of the compound of the invention and a suitable powder base (carrier substance) such as lactose or starch. Use of lactose is preferred.
  • a suitable powder base such as lactose or starch.
  • lactose is preferred.
  • Each capsule or cartridge may generally contain between 2 ⁇ g and 150 ⁇ g of each therapeutically active ingredient.
  • the active ingredient (s) may be presented without excipients.
  • Packaging of the formulation for inhalation may be carried out by using suitable inhaler devices such as the NOVOLIZER ® SD2FL or GENUAIR ® which are described in the following patent applications: WO 97/000703, WO 03/000325 and WO 03/061742.
  • suitable inhaler devices such as the NOVOLIZER ® SD2FL or GENUAIR ® which are described in the following patent applications: WO 97/000703, WO 03/000325 and WO 03/061742.
  • compositions for nasal delivery include those mentioned above for inhalation and further include non-pressurized compositions in the form of a solution or suspension in an inert vehicle such as water optionally in combination with conventional excipients such as buffers, anti-microbials, tonicity modifying agents and viscosity modifying agents which may be administered by nasal pump.
  • an inert vehicle such as water
  • excipients such as buffers, anti-microbials, tonicity modifying agents and viscosity modifying agents which may be administered by nasal pump.
  • Typical dermal and transdermal formulations comprise a conventional aqueous or nonaqueous vehicle, for example a cream, ointment, lotion or paste or are in the form of a medicated plaster, patch or membrane.
  • the composition is in unit dosage form, for example a tablet, capsule or metered aerosol dose, so that the patient may administer a single dose.
  • the amount of each active which is required to achieve a therapeutic effect will, of course, vary with the particular active, the route of administration, the subject under treatment, and the particular disorder or disease being treated.
  • Effective doses are normally in the range of 2-2000 mg of active ingredient per day.
  • Daily dosage may be administered in one or more treatments, preferably from 1 to 4 treatments, per day.
  • the active ingredients are administered once or twice a day.
  • active agents When combinations of actives are used, it is contemplated that all active agents would be administered at the same time, or very close in time. Alternatively, one or two actives could be taken in the morning and the other (s) later in the day. Or in another scenario, one or two actives could be taken twice daily and the other (s) once daily, either at the same time as one of the twice-a-day dosing occurred, or separately. Preferably at least two, and more preferably all, of the actives would be taken together at the same time. Preferably, at least two, and more preferably all actives would be administered as an admixture.
  • the above ingredients were sieved through a 60 mesh sieve, and were loaded into a suitable mixer and filled into 50,000 gelatine capsules.
  • COMPOSITION EXAMPLE 2 50,000 tablets, each containing 50 mg of 3-(4-(5-(1-ethyl-7,7-dimethyl-5,6,7,8- tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3-yl)-2,6-dimethylphenyl)propanamide (active ingredient), were prepared from the following formulation:
  • All the powders were passed through a screen with an aperture of 0.6 mm, then mixed in a suitable mixer for 20 minutes and compressed into 300 mg tablets using 9 mm disc and flat bevelled punches.
  • the disintegration time of the tablets was about 3 minutes.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

New compounds having the chemical structure of formula (I) or pharmaceutically acceptable salts or N-oxides thereof wherein A is selected from the group consisting of -N-, -O- and -S-; B and C independently are selected from the group consisting of -N- and -O-, with the proviso that at least two of A, B and C are nitrogen atoms; G1 is selected from the group consisting of nitrogen atoms and -CRc- groups, wherein Rc represents a hydrogen atom, a halogen atom, a C1-4 alkyl group or a C1-4 alkoxy group.

Description

OXADIAZOLE DERIVATIVES AS SlPl RECEPTOR AGONISTS
The present invention relates to new compounds, in particular new tetrahidroisoquinolyl derivatives, to processes for their preparation and to pharmaceutical compositions containing them. These compounds are potent agonists of S1 P1 receptors and thus, they are useful in the treatment, prevention or suppression of diseases and disorders known to be susceptible to improvement by sphingosine-1 -phosphate receptors agonists (S1 P1 ), such as autoimmune diseases, chronic immune and inflammatory diseases, transplant rejection, malignant neoplastic diseases, angiogenic-related disorders, pain, neurological diseases, viral and infectious diseases.
Sphingosine -1 phosphate (S1 P) is a pleiotropic lipid mediator that exhibits a broad spectrum of biological activities, including cell proliferation, survival, lymphocyte trafficking, cytoskeletal organization, and morphogenesis. S1 P is generated from endogenous sphingosine through phosphorylation by specific kinases, named sphingosine kinases 1 and 2. The levels of S1 P in biological fluids and tissues are tightly regulated by the balance between its synthesis by sphingosine kinases and its degradation by S1 P lyase. This tight control is important since an excessive production of S1 P has been associated to various pathological conditions, such as angiogenesis and vascular permeability changes in cancer, inflammation, myocardial infarction or transplant rejection.
Gene deletion studies and reverse pharmacology have provided evidence that most of the effects of S1 P are mediated via five G-protein coupled receptor subtypes, named S1 P1 to S1 P5 (Brinkmann, Pharmacology & therapeutics 115:84-105, 2007). The interest on this family of receptors increased following the discovery that they were the pharmacological target of FTY720. This compound, a synthetic analog of a natural product derived from the fungus lsaria sinclairii, exhibited a peculiar immunomodulatory potential in vivo. When administered in vivo, it caused lymphopenia, due to the sequestration of lymphocytes from the blood into the lymph nodes and Peyer's patches. The close structural similarity of FTY720 to sphingosine, together with the discovery of the formation of phosphorylated FTY720 in vivo (FTY720P) prompted to speculate that FTY720-P could be acting as a mimetic of S1 P. This proven to be the case and it was later on demonstrated that FTY-P binds 4 of the five known S1 P receptors, namely S1 P1 , S1 P3, S1 P4 and S1 P5. Expression analysis identified S1 P1 as the dominant S1 P receptor expressed on lymphocytes. Moreover, the transfer of S1 P1 -deficient T cells to normal mice led to the cells being sequestered in lymph nodes, as occurred with animals treated with fingolimod. These two facts strongly pointed out at S1 P1 as the main receptor involved in the lymphopenic effect of FTY-P in vivo (Baumruker et al, Exp. Opin. Invest. Drugs 2007; 16(3): 283-289). FTY720 is currently in phase III trials for the treatment of relapsing-remitting multiple sclerosis. The drug is presumed to act by causing the retention of pathogenic lymphocytes in lymph nodes, thus preventing them to infiltrate the central nervous system (CNS).
In view of the physiological effects, several S1 P1 agonists have been recently disclosed for the treatment or prevention of autoimmune diseases, such as multiple sclerosis (WO2008000419, WO2008021532), rheumatoid arthritis or Crohn's disease (WO2007091501 ), chronic immune and inflammatory diseases such as asthma, transplant rejection (WO199400943), cancer (WO2003097028), lymphoid malignancies (WO2007143081), angiogenic-related disorders, pain (WO2004110421 , WO2007089715) neurological diseases such as neurodegeneration (WO2005025553) or dementia (WO2005058295), cardiovascular diseases (WO2004010987),.
Autoimmune diseases include but are not limited to rheumatoid arthritis, multiple sclerosis, inflammatory bowel diseases such as Crohn's diseases and ulcerative colitis, psoriatic arthritis, thyroiditis such as Hashimoto's thyroiditis, type I diabetes; systemic lupus erythematosis and Sjόgm's syndrome.
Transplant rejections include but are not limited to rejections of kidney, liver, heart, lung, pancreas, cornea and skin transplants and graft-versus-host disease brought about by stem cell transplantation.
Immune and inflammatory diseases which may be prevented or treated include but are not limited to asthma, COPD, respiratory distress syndrome, acute or chronic pancreatitis and hepatitis; chronic sarcoidosis, contact dermatitis, atopic dermatitis, allergic rhinitis, allergic conjunctivitis, Behcet syndrome, inflammatory eye conditions such as conjunctivitis and uveitis.
Malignant neoplastic diseases that may be prevented or treated include but are not limited to solid cancer, tumor metastasis and lymphoid malignancies. Angiogenesis-related disorders that may be prevented or treated include but are not limited to hemangiomas, ocular neovascularization, macular degeneration or diabetic retinopathy.
Pain, including neuropathic pain, that may be prevented or treated includes but is not limited to prophylaxis or treatment of chronic pain, wherein chronic pain is selected from chronic muscular diseases such as back pain, pain during menstruation, pain during osteoarthritis, pain during rheumatoid arthritis, pain during gastrointestinal inflammation, pain during inflammation of the heart muscle, pain during multiple sclerosis, pain during neuritis, pain during AIDS, pain during chemotherapy, tumor pain, neuropathic pain e. g. after amputation, trigeminal neuralgia, migraine or post herpetic neuralgia.
Cardiovascular diseases which may be prevented or treated include but are not limited to chronic heart failure, congestive heart failure, arrhythmia or tachyarrythmia, unstable angina, acute myocardial infarction and complications from cardiac surgery. Cardiovascular diseases may also refer to improving heart energy efficiency or cardiac output.
Neurological diseases including neurodegeneration, dementia or brain degeneration that may be prevented or treated include but are not limited to neurological disorders including Parkinson's desease, Parkinsonian disorders, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, spinal ischemia, ischemic stroke, spinal cord injury, cancer-related brain injury, and cancer-related spinal cord injury, Shy-Drager syndrome, progressive supranuclear palsy, Lewy body disease, stroke, cerebral infarction, multi-infarct dementia, and geriatric dementia,
Viral diseases which may be prevented or treated include but are not limited to HIV infection, hepatitis C and cytomegalovirus infection.
Infectious diseases which may be prevented or treated include but are not limited to pathogenic fungal diseases.
It has now been found that certain tetrahidroisoquinolyls derivatives are novel and potent agonists of S1P1 and can therefore be used in the treatment or prevention of these diseases. Thus the present invention is directed to new tetrahidroisoquinolyls derivatives of formula (I) or pharmaceutically acceptable salts or N-oxides thereof
Figure imgf000005_0001
Formula (I) wherein
A is selected from the group consisting of -N-, -O- and -S-;
B and C independently are selected from the group consisting of -N- and -O-, with the proviso that at least two of A1 B and C are nitrogen atoms;
G1 is selected from the group consisting of nitrogen atoms and -CRC- groups, wherein Rc represents a hydrogen atom, a halogen atom, a Ci-4 alkyl group or a Ci-4 alkoxy group;
R1 is selected from the group consisting of hydrogen atoms, Ci-4 alkyl groups, C1^ alkoxy groups, C3-4 cycloalkyl groups, and -NRdRe groups wherein Rd and Re are independently selected from hydrogen atoms and C1-4 alkyl groups;
R2 and R3 are independently selected from the group consisting of hydrogen atoms and C1-4 alkyl groups;
R4, R5 and R7 are independently selected from the group consisting of hydrogen atoms, halogen atoms, C1-4 alkyl groups, Ci-4 alkoxy groups and
Figure imgf000005_0002
haloalkyl groups;
R6 represents a C1-4 alkyl group or a C1-4 hydroxyalkyl group; or R6 is selected from the group consisting of -S(O)2-NRaRb groups,
Figure imgf000005_0003
groups, -(CH2)n-NRaRb groups, -O-(CH2)n-NRaRb groups, -(CH2Jn-COOH groups, -(CH2)n-NRa- CO-Rb' groups, -(CH2)n-NRa-(CH2)p-(NH)q-SO-CH3 groups and -(CH2)n-CO-NRaRb groups, wherein
n, p, x and y are each independently integers from 0 to 3; q is 0 or 1 ;
Rf, R9, Rh, R', RJ and Rk independently represent hydrogen atoms or halogen atoms;
Rb is selected from the group consisting of methylsulphonyl groups, C1-4 alkyl groups, Ci-4 hydroxyalkyl groups, C1-4 carboxyalkyl groups, and C1-4 haloalkyl groups;
Ra and Rb are independently selected from the group consisting of hydrogen atoms, methylsulphonyl groups, C1-4 alkyl groups, C1^ hydroxyalkyl groups, C1-4 carboxyalkyl groups, and C1-4 haloalkyl groups, or
Ra and Rb or Ra and Rb together with the nitrogen atom to which they are attached form a 4 to 6 membered, saturated heterocyclic group, which contains, as heteroatoms, one or two nitrogen atoms and which is substituted by a carboxyl group or a C1-4 carboxyalkyl group; or
Rc together with R6 form a C5-8 carbocyclic ring optionally substituted by -NHR' wherein R' represents a hydrogen atom or a C1-4 carboxyalkyl group.
Further objectives of the present invention are to provide a method for preparing said compounds; pharmaceutical compositions comprising an effective amount of said compounds; the use of the compounds in the manufacture of a medicament for the treatment of pathological conditions or diseases susceptible to improvement by sphingosine-1 -phosphate receptors agonists (S1 P1 ), wherein the pathological condition or disease is selected from autoimmune diseases, chronic immune and inflammatory diseases, transplant rejection, malignant neoplastic diseases, angiogenic- related disorders, pain, neurological diseases.viral and infectious diseases, and methods of treatment of pathological conditions or diseases susceptible to amelioration by sphingosine-1 -phosphate receptors agonists (S1 P1 ), wherein the pathological condition or disease is selected from autoimmune diseases, chronic immune and inflammatory diseases, transplant rejection, malignant neoplastic diseases, angiogenic- related disorders, pain, neurological diseases.viral and infectious diseases comprising the administration of a therapeutically effective amount of the compounds of the invention to a subject in need of such treatment. As used herein the term C1-4 alkyl embraces optionally substituted, linear or branched hydrocarbon radicals having 1 to 4 carbon atoms. Preferred substituents on the alkyl groups are halogen atoms and hydroxy groups, and are more preferably halogen atoms. Examples include methyl, ethyl, π-propyl, /-propyl, n-butyl, /-butyl, sec-butyl and te/f-butyl radicals.
As used herein, the term C1-4 haloalkyl group is an alkyl group, for example a C1-4 or C1- 2 alkyl group, which is attached to 1 , 2 or 3 halogen atoms. Preferably, said C1-4 haloakyl group is chosen from -C(-)CI-, -CHCI-, -CCI2-, -CHCI2, -CCI3, -C(-)F-, -CHF-, -CF2-, -CHF2, -CF3 and -CH2CHF2. More preferably, said C1^ haloalkyl group is chosen from -CH2CI, -CHCI2, -CCI3, -CH2F, -CHF2, -CF3 and -CH2CHF2, most preferably - CH2CHF2.
As used herein, the term C1-4 hydroxyalkyl embraces linear or branched alkyl radicals having 1 to 4 carbon atoms, any one of which may be substituted with one or more hydroxyl radicals. Examples of such radicals include hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, dihydroxyethyl, 1 ,3-dihydroxypropyl, 2,3-dihydroxypropyl, 1 ,3-dihydroxy isopropyl, 2,3-dihydroxybutyl and 3,4-dihydroxybutyl radicals.
As used herein, the term C1-4 alkoxy (or alkyloxy) embraces optionally substituted, linear or branched oxy-containing radicals each having alkyl portions of 1 to 4 carbon atoms. More preferred alkoxy radicals are alkoxy radicals having 1 to 2 carbon atoms. An alkoxy group is typically unsubstituted or substituted with 1 , 2 or 3 substituents which may be the same or different. The substituents are preferably selected from halogen atoms, preferably chlorine or fluorine atoms and hydroxy groups. Typically, the substituents on an alkoxy group are themselves unsubstituted. Preferred alkoxy radicals include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, sec-butoxy, t-butoxy, trifluoromethoxy, difluoromethoxy, hydroxymethoxy, 2-hydroxyethoxy and 2- hydroxypropoxy.
As used herein, the term carboxyl embraces a -COOH group.
As used herein, the term C1-4carboxyalkyl group embraces optionally substituted, linear or branched carboxyl-containing radicals having 1 to 4 carbon atoms. Preferred substituents on the alkyl group of the carboxyalkyl groups are halogen atoms and hydroxy groups. As used herein, the term cycloalkyl embraces saturated carbocyclic radicals and, unless otherwise specified, a cycloalkyl radical typically has from 3 to 6 carbon atoms, preferably from 3 to 4 carbon atoms. Examples include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. When a cycloalkyl radical carries 2 or more substituents, the substituents may be the same or different. Preferred substituents on the cycloalkyl groups are halogen atoms and hydroxy groups, and are more preferably halogen atoms.
As used herein, the term heterocyclic group embraces typically a non-aromatic, saturated or unsaturated 4 to 6 membered ring system, in which one or more, for example 1 , 2, or 3 of the carbon atoms preferably 1 or 2 of the carbon atoms are replaced by nitrogen. Saturated heterocyclyl radicals are preferred. A heterocyclic radical may be a single ring or two or more fused rings wherein at least one ring contains a heteroatom. When a heterocyclyl radical carries 2 or more substituents, the substituents may be the same or different.
A said optionally substituted heterocyclic group is typically unsubstituted or substituted with 1 or 2 substituents which may be the same or different. The substituents are preferably a carboxyl group or a C1-4 carboxyalkyl group. Typically, the substituents on a heterocyclyl group are themselves unsubstituted. Where the heterocyclic group carries 2 or more substituents, the substituents may be the same or different.
Examples of heterocyclic radicals include azetidyl, piperidyl, pyrrolidyl, pyrrolinyl, piperazinyl, pyrazolinyl and pyrazolidinyl. Azetidyl and piperazinyl are preferred.
As used herein, some of the atoms, radicals, moieties, chains or cycles present in the general structures of the invention are "optionally substituted". This means that these atoms, radicals, moieties, chains or cycles can be either unsubstituted or substituted in any position by one or more, for example 1 , 2, 3 or 4, substituents, whereby the hydrogen atoms bound to the unsubstituted atoms, radicals, moieties, chains or cycles are replaced by chemically acceptable atoms, radicals, moieties, chains or cycles. When two or more substituents are present, each substituent may be the same or different. As used herein, the term halogen atom embraces chlorine, fluorine, bromine or iodine atoms typically a fluorine, chlorine or bromine atom, most preferably chlorine or fluorine. The term halo when used as a prefix has the same meaning.
As used herein, the term pharmaceutically acceptable salt embraces salts with a pharmaceutically acceptable acid or base. Pharmaceutically acceptable acids include both inorganic acids, for example hydrochloric, sulphuric, phosphoric, diphosphoric, hydrobromic, hydroiodic and nitric acid and organic acids, for example citric, fumaric, maleic, malic, mandelic, ascorbic, oxalic, succinic, tartaric, benzoic, acetic, methanesulphonic, ethanesulphonic, benzenesulphonic or p-toluenesulphonic acid. Pharmaceutically acceptable bases include alkali metal (e.g. sodium or potassium) and alkali earth metal (e.g. calcium or magnesium) hydroxides and organic bases, for example alkyl amines, arylalkyl amines and heterocyclic amines.
Other preferred salts according to the invention are quaternary ammonium compounds wherein an equivalent of an anion (X-) is associated with the positive charge of the N atom. X- may be an anion of various mineral acids such as, for example, chloride, bromide, iodide, sulphate, nitrate, phosphate, or an anion of an organic acid such as, for example, acetate, maleate, fumarate, citrate, oxalate, succinate, tartrate, malate, mandelate, trifluoroacetate, methanesulphonate and p-toluenesulphonate. X- is preferably an anion selected from chloride, bromide, iodide, sulphate, nitrate, acetate, maleate, oxalate, succinate or trifluoroacetate. More preferably X- is chloride, bromide, trifluoroacetate or methanesulphonate.
As used herein, an N-oxide is formed from the tertiary basic amines or imines present in the molecule, using a convenient oxidising agent.
Preferably, when Ra and Rb together with the nitrogen atom to which they are attached do not form a 4 to 6 membered, saturated heterocyclic group, which contains, as heteroatoms, one or two nitrogen atoms and which is substituted by a carboxyl group or a Ci-4 carboxyalkyl group, then either (a) Ra and Rb are independently selected from the group consisting of hydrogen atoms, methylsulphonyl groups, Ci-4 alkyl groups, C^ hydroxyalkyl groups, and C1-4 carboxyalkyl groups, or (b) Ra and Rb each independently represents a C1-4 alkyl group or a Ci-4 haloalkyl group. Typically, in the compound of formula (I), A is selected from the group consisting of -N- and -O-. Preferably, A represents -N-.
The dotted line in the ring containing A, B and C denotes that the ring may be saturated, unsaturated or aromatic. Preferably, the ring is aromatic, i.e. is represented by the formula
Figure imgf000010_0001
Typically, in groups of formula -S(O)2-NRaRb, -(CRfR9)n-(CRhR')x-(CRJRk)y-NRaRb, -(CH2)n-NRaRb, -O-(CH2)n-NRaRb, and -(CH2)n-CO-NRaRb, Ra and Rb are not simultaneously methylsulphonyl groups.
More typically, in groups of formula -S(O)2-NR3R6, -(CRfR9)n-(CRhR')x-(CRJRk)y-NRaRb, -(CH2)n-NRaRb, -O-(CH2)n-NRaRb, and -(CH2)n-CO-NRaRb, Ra is hydrogen and Rb is selected from the group consisting of hydrogen atoms, methylsulphonyl groups, C1-4 alkyl groups, C1-4 hydroxyalkyl groups, C1-4 carboxyalkyl groups, and C1^ haloalkyl groups, or Ra and Rb together with the nitrogen atom to which they are attached form a 4 to 6 membered, saturated heterocyclic group, which contains, as heteroatoms, one or two nitrogen atoms and which is substituted by a carboxyl group or a C1-4 carboxyalkyl group.
Preferably, in groups of formula -S(O)2-NRaRb, -(CRfR9)n-(CRhR')x-(CRJRk)y-NRaRb, -(CH2)n-NRaRb, -O-(CH2)n-NRaRb, and -(CH2)n-CO-NRaRb, Ra is hydrogen and Rb is selected from the group consisting of hydrogen atoms, methylsulphonyl groups, C1-4 alkyl groups, C1-4 carboxyalkyl groups, and C1-4 haloalkyl groups, or Ra and Rb together with the nitrogen atom to which they are attached form a 4 to 6 membered, saturated heterocyclic group, which contains, as heteroatoms, one or two nitrogen atoms and which is substituted by a carboxyl group or a C1^ carboxyalkyl group.
More preferably, in groups of formula -S(O)2-NRaRb, -(CRfR9)n-(CRhR')x-(CRJRk)y-
NRaRb, -(CH2)n-NRaRb, -O-(CH2)n-NRaRb, and -(CH2)n-CO-NRaRb, Ra is hydrogen and Rb is selected from the group consisting of hydrogen atoms, methylsulphonyl groups, C1-2 carboxyalkyl groups, and C1-2 haloalkyl groups, or Ra and Rb together with the nitrogen atom to which they are attached form an azetidine or piperazine group which groups are substituted by a carboxyl group or a C^2 carboxyalkyl group.
Typically, in the compound of formula (I), G1 represents a -CRC- group, wherein Rc represents a hydrogen atom, chlorine atom, fluorine atom or a C1^ alkyl group.
Preferably, G1 represents a -CRC- group, wherein Rc represents a hydrogen atom or a methyl group.
Typically, in the compound of formula (I), R1 represents a hydrogen atom, a C1-4 alkyl group or a C3-4 cycloalkyl group. Preferably, R1 is selected from the group consisting of hydrogen atoms, ethyl groups and C3-4 cycloalkyl groups.
Typically, R2 represents a hydrogen atom or a C1-4 alkyl group, preferably R2 represents a hydrogen atom or a methyl group. More typically R2 represents a C1-4 alkyl group.
Typically, R3 represents a hydrogen atom or a C1-4 alkyl group, preferably R3 represents a hydrogen atom or a methyl group. More typically R3 represents a C1-4 alkyl group.
Typically, R4 represents a hydrogen atom, a C1-4 alkyl group or a -CF3 group, preferably a hydrogen atom or a methyl group, more preferably a hydrogen atom.
Typically, R5 represents a hydrogen atom, a C1-4 alkyl group or a -CF3 group, preferably a hydrogen atom or a C1-4 alkyl group, more preferably a hydrogen atom or a methyl group, being the most preferred a methyl group.
Typically, R7 represents a hydrogen atom, a C1-4 alkyl group or a -CF3 group, preferably a hydrogen atom or a methyl group, more preferably a hydrogen atom.
Typically, at least one of R4, R5 and R7 is a hydrogen atom. More typically, 1 or 2 of R4, R5 and R7 are hydrogen atoms. Preferably, two of R4, R5 and R7 are hydrogen atoms. More preferably, two of R4, R5 and R7 are hydrogen atoms and the other is methyl. Even more preferably, R4, and R7 are hydrogen atoms and R5 is methyl. Typically, R6 represents a C1^, alkyl group, or a C1-4 hydroxyalkyl group; or R6 is selected from the group consisting of -(CH2)n-NRaRb groups, -(CH2XrCOOH groups, -(CH2)n-NRa-(CH2)p-(NH)q-SO-CH3 groups and -(CH2)n-C0-NRaRb groups, wherein
n and p are each independently integers from 0 to 3,
q is 0 or 1 ,
Ra and Rb are independently selected from the group consisting of hydrogen atoms, methylsulphonyl groups, C1-4 carboxyalkyl groups, C1-4 alkyl groups and C1^ haloalkyl groups, or
Ra and Rb together with the nitrogen atom to which they are attached form a 4 to 6 membered, saturated heterocyclic group, which contains, as heteroatoms, one or two nitrogen atoms and which is substituted by a carboxyl group or a C1-4 carboxyalkyl group.
In a particularly preferred embodiment, in the compound of formula (I)
A represents -N-;
G1 represents a -CRC- group, wherein Rc represents a hydrogen atom or C1-4 alkyl group;
R2 and R3 independently represent C1-4 alkyl groups;
R4, R5 and R7 are independently selected from the group consisting of hydrogen atoms and C1-4 alkyl groups;
R6 represents a C1-4 alkyl group or a C1-4 hydroxyalkyl group, or R6 is selected from the group consisting of -S(O)2-NRaRb groups, -(CH2)n-NRaRb groups, -(CH2)n-COOH groups, -(CH2)n-NRa-(CH2)p-(NH)q-SO-CH3 groups and -(CH2)n-CO-NRaRb groups, wherein
n and p are each independently integers from 0 to 3,
q is 0 or 1 , Ra and Rb independently are selected from the group consisting of hydrogen atoms, methylsulphonyl groups, Ci-4 carboxyalkyl groups, C1^, alkyl groups and Ci-4 haloalkyl groups, or
Ra and Rb together with the nitrogen atom to which they are attached form a 4 to 6 membered, saturated heterocyclic group, which contains, as heteroatoms, one or two nitrogen atoms and which is substituted by a carboxyl group or a C1-4 carboxyalkyl group; or
Rc together with R6 form a C5-8 carbocyclic ring optionally substituted by -NHR' wherein R' represents a hydrogen atom or a C1-4 carboxyalkyl group.
In a further particularly preferred embodiment, compounds of the present invention are compounds of formula (I1), or a pharmaceutically acceptable salts or N-oxides thereof,
Figure imgf000013_0001
Formula (I1) wherein
G1 is selected from the group consisting of nitrogen atoms and -CRC- groups, wherein Rc represents a hydrogen atom, a chlorine atom, or a Ci-2 alkyl group;
R1 is selected from the group consisting of hydrogen atoms, Ci-2 alkyl groups, cyclopropyl groups, -NH2 groups, -NHMe, and -NMe2 groups;
R4, R5 and R7 are independently selected from the group consisting of hydrogen atoms, chlorine atoms, C1-2 alkyl groups;
R6 represents a Ci.2 alkyl group or a C1-4 hydroxyalkyl group; or R6 is selected from the group consisting of -S(O)2-NHR6 groups, -(CH2)n-NHRb groups, -(CH2)n-COOH groups, -(CH2)n-CO-NHRb groups, and -O-(CH2)n-NHRb groups wherein n is 2 or 3,
Rb is selected from the group consisting of hydrogen atoms, methylsulphonyl groups, C1-2 carboxyalkyl groups, and C1-2 haloalkyl groups, or
Ra and Rb together with the nitrogen atom to which they are attached form an azetidine or piperazine group which groups are substituted by a carboxyl group or a C1-2 carboxyalkyl group; or
Rc together with R6 form a C6 carbocyclic ring substituted by -NHR' wherein R' represents a hydrogen atom or a C1-2 carboxyalkyl group.
In a further particularly preferred embodiment, compounds of the present invention are compounds of formula (I1), or pharmaceutically acceptable salts or N-oxides thereof,
Figure imgf000014_0001
Formula (I1) wherein
G1 is selected from the group consisting of nitrogen atoms and -CRC- groups, wherein Rc represents a hydrogen atom, a chlorine atom, or a C1-2 alkyl group;
R1 is selected from the group consisting of hydrogen atoms, C1-2 alkyl groups, cyclopropyl groups, and -NH2 groups;
R4, R5 and R7 are independently selected from the group consisting of hydrogen atoms, chlorine atoms, Ci-2 alkyl groups;
R6 represents a C1-2 alkyl group or a C1-4 hydroxyalkyl group; or R6 is selected from the group consisting of -S(O)2-NHR" groups, -(CH2)n-NHRb groups, -(CH2)n-COOH groups, and -(CH2)n-CO-NHRb groups, wherein n is 2 or 3,
Rb is selected from the group consisting of hydrogen atoms, methylsulphonyl groups, C1-2 carboxyalkyl groups, and C1-2 haloalkyl groups, or
Ra and Rb together with the nitrogen atom to which they are attached form an azetidine or piperazine group which groups are substituted by a carboxyl group or a C1-2 carboxyalkyl group; or
Rc together with R6 form a C6 carbocyclic ring substituted by -NHR' wherein R' represents a hydrogen atom or a C1-2 carboxyalkyl group.
In a further particularly preferred embodiment, R6 represents a C1-4 alkyl group, or a C1-4 hydroxyalkyl group, or
R6 is selected from the group consisting of -S(O)2-NRaRb groups, -(CH2)n-NRaRb groups, -(CH2XrCOOH groups, and -(CH2)n-C0-NRaRb groups, wherein,
n is an integer from 0 to 3,
Ra and Rb are independently selected from the group consisting of hydrogen atoms, methylsulphonyl groups and C1-4 carboxyalkyl groups, C1-4 alkyl groups and C1-4 haloalkyl groups, or
Ra and Rb together with the nitrogen atom to which they are attached form a 4 to 6 membered, saturated heterocyclic group, which contains, as heteroatoms, one or two nitrogen atoms and which is substituted by a carboxyl group or a C1^, carboxyalkyl group; or
Rc together with R6 form a C5-8 carbocyclic ring optionally substituted by -NHR' wherein R' represents a hydrogen atom or a C1-4 carboxyalkyl group.
In a preferred embodiment, in compounds of formula (I) both A and B represent -N- and C represents -O-, G1 represents a -CRC- group wherein Rc represents a C1-4 alkyl group,
R1 represents a -NRdRe group, wherein Rd and Re are independently selected from hydrogen atom and C1-4 alkyl group, Both R2 and R3 represent a methyl group, Both R4 and R7 represent a hydrogen atom, R5 represents a C1-4 alkyl group, and
R6 represents a C1-4 hydroxyalkyl group, -O-(CH2)n-NRaRb or -(CH2)n-NRaRb, wherein Ra and Rb independently represent a hydrogen atom or a C1-4 alkyl group.
Particular individual compounds of the invention include:
(4-(5-(1-ethyl-7,7-dimethyl-5,67,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3- yl)phenyl)methanol
4-(5-(1-ethyl-7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3- yl)benzenesulfonamide
3-(4-(4-(5-(1-ethyl-7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-
3-yl)phenyl)piperazin-1 -yl)propanoic acid 3-(4-(5-(1-ethyl-7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3- yl)phenylsulfonamido)propanoic acid
3-(4-(5-(1-ethyl-7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3- yl)-2,6-dimethylphenyl)propanoic acid
3-(4-(5-(1-ethyl-7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3- yl)-2,6-dimethylphenyl)propanamide
2-(4-(5-(1-ethyl-7,7-dimethyl-5,6,7)8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3- yl)-2,6-dimethylphenyl)ethanamine
3-(4-(5-(1-cyclopropyl-7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4- oxadiazol-3-yl)-2,6-dimethylphenyl)propanoic acid 3-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3-yl)-2,6- dimethylphenyl)propanoic acid
2-(4-(5-(1-cyclopropyl-7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4- oxadiazol-3-yl)-2,6-dimethylphenyl)ethanamine
2-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3-yl)-2,6- dimethylphenyl)ethanamine
3-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3-yl)-3- methylphenyl)propanoic acid
2-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3-yl)-3- methylphenyl)ethanamine 2-(3-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3-yl)-2,6- dimethylphenyl)propanamido)ethanoic acid 3-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3- yl)phenyl)propanoic acid
4-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3- yl)phenyl)butanoic acid 2-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3- yl)phenyl)ethanamine
6-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3-yl)-1 ,2,3,4- tetrahydronaphthalen-2-amine
3-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3-yl)-2,6- dimethylphenyl)propanamide
2-(6-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3-yl)-
1 ,2,3,4-tetrahydronaphthalen-2-ylamino)ethanoic acid
3-(4-(5-(7,7-dimethyl-5,6,7)8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3-yl)-2,6- dimethylphenyl)propan-1 -amine 3-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3-yl)-2,6- dimethylphenyl)propane-1 ,2-diol
N-(3-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3-yl)-
2,6-dimethylphenyl)propyl)methanesulfonamide
N-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3-yl)-2,6- dimethylphenethyl)-2,2-difluoroethanamine
1-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3-yl)-2,6- dimethylphenethyl)azetidine-3-carboxylic acid
3-(5-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3-yl)-3- ethyl-6-methylpyridin-2-yl)propanoic acid 3-(2-chloro-4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3- yl)phenylsulfonamido)propanoic acid
3-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3- yl)phenylsulfonamido)propanoic acid
3-(4-(5-(1-amino-7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3- yl)-2,6-dimethylphenyl)propane-1 ,2-diol
4-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3-yl)-2,6- dimethylphenyl)butanoic acid
1-(4-(5-(1-amino-7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3- yO^.Θ-dimethylphenethyOazetidine-S-carboxylic acid N-(2-{4-[5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3-yl]-
2,6-dimethylphenyl}ethyl)-2,2,2-trifluoroethanamine 3-(4-{5-[7,7-dimethyl-1-(methylamino)-5,6,7,8-tetrahydroisoquinolin-4-yl]-1 ,2,4- oxadiazol-3-yl}-2,6-dimethylphenyl)propane-1 ,2-diol
4-[3-(3,5-dimethyl-4-{2-[(2,2,2-trifluoroethyl)amino]ethyl}phenyl)-1 ,2,4-oxadiazol-5- yl]-N,7,7-trimethyl-5,6,7,8-tetrahydroisoquinolin-1-amine 4-{3-[4-(2-aminoethyl)-3,5-dimethylphenyl]-1 ,2,4-oxadiazol-5-yl}-Nl7,7-trimethyl-
5,6,7,8-tetrahydroisoquinolin-1-amine
4-{3-[4-(2-aminoethoxy)-3,5-dimethylphenyl]-1 ,2,4-oxadiazol-5-yl}-N,7,7-trimethyl- 5,6,7,8-tetrahydroisoquinolin-1-amine
3-(4-{5-[1-(dimethylamino)-7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl]-1 l2l4- oxadiazol-3-yl}-2,6-dimethylphenyl)propane-1 ,2-diol
Of outstanding interest are:
3-(4-(5-(1-ethyl-7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3-yl)- 2,6-dimethylphenyl)propanamide
2-(4-(5-(1-ethyl-7,7-dimethyl-5)6l7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3-yl)-
2,6-dimethylphenyl)ethanamine
3-(4-(5-(1-cyclopropyl-7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-
3-yl)-2,6-dimethylphenyl)propanoic acid 2-(4-(5-(1 -cyclopropyl-7,7-dimethyl-5,6 J,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-
3-yl)-2,6-dimethylphenyl)ethanamine
2-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3-yl)-2,6- dimethylphenyl)ethanamine
3-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3-yl)-2,6- dimethylphenyl)propanamide
3-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3-yl)-2,6- dimethylphenyl)propan-1 -amine
3-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3-yl)-2,6- dimethylphenyl)propane-1 ,2-diol N-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3-yl)-2,6- dimethylphenethyl)-2,2-difluoroethanamine
1-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3-yl)-2)6- dimethylphenethyl)azetidine-3-carboxylic acid
4-{3-[4-(2-aminoethyl)-3,5-dimethylphenyl]-1 ,2,4-oxadiazol-5-yl}-N,7,7-trimethyl-5,6,7,8- tetrahydroisoquinolin-1 -amine
4-{3-[4-(2-aminoethoxy)-3,5-dimethylphenyl]-1 ,2,4-oxadiazol-5-yl}-N,7,7-trimethyl-
5,6,7,8-tetrahydroisoquinolin-1-amine Compounds of general formula (I) may be prepared following the synthetic scheme depicted in figure 1.
Figurei
Figure imgf000019_0001
Thus, compounds of general formula (I) may be prepared by reacting a compound of general formula (II) wherein X can be OH or Cl, with a compound of structure (III) in a one pot reaction in solvent such as DMF, THF, etc., optionally in the presence of one or more coupling agents such as 2-(1 H-benzotriazole-1-yl)-1 ,2,3,3-tetramethyluronium tetrafluoroborate (TBTU), N-(3-dimethylaminopropyl)-N'-ethyl-carbodiimide (EDC), dicyclohexyl carbodiimide (DCC), 1-hydroxybenzotriazole (HOBt), O-(benzotriazol-1- yl)-N,N,N',N'-tetramethyluroniium hexafluorophosphate (HBTU), carbonyl diimidazole (CDI), etc. and optionally in the presence of a base such as triethylamine, Hϋnig's base, sodium hydride, potassium carbonate, etc. at a temperature between 40 and 1500C and in a standard reactor. An alternative method could be following a two steps synthesis by a first coupling as described before and a subsequent cyclization in a solvent such as xylene, toluene, benzene, pyridine, DMF, dichloromethane, acetic acid, trifluoroacetic acid, etc. at rt or elevated temperatures optionally in the presence of auxiliaries such as acid (e.g. trifluoroacetic acid, acetic acid, hydrochloric acid, etc.), bases (e.g., sodium hydride, sodium acetate, sodium carbonate, potassium carbonate, triethylamine, etc.), tetralkylammonium salts or water removing agents such as oxalyl chloride, a carboxylic acid anhydride, phosphoryl trichloride (POCI3), tetrabutylammonium fluoride (TBAF), molecular sieves, etc.
Alternatively compounds of general formula (I) may be prepared as shown in figure 2, by reacting an intermediate of general formula (IV) with an intermediate of formula (V) following the synthetic procedures described above.
Figure 2
Figure imgf000020_0001
Intermediates of general formula (III) and (IV) may be prepared following the synthetic schemes depicted in figure 3.
Figure 3
Figure imgf000020_0002
Figure imgf000020_0003
Intermediates of formula (III) and (IV) may be obtained from the corresponding intermediates of formula (Vl) and (VII) wherein Y is CN, COOH, COCI or COOR' by reacting with hydroxylamine or hydrazine or one of its salts in a solvent such as THF, methanol, ethanol, pyridine, etc., optionally in the presence of a base such as sodium bicarbonate, sodium carbonate, potassium carbonate, triethylamine, sodium ethoxide etc. and at a temperature from room temperature to the boiling point of the solvent. Optionally, the reaction can be carried out in the presence of a coupling agent such as 2-(1 H-benzotriazole-1-yl)-1 ,2,3,3-tetramethyluronium tetrafluoroborate, N-(3- dimethylaminopropyl)-N'-ethyl-carbodiimide, dicyclohexyl carbodiimide, 1- hydroxybenzotriazole, etc. In the particular case of compounds of general formula (I) wherein A and B are nitrogen and C is an oxygen, compounds of general formula (Ia) may be prepared following the synthetic scheme depicted in figure 4.
Figure 4
Figure imgf000021_0001
(Ha)
(HIa) (Ia)
The oxadiazole compounds of general formula (Ia) may be prepared by the condensation of the tetrahidroisoquinoline-4-carboxylic acid (Ma) with the corresponding carboximidamide (Ilia) following the synthetic procedures described above.
Intermediates of general formula (Ma) may be prepared following the synthetic scheme depicted in figure 5.
Figure 5
Figure imgf000021_0002
The intermediates of general formula (IX) may be prepared by the reaction of the corresponding commercial ketone (VIII) with diethylcarbonate in a basic media such as sodium hydride and in an aprotic solvent such as THF or DMF and at a temperature between 0 and the boiling point of the solvent.
The intermediates of general formula (X) may be prepared by the condensation of the intermediates of formula (IX) with 2-cyanoacetamide in basic media such as KOH or NaOH and in a protic solvent such as methanol or ethanol at a temperature between 2O0C and the boiling point of the solvent.
The intermediates of general formula (Xl) may be prepared by the reaction of the intermediates of formula (X) with POCI3 or a mixture of POCI3 and PCI5 with or without a solvent such as toluene in a high pressure reactor and at high temperature.
The intermediates of general formula (XII) may be obtained by the coupling of the intermediates of formula (Xl) with the corresponding alkyl boronic acid or boronate under the conditions of a Suzuki reaction (Miyaura, N.; Suzuki, A. Chem. Rev. 1995, 95, 2457). This reaction may be catalyzed by a palladium catalyst like [1 ,1'- bis(diphenylphosphino)-ferrocene] dichloropalladium (II) complex with dichloromethane (1 :1 ), tetrakis(triphenylphosphine)-palladium(0), bis(triphenylphosphine)palladium(ll) chloride or tris(dibenzylideneacetone)-dipalladium(0) in an aprotic organic solvent such as dioxane, toluene, DMF or DME and in the presence of a base such as cesium carbonate, sodium carbonate, potassium carbonate or potassium phosphate at a temperature from 8O0C to 14O0C.
In the particular case where R1 is a -NRdRe group wherein Rd and Re independently represent hydrogen atoms or a C1-4 alkyl group and when R1 is a C1-4 hydroxyalkyl group, the intermediates of formula (XII) can be obtained by the reaction of the intermediates of formula (Xl) with an excess of the corresponding amine or alcohol with an extra base such as NaH, triethylamine, etc. in a solvent such as MeOH, EtOH or
THF and at temperature between 50 and 1000C.
Intermediates of general formula (XII) can also be obtained following the synthetic scheme shown in figure 6.
Figure 6
Figure imgf000023_0001
The intermediates of general formula (XVI) may be prepared by the reaction of the corresponding commercial ketone (XIV) with the corresponding acyl chloride of formula (XV) in a basic media such as lithiumdiisopropylamide (LDA) and in an aprotic solvent such as THF and at a temperature between -780C and room temperature.
The intermediates of general formula (XVII) may be prepared by the condensation of the intermediates of formula (XVI) with 2-cyanoacetamide in basic media such as triethylamine, KOH or NaOH and in a protic solvent such as methanol or ethanol at a temperature between 200C and the boiling point of the solvent.
Finally, intermediates of general formula (XII) may be prepared as intermediates of general formula (Xl).
Reduction of intermediates of formula (XII) with a palladium catalyst such as Pd/C, palladium(ll) chloride (PdCI2) or dihydroxypalladium (Pd(OH)2) in basic media such as sodium acetate, triethylamine (Et3N) or diisopropylethylamine (DIEA) in a solvent such as methanol or ethanol under hydrogen atmosphere (from 1 to 20 psi), yield the tetrahydroisoquinoline intermediates of formula (XIII).
Hydrolysis of the nitrile compounds of general formula (XIII) with a base such as aqueous NaOH or KOH in a protic solvent such as methanol or ethanol at a temperature between 50 and 1300C or with an acid such as sulphuric acid, hydrochloric acid, in a solvent such as water, dioxane, acetic acid, etc. give the acid compound of formula (Ma).
Intermediates of general formula (Ilia) may be prepared following the synthetic scheme depicted in figure 7.
Figure 7
Figure imgf000024_0001
Intermediates of formula (Ilia) may be obtained by the reaction of hydroxylamine or one of its salts with the corresponding nitrile (XIX) in a solvent such as THF, methanol, ethanol, pyridine, etc. optionally in the presence of a base such as sodium bicarbonate, sodium carbonate, potassium carbonate, triethylamine, etc. and at a temperature from 40 to 1000C. The intermediates of structure (XIX) are commercially available or prepared according to procedures described in the art. A precursor can be the corresponding bromoaryl derivative of formula (XVIII) which react with a source of cyanide such as copper (I) cyanide, in a high boiling point solvent such as NMP, DMF or DMSO at a temperature between 150-2000C to yield the corresponding nitrile of general formula (XIV). Alternatively, dicyanozinc can be also used as a source of cyanide, with a Pd catalyst such as tetrakis(triphenylphosphine)-palladium(0) in a high boiling point solvent, in a standard reactor or a microwave reactor. Depending on the nature of the functionalities present in the residues R4 to R7, these functionalities may require temporary protection. Appropriate protecting groups are known in the art and include e.g a tert-butyl or ethyl or methyl to protect an acid, a tert- butyloxycarbonyl (BOC) to protect an amine, etc. These protecting groups may be employed according to standard methodology (e.g. T.W. Greene, P. G. M. Wuts, Protective Groups in Organic Synthesis, 3rd Edition, Wiley New York, 1991).
In the particular case of intermediates of formula (MIb) where R6 is -(CH2^COOR8 and R8 is a C1-4 alkyl group, said intermediates may be obtained following the synthetic path shown in Figure 8.
Thus, a Heck reaction of the corresponding precursor (XX) wherein X= O-SO2-CF3, bromo or iodo, which are known or can be prepared according to known procedures, with acrylate yield the intermediates of formula (XXI). Reaction of these intermediates with hydroxylamine as described above and followed by catalytic hydrogenation, gave the intermediates of general formula (MIb).
Figure 8
Figure imgf000025_0001
In the particular case of compounds of general formula (I) where R6 is -(CH2)n-NRaRb group and a -(CH2)n-CO-NRaRb group these compounds can be obtained from compounds of general formula (Ib) wherein R6 is a -(CH2)n-COOH group following the synthetic path shown in Figure 9.
Figure 9
Figure imgf000025_0002
(Ib)
(Ic)
Figure imgf000025_0003
Thus, the compounds of general formula (Ic) wherein R6 is a -(CH2)n-CO-NRaRb group can be prepared from the corresponding acid of general formula (Ib) by reacting with ammonia, an amine or an aminoacid of general formula HNRaRb in the presence of an activating agent such as N-(3-dimethylaminopropyl)-N'-ethyl-carbodiimide (EDC), dicyclohexyl carbodiimide (DCC), 1-hydroxybenzotriazole (HOBt), (benzotriazol-1- yloxy)-tris-(dimethylamino)-phosphonium hexafluorophosphate (BOP), bis-(2-oxo-3- oxazolidinyl)-phosphonic acid chloride (BOP-CI)1 etc. in a solvent such as THF, dioxane, DMF, dichloromethane, acetonitrile, etc.
Reduction of primary amides of general formula (Ic) wherein Ra=Rb=H with BH3-SMe2 in a solvent such as THF, yield the corresponding primary amine of general formula (Id).
Moreover, primary amines of general formula (Ie) can be prepared by Curtius rearrangement of the acids of general formula (Ib) using an azide such as sodium azide, diphenylphosphoryl azide (DPPA), etc, in acidic media such as sulphuric acid or basic media such as triethylamine, in solvent such as toluene, chloroform, THF, etc. or in a protic solvent such as terf-butanol or benzyl alcohol to yield the te/t-butylcarbonyl (BOC) or benzyloxycarbonyl (CBZ or Z) protected amine and subsequent deprotection as known in the art yield the final compounds of formula (Ie).
In the particular case where R6 is -(CH2)2NHRaRb the compounds of formula (Ig) may be obtained following the synthetic path shown in Figure 10.
Figure 10
Figure imgf000026_0001
The compounds of general formula (Ig) may be prepared by the reductive amination of the aldehyde derivatives of general formula (XXIV) with the corresponding amine or aminoacid of formula HNRaRb in acidic media such as acetic acid, in a protic solvent such as methanol or ethanol and with a reductive agent such as sodium borohydride or sodium cyanoborohydride at a temperature from O0C to the boiling point of the solvent.
Intermediates of formula (XXIV) may be obtained by oxidation of diols of general formula (If) with an oxidative reagent such as NaIO4, NaCIO4, KIO4, etc. in a solvent such as methanol, ethanol, THF, dioxane, ether, etc. with the presence or absence of water.
Compounds of general formula (If) may be prepared by oxidation of the allyl intermediates of general formula (XXIII) using an oxidative reagent such as N-methyl- morpholine-N-oxide, sodium periodate, sodium perchlorate, potassium periodate, etc. in the presence of a catalyst such us sodium tetraoxide solid or a solution in water or tert-butanol, in a solvent such as methanol, ethanol, THF, dioxane, ether, acetone, etc. with the presence or absence of water.
Allyl intermediates of general formula (XXIII) may be prepared by the condensation of the corresponding carboximidamide of formula (IHc) with the corresponding acid of general formula (Ma) as described above.
Finally, as shown in figure 11 , intermediates of formula (lllc) wherein R6 is - CH2CH=CH2 may be obtained by standard StMIe reaction of the corresponding precursor (XX) where X= O-SO2-CF3, bromine or iodine, using an allylstannane and a catalyst such as tetrakis(triphenylphosphine)-palladium(0), palladium acetate, bis(triphenylphosphine)palladium(ll) chloride or tris(dibenzylideneacetone)- dipalladium(O), in a solvent such DMF, acetonitrile, etc. and subsequent reaction with hydroxylamine as described before.
Figure 11
Figure imgf000027_0001
(XX) CXXV) (HIc)
Compounds of general formula (Ih) may be obtained as shown in figure 12. Figure 12
Figure imgf000028_0001
Figure imgf000028_0002
The compounds of formula (Ih) may be obtained by the reaction of compounds of general formula (XXVII) with the corresponding alkylating agent in basic media such as sodium hydride in a solvent such as THF or DMF at a temperature from 0 to 15O0C. Alternatively, the phenolic functionality of (XXVII) may be coupled to suitable alcohol derivatives using a Mitsunobu coupling procedure (Mitsunobu, O., Synthesis 1 (1981 )). Preferred coupling conditions include the use of a thalkylphosphine or triarylphosphine, such as tri-n-butylphosphine or triphenylphosphine, in a suitable solvent, such as tetrahydrofuran or dichloromethane, and an azodicarbonyl reagent, such as diethyl azodicarboxylate or 1 ,1'-(azodicarbonyl)dipipehdine.
The compounds of general formula (XXVII) may be prepared by demethylation of the corresponding compound of general formula (XXVI) using BBr3 or AIBr3 or BF3 or iodotrimethylsilane as demethylating agent in a solvent such as dichloromethane or 1 ,2-dichloroethane, chloroform at a temperature between 0 and the 6O0C. Alternatively compounds of general formula (XXVII) may be prepared by demethylation using HBr in acetic acid as a solvent.
Finally, compounds of general formula (XXVI) may be prepared according to the general procedures described in figures 1 and 2 for compounds of general formula (I).
The syntheses of the compounds of the invention and of the Preparations for use therein are illustrated by the following Examples (1 to 37) including Preparation Examples (Preparations 1 to 87) which do not limit the scope of the invention in any way.
1H Nuclear Magnetic Resonance Spectra were recorded on a Varian Mercury 200 spectrometer. Low Resolution Mass Spectra (m/z) were recorded on a Micromass ZMD mass spectrometer using ESI ionization. The chromatographic separations were obtained using a Waters 2690 system equipped with a Symmetry C18 (2.1 x 50 mm, 3.5 μM) column for method A and B and a Symmetry C18 (2.1 x 100 mm, 3.5 μM) for method C. The mobile phase was formic acid (0.4 ml_), ammonia (0.1 ml_), methanol (500 tnL) and acetonitrile (500 ml.) (B) and formic acid (0.46 ml_), ammonia (0.115 ml.) and water (1000 ml.) (A), the gradients are specified in the following table for each methode used. The reequilibration time between two injections was 1 min. The flow rate was 0.8 mLΛnin for method A and 0.4 mL/min for method B and C. The injection volume was 5 microliter for method A and B and 3 microliter for method C. Diode array chromatograms were collected at 210 nM.
Figure imgf000029_0001
General purification method:
The solid was dissolved in DMSO/MeOH, injected into a Biotage C18 silica column (4OM, 25M or 25S according to the crude amount) and eluted on the SP1® automated purification system from Biotage. The gradient used was H2O/Acetonitrile/MeOH (1 :1 ) (0.1% v/v HCOONH4 both phases) from 0% to 100% acetonitrile/MeOH (1 :1 ) in 80 column volumes. The appropriate fractions were collected and the organic solvent evaporated under reduced pressure or liofilized.
GENERAL SYNTHETIC METHODS:
General method 1 :
A mixture of the corresponding benzonitrile (39.2mmol) in methanol (5OmL), hydroxylamine hydrochloride (5.45g, 78.4mmol) and sodium bicarbonate (13.17g, 156.8mmol) was stirred at 750C for 6h. The mixture was filtered off and the filtrate evaporated to dryness to yield the title compound (75-100% yield) as a white solid. General method 2:
A mixture of the corresponding acid derivative (1.13mmol), EDC (1.13mmol) and HOBt (1.13mmol) in DMF (5mL) was stirred at room temperature for 10 min. Then the corresponding benzimidamide (1.13mmol) was added and the mixture stirred at 14O0C for 4h. The reaction mixture was poured over basic ice/water and the solid formed filtered and washed with water, dried in a vacuum oven to give the desired compound (40-90% yield) as a white solid.
General method 3: To a mixture of the corresponding methyl or ethyl esther (0.67mmol) in methanol or ethanol (3ml_) respectively was added a 2M solution of aqueous NaOH (12mmol) and the reaction mixture stirred at 9O0C overnight. The organic solvent was evaporated, water was added and the mixture extracted with diethyl ether. The pH of the aqueous layer was adjusted to 5-6 and the solid formed filtered and dried in the vacuum oven. The desired compound (60-95% yield) was obtained as a white solid.
General method 4:
A mixture of the corresponding te/t-butyl ester (0.56mmol) in 4M HCI in dioxane (3.5ml_) was stirred at r.t. overnight. The solvent was evaporated and the solid obtained washed with diisopropyl ether twice. The solid was dried in the vacuum oven to yield (70-95% yield) of the desired compound.
General method 5:
A mixture of the corresponding acid (0.46mmol), EDC (133mg, 0.69mmol), HOBt (94mg, 0.69mmol) and 32% solution of aqueous ammonia (85 μl, 0.69mmol) in DMF (6.5ml_) was stirred overnight at room temperature. Then ethyl acetate and water were added and the organic layer separated, washed with 4% NaHCO3, water and brine and dried to give the title compound (5-77% yield) as a white solid.
General method 6:
A mixture of the corresponding acid derivative (0.77mmol), DPPA (189μL, O.δδmmol) and triethylamine (235μl_, 0.51 mmol) in tert-butanol (4ml_) was stirred at 1000C overnight. Ethyl acetate was added and the organic layer washed with 4% NaHCO3 and brine, dried and concentrated. The residue was redissolved in 4M HCI in dioxane (1OmL) and the mixture stirred overnight at room temperature. The reaction mixture was concentrated and the residue purified according to General purification method. The solid obtained was redissolved in 4M HCI in dioxane and stirred for 2h at r.t. Then the solvent was concentrated and the product crystallized in diethyl ether. The title compound was obtained (5-40% yield) as hydrochloride salt.
General method 7: To a solution of the corresponding amide (75mg, 0.18mmol) in THF (4mL) was added BH3.SMe2 (107μL, 0.21 mmol) dropwise. The reaction mixture was stirred overnight at 650C. Solvent was concentrated and ethyl acetate was added. The organic layer was washed with 4% NaHCO3 and brine, dried and concentrated. The residue was purified according to General purification method. The solid obtained was redissolved in 5N HCI in dioxane and stirred for 2h at r.t. Then the solvent was concentrated and the product crystallized in diethyl ether. The title compound was obtained (20-65% yield) as hydrochloride salt.
PREPARATION EXAMPLES
Preparation 1
Ethyl S.δ-dimethyl^-oxocyclohexanecarboxylate
Figure imgf000031_0001
To a suspension of 60% NaH (74g, 1.85mol) in THF (143OmL) was added diethyl carbonate (269mL, 2.22mol) and the mixture was warm up to reflux. Then a solution of 4,4-dimethylcyclohexanone (93.44g, 0.74mol) in THF (1305mL) was added dropwise for 2.5h. The reaction mixture was stirred an extra 4h and then allowed to cool down to room temperature. Saturated solution of NH4CI was added carefully and the mixture stirred overnight. Organic layer was separated and the aqueous layer extracted with diethyl ether twice. The combined organic layer was washed with water and brine, dried over sodium sulphate and concentrated to yield 174g of an orange oil which was used without further purification. LRMS: m/z 199 (M+1 )+ Retention time: 6.10 min (Method B)
Preparation 2 1 ,3-dihydroxy-7,7-dimethyl-5,6,7,8-tetrahydroisoquinoline-4-carbonitrile
Figure imgf000032_0001
To a solution of Preparation 1 (139.50 g, 0.70mol) in methanol (436 mL) was added 2- cyanoacetamide (59.16 g, 0.70mol). Then a solution of KOH (48.56 g, 0.87mol) in MeOH (315mL) was added dropwise and the mixture stirred for an hour at room temperature and at reflux for 3h. Then the reaction mixture was allowed to cool down to room temperature and concentrated HCI was added until pH 3-4. The solid obtained was filtered and washed with methanol and diethyl ether. The solid was recrystallized in acetic acid (100OmL), filtered and washed with acetic acid and diethyl ether. After drying the solid in the vacuum oven at 12O0C the desired compound (144.32g, 89% yield) was obtained as a yellow solid. LRMS: m/z 219 (M+1 )+ Retention time: 10.22 min (Method C)
Preparation 3 1.S-dichloro-TJ-dimethyl-S.ΘJ.δ-tetrahydroisoquinoline^-carbonitrile
Figure imgf000032_0002
In a high pressure reactor containing Preparation 2 (14.2g, 0.07mol) was added POCI3 86OmL, 0.66mol) and the mixture stirred at 1700C overnight. The reaction mixture was then concentrated and the residue redissolved in dichloromethane and poured over ice/water. The mixture was neutralized with concentrated NaOH and the organic layer separated, washed with 4% solution of NaHCO3 and brine, dried over sodium sulphate and concentrated. A light brown solid (10.23g) was obtained as the desired compound (yield=62%).
LRMS: no signal Retention time: 7.15 min (Method B)
Preparation 4 a-chloro-i-ethyl^J-dimethyl-S.ΘJ.δ-tetrahydroisoquinoline^-carbonitrile
Figure imgf000033_0001
To a mixture of Preparation 3 (3.28g, 12.86mmol), ethylboronic acid (1g, 13.53mmol) and potassium carbonate (5.33g, 38.56mmol) in dioxane (82mL), was added Pd(PPh3)4 (0.15g, 0.13mmol) and the mixture stirred at 11O0C under nitrogen atmosphere overnight. Ethyl acetate was added and the organic layer washed with water twice and brine, dried over magnesium sulphate and concentrated. The desired compound was obtained as oil (88% yield).
LRMS: no signal
Retention time: 16.47 min (Method C)
Preparation 5 1-ethyl-7,7-dimethyl-5,6,7,8-tetrahydroisoquinoline-4-carbonitrile
Figure imgf000033_0002
To a mixture of Preparation 4 (3.86g, 1 1.39mmol), triethylamine (1.97ml_, 14.13mmol) in methanol (10OmL) was added 20% palladium hydroxide on carbon (0.45g, 0.64mmol). The reaction mixture was hydrogenated at 6psi for 45min. The catalyst was filtered off and the filtrate concentrated. The residue was redissolved in ethyl acetate and washed with water. The organic layer was dried over magnesium sulphate and concentrated to yield a white solid (50% yield) as the desired compound.
LRMS: m/z 215 (M+1 )+
Retention time: 5.93 min (Method B)
Preparation 6 1-ethyl-7,7-dimethyl-5,6,7,8-tetrahydroisoquinoline-4-carboxylic acid
Figure imgf000033_0003
Preparation 5 (1.45g, 6.77mmol) was dissolved in ethanol (4OmL) and concentrated NaOH (12.7mL, 101.6mmol) was added. The mixture was stirred overnight at 11O0C. The solvent was removed under vacuum and the residue redissolved in water and acidified with acetic acid until pH 6. This aqueous layer was extracted with ethyl acetate twice. The combined organic layer was washed with water and brine, dried over magnesium sulphate and concentrated. A yellow solid was obtained (33% yield) as a desired compound.
LRMS: m/z 234 (M+1)+
Retention time: 4.13 min (Method B)
Preparation 7 3-chloro-1-cyclopropyl-7,7-dimethyl-5,6,7,8-tetrahydroisoquinoline-4-carbonitrile
Figure imgf000034_0001
Obtained (52%) from Preparation 3 and cyclopropylboronic acid following the experimental procedure describe for Preparation 4. LRMS: no signal Retention time: 7.66 min (Method B)
Preparation 8 i-cyclopropyl-TJ-dimethyl-S.β^δ-tetrahydroisoquinoline^-carbonitrile
Figure imgf000034_0002
Obtained (70%) from Preparation 7 following the experimental procedure describe for Preparation 5.
LRMS: m/z 227 (M+1 )+ Retention time: 6.98min (Method B)
Preparation 9 1-cyclopropyl-7,7-dimethyl-5,6,7,8-tetrahydroisoquinoline-4-carboxylic acid
Figure imgf000035_0001
Obtained (30%) from Preparation 8 following the experimental procedure describe for Preparation 6.
LRMS: m/z 364 (M+1 )+ Retention time: 19.07 min (Method B)
Preparation 10 (Z)-N'-hydroxy-4-(hydroxymethyl)benzimidamide
Figure imgf000035_0002
Obtained from 4-(hydroxymethyl)benzonitrile (100% yield) following the general method 1.
LRMS: m/z 167 (M+1 )+
Retention time: 0.68 min (Method B)
Preparation 1 1
(E)-N'-hydroxy-4-sulfamoylbenzimidamide
Figure imgf000035_0003
Obtained (100% yield) from 4-cyanobenzenesulfonamide following the general method 1. LRMS: m/z 216 (M+1 )+
Retention time: 0.70 min (Method B)
1H NMR (200 MHz, DMSO-D6) δ ppm 5.9 (s, 2 H) 7.8 (s, 4 H).
Preparation 12 Ethyl 3-(4-(4-cyanophenyl)piperazin-1 -yl)propanoate
Figure imgf000036_0001
To a solution of 4-(piperazin-1-yl)benzonitrile (3g, 16.02mmol) in anhydrous acetonitrile (4OmL) under nitrogen atmosphere was added Yb(OTf)3 (0.2g, 0.32mmol) and then ethyl acrylate (3.49ml_, 32.04mmol). The reaction mixture was stirred overnight at room temperature. The catalyst was filtered off and the filtrate concentrated and chromatographied to provide the title compound (86% yield) of a solid.
LRMS: m/z 288 (M+1 )+ Retention time: 3.60 min (Method B)
1H NMR (200 MHz, CHLOROFORM-D) δ ppm 1.3 (t, J=7.2 Hz, 3 H) 2.6 (m, 6 H) 2.8 (t, J=7.0 Hz, 2 H) 3.3 (m, 4 H) 4.2 (q, J=7.0 Hz, 2 H) 6.8 (d, J=8.6 Hz1 2 H) 7.5 (d, J=8.6 Hz, 2 H)
Preparation 13
(Z)-ethyl 3-(4-(4-(N'-hydroxycarbamimidoyl)phenyl)piperazin-1-yl)propanoate
Figure imgf000036_0002
Obtained (37% yield) from Preparation 12 following the general method 1.
LRMS: m/z 321 (M+1 )+ Retention time: 0.58 min (Method B)
1 H NMR (200 MHz, DMSO-D6) δ ppm 1.2 (t, J=7.2 Hz, 3 H) 2.5 (m, 8 H) 2.6 (t, J=6.4 Hz, 2 H) 3.1 (m, 2 H) 4.1 (q, J=7.3 Hz1 2 H) 5.6 (s, 2 H) 6.9 (d, J=9.0 Hz, 2 H) 7.5 (d, J=9.0 Hz, 2 H) 8.3 (s, 1 H).
Preparation 14
Ethyl 3-(4-(4-(5-(1 -ethyl-7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4- oxadiazol-3-yl)phenyl)piperazin-1-yl)propanoate
Figure imgf000037_0001
Obtained (8% yield) from Preparation 13 and Preparation 6 following the general method 2.
LRMS: m/z 518 (M+1)+ Retention time: 6.63 min (Method B)
Preparation 15
Methyl 3-(4-cyanophenylsulfonamido)propanoate
Figure imgf000037_0002
To a solution of 4-cyanobenzenesulfonamide (2g, 11 mmol) in ACN (8ml_) was added DBU (O.δmL, 5.48mmol) and methyl acrylate (1.42g, 16.49mmol) and the mixture stirred at room temperature for 2h. The crude was purified according to the general purification method to give 0.6g (41 % yield) of the desired compound as a white solid.
LRMS: m/z 267 (M-I)- Retention time: 4.74 min (Method B)
Preparation 16
(E)-Methyl 3-(4-(N'-hydroxycarbamimidoyl)phenylsulfonamido)propanoate
Figure imgf000037_0003
Obtained (100% yield) from Preparation 15 following the general method 1. 1H NMR (200 MHz, DMSO-D6) δ ppm 2.0 (t, J=7.0 Hz, 2 H) 2.5 (s, 3 H) 2.9 (t, J=7.0 Hz, 2 H) 5.9 (s, 2 H) 7.8 (m, 4 H)
Preparation 17 Methyl 3-(4-(5-(1-ethyl-7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4- oxadiazol-3-yl)phenylsulfonamido)propanoate
Figure imgf000038_0001
Obtained (20 % yield) from Preparation 16 and Preparation 6 following the general method 2. LRMS: no signal
Retention time: 7.21 min (Method B)
Preparation 18
4-cyano-2,6-dimethylphenyl trifluoromethanesulfonate
Figure imgf000038_0002
To a suspension of 4-hydroxy-3,5-dimethylbenzonitrile (5.1Og, 34.65mmol) in DCM
(10OmL) was added triethylamine (7.25mL, 52.02mmol). To the solution obtained was added 1 ,1 ,1-trifluoro-N-phenyl-N-(trifluoromethylsulfonyl)methansulfonamide (14.9g,
41.7mmol) and the mixture stirred overnight at room temperature. More DCM was added and then washed with 0.5N NaOH, water and brine. The organic layer was dried over magnesium sulphate and concentrated to yield 11.8g of the desired compound as a solid (yield=100%).
LRMS: no signal
Retention time: 6.90 min (Method B)
Preparation 19
(E)-Methyl 3-(4-cyano-2,6-dimethylphenyl)acrylate
Figure imgf000039_0001
To a mixture of Preparation 18 (6.07g, 21.74mmol), methyl acrylate (5.87mL, 65.18mmol), 1 ,3-bis-(diphenylphosphino)propane (0.45g, 1.09mmol) and triethylamine (6.06mL, 43.48mmol) in DMF (3OmL), was added palladium acetate (0.25g, 1.11mmol) under nitrogen atmosphere. The reaction mixture was stirred overnight at 1100C. After cooling to room temperature, the mixture was poured over water and extracted with diethyl ether twice. The combined organic layer was washed with water and brine, dried over magnesium sulphate and concentrated. A brown oil was obtained (68% yield) as the desired compound. LRMS: no signal
Retention time: 6.13 min (Method B)
Preparation 20
(E)-Methyl 3-(4-((Z)-N'-hydroxycarbamimidoyl)-2,6-dimethylphenyl)acrylate
Figure imgf000039_0002
Obtained (75% yield) from Preparation 19 following the general method 1. LRMS: m/z 249 (M+1 )+ Retention time: 3.88 min (Method B)
Preparation 21
(E)-Methyl 3-(4-(N'-hydroxycarbamimidoyl)-2,6-dimethylphenyl)propanoate
Figure imgf000039_0003
Preparation 20 (1.1g, 4.43mmol) was dissolved in methanol (35ml_) and sodium acetate (0.55g, 6.70mmol) was added. Finally palladium chloride (0.16g, 0.90mmol) was added and the mixture hydrogenated at 15 psi for 5h. The catalyst was filtered off and the filtrate concentrated. The residue was redissolved in DCM and washed with water. The organic layer was dried over magnesium sulphate and concentrated to yield an oil (82% yield) as the desired compound.
LRMS: m/z 251 (M+1 )+
Retention time: 3.64 min (Method B)
Preparation 22
Methyl 3-(4-(5-(1 -ethyl-7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4- oxadiazol-3-yl)-2,6-dimethylphenyl)propanoate
Figure imgf000040_0001
Obtained (56% yield) from Preparation 21 and Preparation 6 following the general method 2.
LRMS: m/z 448 (M+1 )+
Retention time: 8.07 min (Method B)
Preparation 23 (E)-terf-butyl 3-(4-cyano-2,6-dimethylphenyl)acrylate
Figure imgf000040_0002
Obtained (64%) from Preparation 18 and fert-butyl acrylate following the experimental procedure describe for Preparation 19.
LRMS: m/z 258 (M+1 )+ Retention time: 7.18 min (Method B)
Preparation 24
(E)-terf-butyl 3-(4-((E)-N'-hydroxycarbamimidoyl)-2,6-dimethylphenyl)acrylate
Figure imgf000041_0001
Obtained (76%) from Preparation 23 following the general method 1. LRMS: m/z 291 (M+1 )+ Retention time: 4.89 min (Method B)
Preparation 25
( E) -f erf-butyl 3-(4-(N'-hydroxycarbamimidoyl)-2,6-dimethylphenyl)propanoate
Figure imgf000041_0002
Obtained (77%) from Preparation 24 following the experimental procedure describe for Preparation 21.
LRMS: m/z 293 (M+1 )+
Retention time: 4.66 min (Method B)
Preparation 26 Te/t-butyl 3-(4-(5-(1-cyclopropyl-7,7-dimethyl-5,6 J,8-tetrahydroisoquinolin-4-yl)- 1,2,4-oxadiazol-3-yl)-2,6-dimethylphenyl)propanoate
Figure imgf000041_0003
Obtained (30% yield) from Preparation 25 and Preparation 9 following the general method 2.
LRMS: m/z 502 (M+1 )+
Retention time: 7.18 min (Method B)
Preparation 27 7,7-dimethyl-5,6,7,8-tetrahydroisoquinoline-4-carbonitrile
Figure imgf000041_0004
Obtained (100%) from Preparation 3 following the experimental procedure describe for Preparation 5.
LRMS: m/z 187 (M+1 )+ Retention time: 5.96 min (Method B)
Preparation 28
7,7-dimethyl-5,6,7,8-tetrahydroisoquinoline-4-carboxylic acid
Figure imgf000042_0001
Obtained (75%) from Preparation 27 following the experimental procedure describe for Preparation 6.
LRMS: m/z 206 (M+1 )+
Retention time: 3.75 min (Method B)
Preparation 29 Terf-butyl 3-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol- 3-yl)-2,6-dimethylphenyl)propanoate
Figure imgf000042_0002
Obtained (42% yield) from Preparation 28 and Preparation 25 following the general method 2. LRMS: m/z 462 (M+1 )+
Retention time: 6.63min (Method B)
Preparation 30
Ethyl 3-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1,2,4-oxadiazol-3- yl)-3-methylphenyl)propanoate
Figure imgf000042_0003
Obtained (29% yield) from Preparation 28 and Preparation 31 following the general method 2.
LRMS: m/z 420 (M+1 )+
Retention time: 7.92min (Method B)
Preparation 31
(Z)-Ethyl 3-(4-(N'-hydroxycarbamimidoyl)-3-methylphenyl)propanoate
Figure imgf000043_0001
Obtained (56% yield) from Preparation 32 following the general method 1. LRMS: m/z 251 (M+1 )+
Retention time: 3.56 min (Method B)
Preparation 32
Ethyl 3-(4-cyano-3-methylphenyl)propanoate
Figure imgf000043_0002
Preparation 33 (7.7g, 33.63mmol) was dissolved in methanol (20OmL) and under nitrogen atmosphere was added Pd/C (0.07g, 0.07mmol). The mixture was hydrogenated at 1 psi for 1 h. The catalyst was filtered off and the filtrate concentrated to give the title compound (yield=97%). LRMS: m/z 218 (M+1)+
Retention time: 6.06 min (Method B)
1 H NMR (200 MHz, CHLOROFORM-cQ δ ppm 1.2 (t, J=7.2Hz, 3 H) 2.5 (s, 3 H) 2.6 (t, J=7.6Hz, 2H) 2.9 (t, J=7.6Hz, 2H) 4.1 (q, J=7.2Hz, 2H) 7.1 (m, 2H) 7.5 (d, J=7.8Hz, 1 H)
Preparation 33
(E)-Ethyl 3-(4-cyano-3-methylphenyl)acrylate
Figure imgf000043_0003
Obtained (66% yield) from 4-bromo-2-methylbenzonitrile and ethyl acrylate following the experimental procedure described for Preparation 19.
LRMS: m/z 216 (M+1 )+
Retention time: 6.29 min (Method B) 1 H NMR (200 MHz, CHLOROFORM-αf) δ ppm 1.3 (t, J=7.2Hz, 3 H) 2.6 (s, 3 H)
4.3 (q, J=7.2Hz, 2H) 6.5 (d, J=16Hz, 1 H) 7.5 (m, 4H)
Preparation 34 re/t-butyl 2-(3-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1,2,4- oxadiazol-3-yl)-2,6-dimethylphenyl)propanamido)acetate
Figure imgf000044_0001
A mixture of Example 9 (100mg, 0.25mmol), tert-butyl 2-aminoacetate hydrochloride (62mg, 0.37mmol), HATU (94mg, 0.25mmol) and DIEA (130 μl, 0.75mmol) in DMF (3mL) was stirred overnight at r.t. The mixture was poured over ice/water and stirred for 15min. The solid formed was filtered off, washed with water and dried in the vacuum oven and used without further purification.
LRMS: m/z 519 (M+H)+
Retention time: 7.72min (Method B)
Preparation 35
Methyl 3-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1,2,4-oxadiazol-3- yl)phenyl)propanoate
Figure imgf000044_0002
Obtained (58%) from Preparation 37 and Preparation 28 following the general method 2.
LRMS: m/z 392 (M+H)+
Retention time: 7.63min (Method B) Preparation 36
(Z)-Methyl 3-(4-(N'-hydroxycarbamimidoyl)phenyl)propanoate
Figure imgf000045_0001
Obtained (69% yield) from Preparation 38 following the general method 1. LRMS: m/z 223 (M+H)+ Retention time: 3.07min (Method B)
Preparation 37
Methyl 3-(4-cyanophenyl)propanoate
Figure imgf000045_0002
To a solultion of Preparation 39 (680mg, 3.88mmol) in methanol (8ml_) and dichloromethane (8ml_) at O0C was added trimethylsilyldiazomethane (2M in hexane, 3.9mL) until a yellow color persisted. The reaction mixture was stirred at room temperature for 1 h and was concentrated to dryness to give the title compound, which was used without further purification (87% yield).
LRMS: no signal
Retention time: 5.42min (Method B)
1 H NMR (200 MHz, CHLOROFORM-D) δ ppm 2.7 (t, J=7.4 Hz, 2 H) 3.0 (t,
J=7.4 Hz, 2 H) 3.7 (s, 3 H) 7.3 (d, J=8A Hz1 2 H) 7.6 (d, J=8.4 Hz, 2 H)
Preparation 38 3-(4-cyanophenyl)propanoic acid
Figure imgf000045_0003
Obtained (52% yield) from Preparation 40 following the experimental procedure described for Preparation 21.
LRMS: m/z 174(M-H)"
Retention time: 4.70(Method B) Preparation 39 (E)-3-(4-cyanophenyl)acrylic acid
Figure imgf000046_0001
A suspension of 4-formylbenzonitrile (1g, 7.63mmol) and malonic acid (1.59g, 15.28mmol) in pyridine (1OmL) was stirred at 450C until a solution was obtained. Then piperidine (0.15ml_, 1.53mmol) was added and the reaction mixture stirred at 850C for 30min and at reflux for 4h.5N HCI was added dropwise and the white solid formed was filtered off, washed with water and dried in the vacuum oven (93% yield).
LRMS: m/z 172 (M-H)-
Retention time: 4.84min (Method B)
Preparation 40
Methyl 4-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1,2,4-oxadiazol-3- yl)phenyl)butanoate
Figure imgf000046_0002
Obtained (51% yield) from Preparation 42 and Preparation 28 following the general method 2.
LRMS: m/z 406 (M+H)+
Retention time: 7.78min (Method B)
Preparation 41
(Z)-Methyl 4-(4-(N'-hydroxycarbamimidoyl)phenyl)butanoate
Figure imgf000046_0003
Obtained (100% yield) from Preparation 43 following the general method 1. LRMS: m/z 237 (M+H)+ Retention time: 3.39min (Method B) Preparation 42
Methyl 4-(4-cyanophenyl)butanoate
Figure imgf000047_0001
Obtained (99% yield) from Preparation 44 following the experimental procedure described for Preparation 38.
LRMS: no signal
Retention time: 5.70min (Method B)
Preparation 43 4-(4-cyanophenyl)butanoic acid
Figure imgf000047_0002
4(4-iodophenyl)butanoic acid (0.5 g, 1.72mmol) was dissolved in DMF (5mL) and dicyanozinc (0.25g, 2.09mmol) and Pd(PPh3J4 (0.22g, 0.19mmol) were added. The mixture was heated under nitrogen atmosphere at 12O0C for 2h. The mixture was filtered through Decalite and washed with ethyl acetate and water. 2N NaOH was added and the organic layer separated. The aqueous phase was acidified with 5N HCI and extracted twice with ethyl acetate. This organic layer was washed with water, brine, dried over magnesium sulphate and concentrated to give an oil as the title compound. Yield=83%.
LRMS: m/z 188 (M-H)"
Retention time: 5.08min (Method B)
Preparation 44
Tert-butyl 6-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1,2,4-oxadiazol-3- yl)-1,2,3,4-tetrahydronaphthalen-2-ylcarbamate
Figure imgf000047_0003
Obtained (55% yield) from Preparation 46 and Preparation 28 following the general method 2. LRMS: m/z 475 (M+H)+ Retention time: 7.93min (Method B)
Preparation 45
(Z)-fert-butyl 6-(N'-hydroxycarbamimidoyl)-1,2,3,4-tetrahydronaphthalen-2- ylcarbamate
Figure imgf000048_0001
Obtained (100% yield) from Preparation 47 following the general method 1.
LRMS: m/z 306 (M+1 )+
Retention time: 4.09min (Method B)
Preparation 46 ferf-butyl 6-cyano-1 ,2,3,4-tetrahydronaphthalen-2 -ylcarbamate
Figure imgf000048_0002
Obtained (79% yield) from Preparation 48 following the experimental procedure described for Preparation 44. LRMS: m/z 273 (M+1 )+ Retention time: 6.31 min (Method B)
Preparation 47 Terf-butyl 6-bromo-1, 2, 3,4-tetrahydronaphthalen-2 -ylcarbamate
Figure imgf000048_0003
A mixture of Preparation 49 (1.31g, 5.79mmol), BOC2O (1.39g, 6.37mmol) and Et3N (1.21mL, 8.68mmol) in DCM (10OmL) was stirred at r.t. overnight. The reaction was diluted with DCM, washed with saturated aqueous NaHCO3, dried over magnesium sulphate and concentrated in vacuo to afford the crude material, 1.91g of a grey solid (99% yield).
LRMS: m/z 326, 328 (M+1 )+
Retention time: 7.14min (Method B)
Preparation 48
6-bromo-1 ,2,3,4-tetrahydronaphthalen-2-amine
Figure imgf000049_0001
To a solution of the 6-bromo 2-tetralone (2g, 8.89mmol) and NH4OAc (5.52g,
71.61 mmol) in MeOH (100 ml.) was added NaCNBH3 (0.67g, 10.66mmol) at room temperature. The resulting yellow solution was stirred at that temperature for 20 hours. The reaction mixture was acidified with 2 M HCI, stirred for 10min and methanol evaporated. The mixture was extracted with CH2CI2 twice. The aqueous layer was basified with 1.0 N NaOH to pH 10 then extracted with CH2CI2 two times. The extracts are dried over anhydrous MgSO4 and concentrated in vacuo to afford 1.31 g
(65percent yield) of the desired product as a yellow oil which is used without further purification.
LRMS: m/z 226.1 (M+H)+, 209 (M+H- NH3)+. Retention time: 3.84min (Method B)
1 H NMR (300 MHz, CD3OD) δ 7.27-7.35 (m, 8H), 7.05 (d, J = 8.4 Hz1 4H), 3.56 (m, IH), 3.17 (dd, J = 3.9, 16.2 Hz, IH), 2.95 (m, 2H), 2.81 (dd, J = 9.9, 16.2 Hz, IH), 2.19-2.29 (m, IH), 1.79-1.92 (m, IH)
Preparation 49
Ethyl 2-(6-(5-(7,7-dimethyl-5,6,7>8-tetrahydroisoquinolin-4-yl)-1,2,4-oxadiazol-3- yl)-1,2,3,4-tetrahydronaphthalen-2-ylamino)acetate
Figure imgf000049_0002
A mixture of Example 18 (172mg, 0.46mmol), ethyl 2-oxoacetate (146Dl, 0.74mmol) and AcOH (239μl, 4.18mmol) in methanol (5ml_) was stirred at room temperature for 1 h. Then NaBH3CN (20mg, 0.32mmol) was added and the reaction mixture stirred at r.t. overnight. Solvent was concentrated and the residue dissolved in ethyl acetate, washed with water and brine, dried over magnesium sulphate, filtered and concentrated. The crude obtained was purified according the General purification method to give the desired compound (50% yield).
LRMS: m/z 461 (M+H)+
Retention time: 5.74min (Method B) Preparation 50
3-(4-allyl-3,5-dimethylphenyl)-5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-
1,2,4-oxadiazole
Figure imgf000050_0001
Obtained (55% yield) from Preparation 28 and Preparation 52 following the general method 2.
LRMS: m/z 374 (M+H)+
Retention time: 8.46min (Method B)
Preparation 51 (Z)-4-allyl-N'-hydroxy-3,5-dimethylbenzimidamide
Figure imgf000050_0002
Obtained (69% yield) from Preparation 53 following the general method 1. LRMS: m/z 205 (M+H)+ Retention time: 4.07min (Method B)
Preparation 52 4-allyl-3,5-dimethylbenzonitrile
Figure imgf000050_0003
To a solution of Preparation 18 (5g, 14.74mmol) in DMF (175mL) under nitrogen atmosphere, was added allyltributylstannane (5.5OmL, 17.74mmol) and Pd(PPh3)4 (1.71g, 1.48mmol) and the mixture stirred overnight at 9O0C. The reaction mixture was poured over ice/water and ethyl acetate was added. The mixture was filtered over Decalite and the organic layer separated, washed with water and brine, dried over magnesium sulphate and concentrated. The crude obtained was used without further purification (80% yield). LRMS: no signal
Retention time: 6.69min (Method B)
Preparation 53
2-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1,2,4-oxadiazol-3-yl)-2,6- dimethylphenyl)acetaldehyde
Figure imgf000051_0001
To a solution of example 22 (660mg, 1.62mmol) in methanol (18ml_) and water (2ml_) was added NaIO4 (520mg, 2.05mmol) and the mixture stirred overnight at room temperature. Methanol was concentrated and the residue dissolved in ethyl acetate and water. Organic layer was separated, washed with water and brine, dried over magnesium sulphate and concentrated to give the title compound (87% yield). LRMS: m/z 376 (M+H)+ Retention time: 6.12min (Method B)
Preparation 54 methyl 3-(5-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1,2,4-oxadiazol-3- yl)-3-ethyl-6-methylpyridin-2-yl)propanoate
Figure imgf000051_0002
Obtained (60% yield) from Preparation 28 and Preparation 56 following the general method 2.
LRMS: m/z 435 (M+1 )+
Retention time: 7.72 min (Method B)
Preparation 55
(Z)-methyl 3-(3-ethyl-5-(N'-hydroxycarbamimidoyl)-6-methylpyridin-2- yl)propanoate
Figure imgf000051_0003
Obtained (51% yield) from Preparation 57 and Preparation following the general method 1.
LRMS: m/z 266 (M+1 )+
Retention time: 3.00 min (Method B)
Preparation 56
Methyl 3-(5-cyano-3-ethyl-6-methylpyridin-2-yl)propanoate
Figure imgf000052_0001
To a solution of Preparation 58 (100mg, 0,43mmol) in MeOH (4mL) was added Pd/C in catalytic quantity and submitted under hydrogen atmosphere at atmospheric pressure for 30min. After filtration of the catalyst and concentration 94 mg of the desired compound were obtained as a solid (86% yield). LRMS: m/z 233 (M+1 )+ Retention time: 5.73 min (Method B)
Preparation 57
(E)-Methyl 3-(5-cyano-3-ethyl-6-methylpyridin-2-yl)acrylate
Figure imgf000052_0002
Obtained (44% yield) from Preparation 59 and methyl acrylate following the experimental procedure described for Preparation 19. LRMS: m/z 231 (M+1 )+ Retention time: 6.20 min (Method B)
Preparation 58 6-bromo-5-ethyl-2-methylnicotinonitrile
Figure imgf000052_0003
A mixture of δ-ethyl-e-hydroxy^-methylnicotinonitrile (1 ,1g, 6,8mmol), phosphoryl tribromide (2g, 7mmol) and tribromophosphine (0,7mL, 7,4mmol) was stirred at 1200C for 3h. The resulting mixture was slowly added to a mixture of ice and water. DCM was added and then washed with water and brine. The organic layer was dried over magnesium sulphate and concentrated to yield 1 ,53g of the desired compound as a solid (94% yield).
LRMS: m/z 225, 227 (M+1 )+
Retention time: 3.08 min (Method A)
Preparation 59
Terf-butyl 3-(2-chloro-4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1,2,4- oxadiazol-3-yl)phenylsulfonamido)propanoate
Figure imgf000053_0001
Obtained (52% yield) from Preparation 28 and Preparation 61 following the general method 2.
LRMS: m/z 547, 549 (M+1 )+ Retention time: 7.73min (Method B)
Preparation 60
(Z)-Tert-butyl 3-(2-chloro-4-(N'-hydroxycarbamimidoyl)phenylsulfonamido) propanoate
Figure imgf000053_0002
Obtained (98% yield) from Preparation 62 following the general method 1. LRMS: m/z 378, 380 (M+1 )+
Retention time: 5.12min (Method B)
Preparation 61 tert-butyl 3-(2-chloro-4-cyanophenylsulfonamido)propanoate
Figure imgf000054_0001
To a mixture of tert-butyl 3-aminopropanoate hydrochloride (1.54g, 8.48mmol) and triethylamine (2.48ml_, 17.79mol) in DCM (25mL) was added 2-chloro-4- cyanobenzene-1-sulfonyl chloride (2,Og, 8.47mmol) slowly and the reaction mixture stirred for 3h at room temperature. Reaction mixture was diluted with ethyl acetate and washed with water and brine. Organic layer was dried over magnesium sulphate, filtered and concentrated to give the title compound as an oil (100% yield).
LRMS: m/z 362, 364 (M+17)+
Retention time: 6.10min (Method B)
Preparation 62
Tert-butyl 3-(4-(5-(7J-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1,2,4-oxadiazol-
3-yl)phenylsulfonamido)propanoate
Figure imgf000054_0002
Obtained (91% yield) from Preparation 28 and Preparation 64 following the general method 2.
LRMS: m/z 513 (M+1 )+
Retention time: 7.55min (Method B)
Preparation 63
(Z)-Terf-butyl 3-(4-(N'-hydroxycarbamimidoyl)phenylsulfonamido)propanoate
HO
Figure imgf000054_0003
Obtained (74% yield) from Preparation 65 following the general method 1. LRMS: m/z 344 (M+1 )+ Retention time: 4.55min (Method B)
Preparation 64
Tert-butyl 3-(4-cyanophenylsulfonamido)propanoate
Figure imgf000055_0001
Obtained (57% yield) from 4-cyanobenzene-1-sulfonyl chloride following the experimental procedure described for Preparation 62.
LRMS: m/z 309 (M-I )-
Retention time: 5.88min (Method B)
Preparation 65
4-(3-(4-allyl-3,5-dimethylphenyl)-1 ,2,4-oxadiazol-5-yl)-7,7-dimethyl-5,6,7,8- tetrahydroisoquinolin-1 -amine
Figure imgf000055_0002
Obtained (22% yield) from Preparation 67 and Preparation 52 following the general method 2.
LRMS: m/z 389 (M+H)+
Retention time: 7.92min (Method B)
Preparation 66 1-amino-7,7-dimethyl-5,6,7,8-tetrahydroisoquinoline-4-carboxylic acid
Figure imgf000055_0003
Obtained (80% yield) from Preparation 68 following the experimental procedure described for Preparation 6. LRMS: m/z 221 (M+H)+
Retention time: 3.64min (Method B)
Preparation 67 1-amino-7,7-dimethyl-5,6,7,8-tetrahydroisoquinoline-4-carbonitrile
Figure imgf000056_0001
Obtained (56% yield) from Preparation 69 following the experimental procedure described for Preparation 5 and purified according the General purification method.
LRMS: m/z 202 (M+H)+
Retention time: 4.97min (Method B)
Preparation 68 i-amino-S-chloro^J-dimethyl-S.βJ.δ-tetrahydroisoquinoline^-carbonitrile
Figure imgf000056_0002
In a pressure reactor Preparation 3 (1.0g, 3.92mmol) was dissolved in 7N ammonia in methanol. The reaction mixture was stirred at 600C for 16h. Solvent was evaporated and the residue redissolved in ethyl acetate, washed with water and brine, dried over magnesium sulphate and concentrated. The title compound was obtained as a solid (52% yield). LRMS: m/z 236, 238 (M+H)+
Retention time: 6.17min (Method B)
Preparation 69
Methyl 4-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1,2,4-oxadiazol-3- yl)-2,6-dimethylphenyl)butanoate
Figure imgf000056_0003
Obtained (14% yield) from Preparation 28 and Preparation 71 following the general method 2.
LRMS: m/z 434 (M+H)+
Retention time: 7.92min (Method B)
Preparation 70
(Z)-Methyl 4-(4-(N'-hydroxycarbamimidoyl)-2,6-dimethylphenyl)butanoate
Figure imgf000057_0001
Obtained (30% yield) from Preparation 72 following the experimental procedure described for Preparation 21. LRMS: m/z 265 (M+1 )+ Retention time: 4.03min (Method B)
Preparation 71 (E)-Methyl 4-(4-((Z)-N'-hydroxycarbamimidoyl)-2,6-dimethylphenyl)but-2-enoate
Figure imgf000057_0002
Obtained (74% yield) from Preparation 73 following the general method 1. LRMS: m/z 263 (M+1 )+ Retention time: 4.01 min (Method B)
Preparation 72
(E)-Methyl 4-(4-cyano-2,6-dimethylphenyl)but-2-enoate
Figure imgf000057_0003
Obtained (30% yield) from Preparation 74 following the experimental procedure described for Preparation 38. LRMS: no signal
Retention time: 6.20 min (Method B)
Preparation 73 (E)-4-(4-cyano-2,6-dimethylphenyl)but-2-enoic acid
Figure imgf000058_0001
Obtained (30% yield) from Preparation 75 following the experimental procedure described for Preparation 40.
LRMS: m/z 214 (M-I )-
Retention time: 5.65 min (Method C)
Preparation 74 3,5-dimethyl-4-(2-oxoethyl)benzonitrile
Figure imgf000058_0002
Obtained (90% yield) from Preparation 53 following the experimental procedure described for Example 22 and then following the experimental procedure described for Preparation 54.
LRMS: m/z 174 (M+1 )+
Retention time: 5.23 min (Method C)
Preparation 75
2-(4-(5-(1-amino-7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1,2,4-oxadiazol-
3-yl)-2,6-dimethylphenyl)acetaldehyde
Figure imgf000058_0003
Obtained (92% yield) from Example 29 following the experimental procedure described for Preparation 54.
LRMS: m/z 391 (M+1 )+
Retention time: 6.78 min (Method C)
PREPARATION 76
4-(3-(4-allyl-3,5-dimethylphenyl)-1 ,2,4-oxadiazol-5-yl)-N,7,7-trimethyl-5,6,7,8- tetrahydroisoquinolin-1 -amine
Figure imgf000059_0001
Obtained (48% yield) from Preparation 77 and Preparation 51 following General Method 2.
LRMS: m/z 403 (M+1 )+
Retention time: 8.18 min (Method B)
PREPARATION 77
7,7-dimethyl-1-(methylamino)-5,6,7,8-tetrahydroisoquinoline-4-carboxylic acid
Figure imgf000059_0002
A suspension of Preparation 78 (5.7 g, 26.5 mmol) in concentrated HCI (75 mL) was heated overnight at 1450C in a preassure reactor. Solvent was removed and the crude obtained was resuspended in AcOEt, filtered and recristallized in EtOH to yield the title compound as the hydrochloride salt (89%). LRMS: m/z 235 (M+1 )+ Retention time: 3.60 min (Method B)
1H NMR (300 MHz, METHANOL-Qf4) δ ppm 1.05 (s, 6 H) 1.60 (t, J=6.04 Hz, 2 H) 2.26 (s, 2 H) 3.13 (s, 3 H) 3.21 (t, 2 H) 8.33 (s, 0 H).
PREPARATION 78 7,7-dimethyl-1-(methylamino)-5,6,7,8-tetrahydroisoquinoline-4-carbonitrile
Figure imgf000060_0001
Obtained (87%) from Preparation 79 following the procedure described in Preparation 5.
LRMS: m/z 216 (M+1 )+
Retention time: 5.43 min (Method B)
1H NMR (300 MHz, CHLOROFORM-cQ δ ppm 1.02 (s, 6 H) 1.58 (t, J=6.59 Hz, 2
H) 2.04 (s, 2 H) 2.82 (t, J=6.45 Hz, 2 H) 3.07 (d, J=4.67 Hz, 3 H) 4.70 (br. s., 1
H) 8.28 (s, 1 H).
PREPARATION 79
3-chloro-7,7-dimethyl-1-(methylamino)-5,6,7,8-tetrahydroisoquinoline-4- carbonitrile
Figure imgf000060_0002
Obtained (81 %) from Preparation 3 following the procedure described in Preparation 68 using methylamine 2M in THF and stirring at r.t.
LRMS: m/z 250 (M+ 1 )+
Retention time: 6.57 min (Method B)
1H NMR (300 MHz, CHLOROFORM-αf) δ ppm 1.02 (s, 6 H) 1.58 (t, J=6.73 Hz, 2
H) 2.02 (s, 2 H) 2.81 (t, 2 H) 3.07 (d, J=3.57 Hz, 2 H) 4.82 (br. s., 1 H).
PREPARATION 80
2-(4-(5-(7,7-dimethyl-1-(methylamino)-5,6,7,8-tetrahydroisoquinolin-4-yl)-1,2,4- oxadiazol-3-yl)-2,6-dimethylphenyl)acetaldehyde
Figure imgf000060_0003
Obtained (99%) from Example 33 following the procedure described in Preparation 53. LRMS: m/z 405 (M+1 )+ Retention time: 7.06 min (Method B) PREPARATION 81 terf-Butyl 2-(4-(5-(7,7-dimethyl-1-(methylamino)-5,6)7,8-tetrahydroisoquinolin-4- yl)-1,2,4-oxadiazol-3-yl)-2,6-dimethylphenoxy)ethylcarbamate
Figure imgf000061_0001
In a microwave vial the title compound of Preparation 82 (121 mg, 0.32 mmol), tert- butyl 2-hydroxyethylcarbamate (84 μl_, 0.54 mmol), triphenylphosphine (117 mg, 0.45 mmol) and DIAD (88 μl_, 0.45 mmol) were dissolved in anhydrous THF (2 ml_). Mixture was stirred at 8O0C for 2 h and then solvent was removed, crude redissolved in DCM, washed with water and brine, dried and concentrated. The residue was purified according to General Purification method to yield the title compound (56%).
LRMS: m/z 522 (M+1)+
Retention time: 7.75 min (Method B)
1H NMR (300 MHz, CHLOROFORM-cQ δ ppm 1.07 (s, 6 H) 1.48 (s, 9 H) 1.62 (t, J=6.87 Hz, 2 H) 2.12 (s, 2 H) 2.36 (s, 6 H) 3.12 (d, J=4.94 Hz, 3 H) 3.22 (t,
J=6.32 Hz, 2 H) 3.42 - 3.66 (m, 2 H) 3.89 (t, J=4.94 Hz, 2 H) 7.82 (s, 2 H) 8.86
(s, 1 H).
PREPARATION 82
4-(5-(7,7-dimethyI-1-(methylamino)-5,6,7,8-tetrahydroisoquinolin-4-yl)-1,2,4- oxadiazol-3-yl)-2,6-dimethylphenol
Figure imgf000061_0002
Obtained (58%) from Preparation 83 and Preparation 77 following General Method 2. LRMS: m/z 379 (M+1 )+ Retention time: 6.82 min (Method B)
PREPARATION 83 N',4-dihydroxy-3,5-dimethylbenzimidamide
Figure imgf000062_0001
Obtained (75%) from 4-hydroxy-3,5-dimethylbenzonitrile following General Method 1.
LRMS: m/z 181 (M+1 )+
Retention time: 1.80 min (Method B)
PREPARATION 84
^(a^-allyl-a.S-dimethylphenyO-I^.A-oxadiazol-S-yO-N.NJJ-tetramethyl-S.ej.β- tetrahydroisoquinolin-1 -amine
Figure imgf000062_0002
Obtained (15% yield) from Preparation 85 and Preparation 51 following General Method 2.
LRMS: m/z 417 (M+1 )+
Retention time: 22.02 min (Method C)
PREPARATION 85
1-(dimethylamino)-7,7-dimethyl-5,6,7,8-tetrahydroisoquinoline-4-carboxylic acid
Figure imgf000062_0003
Obtained (63%) from Preparation 86 following the procedure described in Preparation 6. LRMS: m/z 249 (M+1 )+
Retention time: 4.50 min (Method B)
PREPARATION 86 1-(dimethylamino)-7,7-dimethyl-5,6,7,8-tetrahydroisoquinoline-4-carbonitrile
Figure imgf000063_0001
Obtained (93%) from Preparation 87 following the procedure described in Preparation 5.
LRMS: m/z 230 (M+1 )+
Retention time: 6.77 min (Method B)
PREPARATION 87
3-chloro-1-(dimethylamino)-7,7-dimethyl-5,6,7,8-tetrahydroisoquinoline-4- carbonitrile
Figure imgf000063_0002
Obtained (37%) from Preparation 3 following the procedure described in Preparation 68 using dimethylamine 2M in THF and stirring at r.t.
LRMS: m/z 264 (M+1 )+
Retention time: 7.31 min (Method B)
EXAMPLES
EXAMPLE 1
(4-(5-(1-ethyl-7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1,2,4-oxadiazol-3- yl)phenyl)methanol
Figure imgf000063_0003
Obtained (11% yield) from Preparation 6 and Preparation 10 following the general method 2. LRMS: m/z 364 (M+1)+ Retention time: 19.07 min (Method C)
1 H NMR (400 MHz, CDCI3) δ ppm 1.1 (s, 6 H) 1.3 (t, J=7.4 Hz, 3 H) 1.6 (m, 2 H) 2.6 (s, 2 H) 2.9 (q, J=7.4 Hz, 2 H) 3.3 (t, J=6.7 Hz, 2 H) 4.8 (d, J=2.3 Hz, 2 H) 7.5 (d, J=8.2 Hz, 2 H) 8.2 (d, J=8.2 Hz, 2 H) 9.1 (s, 1 H)
EXAMPLE 2
4-(5-(1-ethyl-7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1,2,4-oxadiazol-3- yl)benzenesulfonamide
Figure imgf000064_0001
Obtained (4% yield) from Preparation 6 and Preparation 11 following the general method 2.
LRMS: m/z 364 (M+1 )+
Retention time: 19.07 min (Method C)
1 H NMR (200 MHz, DMSO-D6) δ ppm 1.0 (s, 6 H) 1.2 (t, J=7.2 Hz, 3 H) 1.6 (t, J=6.8 Hz, 2 H) 2.6 (s, 2 H) 2.8 (q, J=7.2 Hz, 2 H) 3.2 (m, 2 H) 8.0 (d, J=8.6 Hz,
2 H) 8.3 (d, J=8.6 Hz, 2 H) 9.0 (s, 1 H).
EXAMPLE 3
3-(4-(4-(5-(1-ethyl-7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol- 3-yl)phenyl)piperazin-1-yl)propanoic acid
Figure imgf000064_0002
Obtained (81 % yield) from Preparation 14 following the general method 3. LRMS: m/z 490 (M+1 )+ Retention time: 15.94 min (Method C)
1H NMR (400 MHz, DMSO-D6) δ ppm 1.0 (m, J=3.9 Hz, 6 H) 1.2 (t, J=7.4 Hz, 3 H) 1.6 (q, 2 H) 2.4 (t, J=7.0 Hz, 2 H) 2.6 (m, 2 H) 2.6 (t, J=7.0 Hz, 2 H) 2.8 (q, J=7.4 Hz, 2 H) 3.2 (m, J=6.5, 6.5 Hz, 2 H) 3.3 (m, 8 H) 7.1 (d, J=8.6 Hz, 2 H) 7.9 (d, J=8.6 Hz, 2 H) 8.9 (s, 1 H) EXAMPLE 4
3-(4-(5-(1-ethyl-7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1,2,4-oxadiazol-3- yl)phenylsulfonamido)propanoic acid
Figure imgf000065_0001
Obtained (5%) from Preparation 17 following the general method 3 and after the General purification method.
LRMS: m/z 485 (M+1 )+
Retention time: 18.67 min (Method C)
1 H NMR (200 MHz, CDCI3) δ ppm 0.9 (m, 2 H) 1.0 (s, 6 H) 1.4 (m, 3 H) 1.6 (d,
J=7.0 Hz, 2 H) 2.3 (m, 2 H) 2.5 (s, 2 H) 2.9 (m, 2 H) 3.3 (m, 2 H) 8.0 (d, J=8.2
Hz, 2 H) 8.3 (d, J=8.2 Hz, 2 H) 9.1 (s, 1 H)
EXAMPLE 5
3-(4-(5-(1-ethyl-7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1,2,4-oxadiazol-3- yl)-2,6-dimethylphenyl)propanoic acid
Figure imgf000065_0002
Obtained (75%) from Preparation 22 following the general method 3. LRMS: m/z 434 (M+1 )+ Retention time: 20.70 min (Method C)
1H NMR (400 MHz1 DMSO-D6) δ ppm 1.0 (s, 6 H) 1.2 (t, J=7.4 Hz, 3 H) 1.6 (t, J=6.3 Hz, 2 H) 2.4 (s, 6 H) 2.6 (s. 2 H) 2.8 (q, J=7A Hz, 2 H) 2.9 (m, 2 H) 3.2 (d, J=5.9 Hz, 2 H) 3.3 (s, 2 H) 7.7 (s, 2 H) 9.0 (s, 1 H) 12.3 (s, 1 H)
EXAMPLE 6
3-(4-(5-(1-ethyl-7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3- yl)-2,6-dimethylphenyl)propanamide
Figure imgf000065_0003
Obtained (45% yield) from Example 5 following the general method 5. LRMS: m/z 433 (M+1 )+ Retention time: 19.95 min (Method C)
1 H NMR (200 MHz, DMSO-D6) δ ppm 1.0 (m, 6 H) 1.2 (t, J=7.4 Hz, 3 H) 1.6 (t, J=6.4 Hz, 2 H) 2.2 (dd, J=10.0, 6.8 Hz, 2 H) 2.4 (s, 6 H) 2.6 (s, 2 H) 2.8 (m, 4 H) 3.2 (t, J=6.1 Hz, 2 H) 6.9 (s, 1 H) 7.4 (s, 1 H) 7.7 (s, 2 H) 9.0 (s, 1 H)
EXAMPLE 7
2-(4-(5-(1-ethyl-7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1,2,4-oxadiazol-3- yl)-2,6-dimethylphenyl)ethanamine
Figure imgf000066_0001
Obtained (26% yield) from Example 5 following the general method 6. LRMS: m/z 405 (M+1 )+ Retention time: 14.51 min (Method C)
1H NMR (200 MHz, CDCI3) δ ppm 1.1 (s, 6 H) 1.3 (t, J=7.6 Hz, 3 H) 1.6 (t, J=6.6 Hz, 2 H) 1.7 (s, 2 H) 2.5 (s, 6 H) 2.5 (s, 2 H) 2.9 (m, 5 H) 3.3 (m, 3 H) 7.8 (s, 2 H) 9.1 (s, 1 H).
EXAMPLE 8
S-t^S^I-cyclopropyl-yj-dimethyl-S.ΘJ.δ-tetrahydroisoquinolin^-yO-i^^- oxadiazol-3-yl)-2,6-dimethylphenyl)propanoic acid
Figure imgf000066_0002
Obtained (90% yield) from Preparation 26 following the general method 4. LRMS: m/z 446 (M+1 )+ Retention time: 21.77 min (Method C)
1H NMR (200 MHz, DMSO-D6) δ ppm 1.1 (m, 4 H) 1.0 (s, 6 H) 1.6 (t, J=6.1 Hz, 2 H) 2.3 (m, 3 H) 2.4 (s, 6 H) 2.7 (s, 2 H) 2.9 (m, 2 H) 3.2 (t, J=6.1 Hz, 2 H) 7.7 (s, 2 H) 8.9 (s, 1 H) EXAMPLE 9
3-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3-yl)-2,6- dimethylphenyl)propanoic acid
Figure imgf000067_0001
Obtained (88%) from Preparation 29 following the general method 4. LRMS: m/z 406 (M+1 )+ Retention time: 19.75 min (Method C)
1H NMR (200 MHz, DMSO-D6) δ ppm 1.0 (s, 6 H) 1.7 (t, J=6.6 Hz, 2 H) 2.4 (m, 2 H) 2.4 (s, 6 H) 2.7 (s, 2 H) 2.9 (dd, J=9.8, 7.0 Hz, 2 H) 3.3 (t, J=6.4 Hz, 2 H) 7.7 (s, 2 H) 8.6 (s, 1 H) 9.1 (s, 1 H)
EXAMPLE 10
2-(4-(5-(1-cyclopropyl-7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1,2,4- oxadiazol-3-yl)-2,6-dimethylphenyl)ethanamine
Figure imgf000067_0002
Obtained (20% yield) from Example 8 following the general method 6. LRMS: m/z 416 (M+1 )+ Retention time: 15.62 min (Method C)
1H NMR (200 MHz, CDCI3) δ ppm 1.1 (m, 4 H) 1.1 (s, 6 H) 1.6 (t, J=6.6 Hz, 2 H) 2.1 (m, 1 H) 2.4 (s, 6 H) 2.7 (s, 2 H) 3.1 (m, 3 H) 3.3 (t, J=6.4 Hz, 2 H) 3.7 (m, 1 H) 4.5 (s, 2 H) 7.8 (s, 2 H) 8.9 (s, 1 H)
EXAMPLE 1 1
2-(4-(5-(7>7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1,2,4-oxadiazol-3-yl)-2,6- dimethylphenyl)ethanamine
Figure imgf000067_0003
Obtained (43% yield) from Example 9 following the general method 6. LRMS: m/z 377 (M+1)+ Retention time: 12.90 min (Method C)
1H NMR (200 MHz, CDCI3) δ ppm 1.0 (s, 6 H) 1.7 (m, 2 H) 2.5 (s, 6 H) 2.6 (s, 2
H) 2.9 (s, 4 H) 3.3 (t, J=6.6 Hz, 2 H) 7.8 (s, 2 H) 8.5 (s, 1 H) 9.1 (s, 1 H)
EXAMPLE 12
3-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1,2,4-oxadiazol-3-yl)-3- methylphenyl)propanoic acid
Figure imgf000068_0001
Obtained (65% yield) from Preparation 34 following the general method 3. LRMS: m/z 392 (M+ 1 )+
Retention time: 19.18 min (Method C)
1 H NMR (400 MHz, DMSO-D6) δ ppm 1.0 (s, 6 H) 1.6 (t, J=6.7 Hz, 2 H) 2.5 (m, 2 H) 2.6 (s, 3 H) 2.6 (s, 2 H) 2.9 (t, J=7.4 Hz, 2 H) 3.2 (t, J=6.7 Hz, 2 H) 7.3 (d, J=8.2 Hz, 1 H) 7.3 (s, 1 H) 7.9 (d, J=8.2 Hz, 1 H) 8.5 (s, 1 H) 9.0 (s, 1 H)
EXAMPLE 13
2-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1,2,4-oxadiazol-3-yl)-3- methylphenyl)ethanamine
Figure imgf000068_0002
Obtained (22% yield) from Example 12 following the general method 6.
LRMS: m/z 363 (M+ 1 )+
Retention time: 12.41 min (Method C)
1 H NMR (200 MHz, DMSO-D6) δ ppm 1.0 (s, 6 H) 1.7 (t, J=6.1 Hz, 2 H) 2.6 (s,
3 H) 2.7 (s, 2 H) 3.0 (m, 4 H) 3.3 (t, J=5.9 Hz, 2 H) 7.3 (m, 2 H) 8.0 (d, J=7Λ Hz, 2 H) 8.1 (bs, NH3 +) 8.6 (s, 1 H) 9.1 (s, 1 H)
EXAMPLE 14
2-(3-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1,2,4-oxadiazol-3-yl)- 2,6-dimethylphenyl)propanamido)ethanoic acid
Figure imgf000069_0001
Obtained (78% yield) from Preparation 35 following the general method 4. LRMS: m/z 463 (M+1 )+ Retention time: 18.46 min (Method C)
1 H NMR (200 MHz1 DMSO-D6) δ ppm 1.0 (s, 6 H) 1.7 (m, 2 H) 2.3 (m, 2 H) 2.4 (s, 6 H) 2.7 (S, 2 H) 2.9 (m, 2 H) 3.3 (m, 2 H) 3.8 (d, J=5.9 Hz, 2 H) 7.7 (s, 1 H) 8.3 (m, 1 H) 8.6 (s, 1 H) 9.1 (s, 1 H)
EXAMPLE 15
3-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1,2,4-oxadiazol-3- yl)phenyl)propanoic acid
Figure imgf000069_0002
Obtained (80% yield) from Preparation 36 following the general method 3. LRMS: m/z 378 (M+1 )+ Retention time: 18.61 min (Method C)
1 H NMR (200 MHz, DMSO-D6) δ ppm 1.0 (s, 6 H) 1.6 (t, J=6.6 Hz, 2 H) 2.5 (m, J=2.0 Hz, 2 H) 2.6 (m, J=7.4 Hz, 2 H) 2.9 (m, J=7.8 Hz, 2 H) 3.2 (t, J=6.4 Hz, 2 H) 7.5 (d, J=7.8 Hz, 2 H) 8.0 (d, J=8.2 Hz, 2 H) 8.5 (s, 1 H) 9.0 (s, 1 H)
EXAMPLE 16
4-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1,2,4-oxadiazol-3- yl)phenyl)butanoic acid
Figure imgf000070_0001
Obtained (41% yield) from Preparation 41 following the general method 3. LRMS: m/z 392(M+1 )+ Retention time: 19.31 min (Method C)
1 H NMR (200 MHz, DMSO-D6) δ ppm 1.0 (s, 6 H) 1.7 (m, 2 H) 1.8 (m, 2 H) 2.3 (t, J=7A Hz, 2 H) 2.7 (s, 2 H) 2.7 (m, 2 H) 3.3 (m, 2 H) 7.4 (d, J=8.2 Hz, 2 H) 8.0 (d, J=8.2 Hz, 2 H) 8.6 (s, 1 H) 9.1 (s, 1 H)
EXAMPLE 17
2-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3- yl)phenyl)ethanamine
Figure imgf000070_0002
Obtained (47% yield) from Example 15 following the general method 6. LRMS: m/z 349 (M+1 )+ Retention time: 11.69 min (Method C)
1 H NMR (200 MHz, DMSO-D6) δ ppm 1.0 (m, 6 H) 1.7 (t, J=6.4 Hz, 2 H) 2.7 (s, 2 H) 3.0 (m, J=12.9 Hz, 4 H) 3.3 (d, J=6Λ Hz, 2 H) 7.5 (d, J=8.2 Hz, 2 H) 8.1 (d, J=8.2 Hz, 2 H) 8.2 (s, 2 H) 8.6 (s, 1 H) 9.1 (s, 1 H)
EXAMPLE 18
6-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3-yl)-1 ,2,3,4- tetrahydronaphthalen-2-amine
Figure imgf000070_0003
Obtained (62% yield) from Preparation 45 following the general method 4. In this case the fumarate salt was isolated by dissolving the free base with dioxane and adding 1 eq of fumaric acid. The mixture was stirred overnight at r.t. The solid was filtered off and washed with dioxane.
LRMS: m/z 375 (M+1 )+
Retention time: 12.25 min (Method C)
1 H NMR (400 MHz, DMSO-D6) δ ppm 1.0 (m, 6 H) 1.6 (t, J=6.5 Hz, 2 H) 1.8 (m,
J=11.7, 5.5 Hz, 2 H) 2.1 (s, 2 H) 2.6 (s, 2 H) 2.9 (m, 5 H) 3.2 (m, 2 H) 7.4 (d,
J=8.2 Hz, 1 H) 7.9 (m, 2 H) 8.5 (s, 1 H) 9.0 (s, 1 H)
EXAMPLE 19
3-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1,2,4-oxadiazol-3-yl)-2,6- dimethylphenyl)propanamide
Figure imgf000071_0001
Obtained (44% yield) from Example 9 following the general method 5. LRMS: m/z 405 (M+1 )+ Retention time: 18.28 min (Method C)
1 H NMR (200 MHz, DMSO-D6) δ ppm 1.0 (s, 6 H) 1.7 (m, 2 H) 2.2 (m, 2 H) 2.4 (s, 6 H) 2.7 (s, 2 H) 2.9 (m, 2 H) 3.3 (m, 2 H) 7.1 (d, J=108.1 Hz, 2 H) 7.7 (s, 2 H) 8.7 (s, 1 H) 9.1 (s, 1 H)
EXAMPLE 20
2-(6-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1,2,4-oxadiazol-3-yl)- 1 ,2,3,4-tetrahydronaphthalen-2-ylamino)ethanoic acid
Figure imgf000071_0002
Obtained (42% yield) from Preparation 50 following the general method 3. LRMS: m/z 433 (M+1 )+ Retention time: 14.98 min (Method C) 1 H NMR (400 MHz, DMSO-D6) δ ppm 1.0 (s, 6 H) 1.6 (t, J=6.3 Hz, 2 H) 2.2 (s, 2 H) 2.6 (s, 2 H) 2.9 (m, 3 H) 3.0 (m, J=16.4 Hz, 2 H) 3.2 (m, 2 H) 3.3 (s, 2 H) 7.3 (d, J=7.4 Hz, 1 H) 7.8 (m, 2 H) 8.5 (s, 1 H) 9.0 (s, 1 H)
EXAMPLE 21
3-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1,2,4-oxadiazol-3-yl)-2,6- dimethylphenyl)propan-1 -amine
Figure imgf000072_0001
Obtained (21% yield) from Example 19 following the general method 7. LRMS: m/z 391 (M+1)+ Retention time: 13.82 min (Method C)
1 H NMR (200 MHz, DMSO-D6) δ ppm 1.0 (m, 6 H) 1.7 (m, 4 H) 2.4 (s, 6 H) 2.7 (s, 2 H) 2.7 (m, 2 H) 2.9 (m, 2 H) 3.3 (m, 2 H) 7.8 (s, 2 H) 8.0 (s, 3 H) 8.6 (s, 1 H) 9.1 (s, 1 H)
EXAMPLE 22
3-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1,2,4-oxadiazol-3-yl)-2,6- dimethylphenyl)propane-1 ,2-diol
Figure imgf000072_0002
To a solution of Preparation 51 (70mg, 0.19mmol) in a mixture of THF/tert-butanol (1.5mL/0.23mL) was added 4-methylmorpholine 4-oxide (44mg, 0.37mmol) and osmium(VIII) oxide (23 μl, 0.004mmol). The reaction mixture was stirred overnight at r.t. Then 40% solution of Na2SO3 was added and the mixture stirred for 30min. Ethyl acetate was added and the organic layer separated, washed twice with water, dried over magnesium sulphate and concentrated to give the title compound (92% yield).
LRMS: m/z 408 (M+1 )+
Retention time: 18.30 min (Method C)
1 H NMR (200 MHz, CHLOROFORM-D) δ ppm 1.1 (s, 6 H) 1.7 (t, J=6.6 Hz, 2 H)
2.4 (m, J=8.2 Hz, 6 H) 2.6 (s, 2 H) 2.9 (m, 2 H) 3.3 (t, J=6.6 Hz, 2 H) 3.7 (m, 2
H) 4.0 (m, 1 H) 7.8 (s, 2 H) 8.4 (s, 1 H) 9.0 (s, 1 H) EXAMPLE 23
N-(3-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1,2,4-oxadiazol-3-yl)-
2,6-dimethylphenyl)propyl)methanesulfonamide
Figure imgf000073_0001
To a solution of Example 21 (75mg, 0.19mmol) in DCM (1OmL) was added triethylamine (94 μL 3.51 mmol) and the mixture stirred for 5 min. Then methanesulfonyl chloride (17μL, 0.22mol) was added and the reaction mixture stirred at room temperature for 6h. Ethyl acetate was added and washed twice with water and once with brine. This organic layer was dried over magnesium sulphate and concentrated to give a white solid which was washed with diisopropyl ether and dried in the vacuum oven (66% yield).
LRMS: m/z 469 (M+1)+
Retention time: 19.47 min (Method C) 1 H NMR (200 MHz, CHLOROFORM-D) δ ppm 1.0 (s, 6 H) 1.8 (m, 4 H) 2.4 (s, 6
H) 2.6 (s, 2 H) 2.8 (m, 2 H) 3.0 (s, 3 H) 3.3 (m, 4 H) 4.4 (t, J=5.9 Hz, 1 H) 7.8 (s,
2 H) 8.5 (s, 1 H) 9.1 (s, 1 H)
EXAMPLE 24
N-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1,2,4-oxadiazol-3-yl)-2,6- dimethylphenethyl)-2,2-difluoroethanamine
Figure imgf000073_0002
Obtained (50% yield) from Preparation 54 and 2,2-difluoroethanamine following the experimental procedure described for Preparation 50 and purified by the General purification method.
LRMS: m/z 441 (M+1 )+
Retention time: 13.94 min (Method C)
1 H NMR (200 MHz, DMSO-D6) δ ppm 1.0 (s, 6 H) 1.7 (m, 2 H) 2.5 (s, 6 H) 2.7
(s, 2 H) 3.1 (m, 4 H) 3.2 (m, 2 H) 3.6 (m, 2 H) 6.5 (dd, 1 H) 7.8 (s, 2 H) 8.6 (s, 1
H) 9.1 (s, 1 H) 10.1 (s, 2 H) EXAMPLE 25
1-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3-yl)-2,6- dimethylphenethyl)azetidine-3-carboxylic acid
Figure imgf000074_0001
Obtained (60% yield) from Preparation 54 and azetidine-3-carboxylic acid following the experimental procedure described for Preparation 50 and purified by the General purification method.
LRMS: m/z 461 (M+1 )+
Retention time: 14.95 min (Method C)
1 H NMR (200 MHz, DMSO-D6) δ ppm 1.0 (s, 6 H) 1.7 (m, 2 H) 2.5 (s, J=9.4 Hz,
6 H) 2.7 (s, 2 H) 3.0 (m, 2 H) 3.3 (m, 4 H) 3.6 (s, J=3.9 Hz, 1 H) 3.7 (m, 2 H) 4.1
(m, 2 H) 7.8 (s, 2 H) 8.7 (s, 1 H) 9.1 (s, 1 H)
EXAMPLE 26
3-(5-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1,2,4-oxadiazol-3-yl)-3- ethyl-6-methylpyridin-2-yl)propanoic acid
Figure imgf000074_0002
Obtained (82% yield) from Preparation 55 following the general method 3. LRMS: m/z 421 (M+1 )+ Retention time: 18.74 min (Method C)
1 H NMR (300 MHz, CHLOROFORM-D) δ ppm 1.1 (s, 6 H) 1.3 (t, J=7.6 Hz, 3 H) 1.7 (m, J=6.6, 6.6 Hz, 2 H) 2.7 (s, 2 H) 2.8 (q, J=7.7 Hz, 2 H) 2.9 (m, 2 H) 2.9 (s, 3 H) 3.3 (m, 4 H) 8.3 (s, 1 H) 8.5 (s, 1 H) 9.2 (s, 1 H)
EXAMPLE 27
3-(2-chloro-4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1,2,4-oxadiazol- 3-yl)phenylsulfonamido)propanoic acid
Figure imgf000075_0001
Obtained (84% yield) from Preparation 60 following the general method 4. LRMS: m/z 491 , 493 (M+1 )+ Retention time: 18.02 min (Method C)
1 H NMR (200 MHz, DMSO-D6) δ ppm 1.0 (s, 6 H) 1.7 (t, J=6.4 Hz, 2 H) 2.4 (t, J=6.8 Hz1 2 H) 2.7 (s, 2 H) 3.1 (m, 2 H) 3.3 (m, J=6.6, 6.6 Hz, 2 H) 8.2 (m, 3 H) 8.6 (s, 1 H) 9.1 (S1 1 H)
EXAMPLE 28
3-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1,2,4-oxadiazol-3- yl)phenylsulfonamido)propanoic acid
Figure imgf000075_0002
Obtained (44% yield) from Preparation 63 following the general method 4. LRMS: m/z 457 (M+1 )+ Retention time: 17.17 min (Method C)
1 H NMR (200 MHz, DMSO-D6) δ ppm 1.0 (s, 6 H) 1.7 (t, J=6.4 Hz, 2 H) 2.4 (t, J=6.8 Hz, 2 H) 2.7 (s, 2 H) 3.0 (m, 2 H) 3.3 (t, J=6.4 Hz, 2 H) 7.9 (t, J=6.2 Hz, 1 H) 8.0 (d, J=8.6 Hz, 2 H) 8.3 (d, J=8.2 Hz, 2 H) 8.6 (s, 1 H) 9.1 (s, 1 H)
EXAMPLE 29
3-(4-(5-(1-amino-7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1,2,4-oxadiazol-
3-yl)-2,6-dimethylphenyl)propane-1,2-diol
Figure imgf000075_0003
Obtained (90% yield) from Preparation 66 following the experimental procedure described for Example 22.
LRMS: m/z 423 (M+1 )+ Retention time: 14.26 min (Method C)
1 H NMR (300 MHz, DMSO-D6) δ ppm 1.0 (s, 6 H) 1.6 (t, J=6.5 Hz, 2 H) 2.2 (s, 2 H) 2.4 (s, 6 H) 2.7 (dd, J=13.5, 8.8 Hz, 1 H) 2.9 (dd, J=13.7, 3.6 Hz, 1 H) 3.1 (t, J=6.3 Hz, 2 H) 3.4 (m, 4 H) 3.6 (m, 2 H) 7.3 (s, 1 H) 7.7 (s, 2 H) 8.6 (m, 1 H)
EXAMPLE 30
4-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1,2,4-oxadiazol-3-yl)-2,6- dimethylphenyl)butanoic acid
Figure imgf000076_0001
Obtained (35% yield) from Preparation 70 following the general method 3. LRMS: m/z 420 (M+1 )+ Retention time: 21 ,34 min (Method C)
1 H NMR (300 MHz, DMSO-D6) δ ppm 1.0 (s. 6 H) 1.7 (t, J=6.7 Hz, 4 H) 2.4 (m, 8 H) 2.7 (m, 4 H) 3.3 (t, J=6.5 Hz, 2 H) 7.7 (s, 2 H) 8.6 (s, 1 H) 9.1 (s, 1 H)
EXAMPLE 31
1-(4-(5-(1-amino-7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1,2,4-oxadiazol- 3-yl)-2,6-dimethylphenethyl)azetidine-3-carboxylic acid
Figure imgf000076_0002
Obtained (13% yield) from Preparation 76 and azetidine-3-carboxylic acid following the experimental procedure described for Preparation 50 and purified by General purification method.
LRMS: m/z 476 (M+1 )+
Retention time: 1 1.58 min (Method C)
1 H NMR (400 MHz, DMSO-D6) δ ppm 1.0 (s, 6 H) 1.6 (t, J=6.5 Hz, 2 H) 2.3 (s, 2 H) 2.4
(s, 6 H) 2.9 (m, 2 H) 3.2 (m, 2 H) 3.7 (m, 1 H) 4.2 (m, 6 H) 7.7 (s, 2 H) 8.6 (s, 1 H) 11.0
(s, 1 H) 11.4 (s, 1 H)
EXAMPLE 32 N-(2-{4-[5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1,2f4-oxadiazol-3-yl]- 2,6-dimethylphenyl}ethyl)-2,2,2-trifluoroethanamine
Figure imgf000077_0001
Obtained (69% yield) from Preparation 53 and 2,2,2-trifluoroethanamine following the procedure described in Preparation 49.
LRMS: m/z 459 (M+1)+
Retention time: 20.57 min (Method C)
1H NMR (200 MHz, DMSO-Cf6) δ ppm 1.00 (s, 6 H) 1.65 (t, 2 H) 2.46 (s, 6 H)
2.67 (s, 2 H) 2.89 - 3.45 (m, 4 H) 7.79 (s, 2 H) 8.61 (s, 1 H) 9.09 (s, 1 H).
EXAMPLE 33
3-(4-{5-[7,7-dimethyl-1-(methylamino)-5,6,7,8-tetrahydroisoquinolin-4-yl]-1,2,4- oxadiazol-3-yl}-2,6-dimethylphenyl)propane-1,2-diol
Figure imgf000077_0002
Obtained (94% yield) from Preparation 76 following the procedure described in
Example 22.
LRMS: m/z 437 (M+1 )+
Retention time: 15.53 min (Method C)
1H NMR (300 MHz, DMSO-d6) δ ppm 1.01 (s, 6 H) 1.57 (t, J=6.32 Hz, 2 H) 2.17
(s, 2 H) 2.40 (s, 6 H) 2.50 (t, J=3.30 Hz, 2 H) 2.67 (dd, J=13.60, 8.93 Hz, 1 H)
2.80 - 2.99 (m, 4 H) 3.10 (t, J=5.77 Hz, 2 H) 3.34 (m, 3 H) 4.49 - 4.85 (m, 2 H)
7.67 (S, 2 H) 8.68 (s, 1 H).
EXAMPLE 34 4-[3-(3,5-dimethyl-4-{2-[(2,2,2-trifluoroethyl)amino]ethyl}phenyl)-1,2,4-oxadiazol- 5-yl]-N,7,7-trimethyl-5,6,7,8-tetrahydroisoquinolin-1 -amine
Figure imgf000078_0001
Obtained (66% yield) from Preparation 80 and 2,2,2-trifluoroethanamine following the procedure described in Preparation 49.
LRMS: m/z 488 (M+1 )+
Retention time: 18.86 min (Method C)
1H NMR (300 MHz, DMSO-Cf6) δ ppm 1.02 (s, 6 H) 1.59 (t, J=5.63 Hz, 2 H) 2.24
(s, 2 H) 2.45 (s, 6 H) 2.85 - 3.32 (m, 9 H) 4.01 - 4.28 (m, 2 H) 7.75 (s, 2 H) 8.56
(s, 1 H).
EXAMPLE 35
4-{3-[4-(2-aminoethyl)-3,5-dimethylphenyl]-1,2,4-oxadiazol-5-yl}-N,7,7-trimethyl- 5,6,7,8-tetrahydroisoquinolin-1 -amine
Figure imgf000078_0002
To a solution of Preparation 80 (300 mg, 0.74 mmol) in methanol (10 mL) hydroxylamine. hydrochloride (51.5 mg, 0.74 mmol) in water (0.5 mL) was added and the reaction mixture was stirred at r.t. overnight. Solvent was removed and the residue redissolved in ethyl acetate and washed with 0.1 N HCI, 4% solution of NaHCO3 and brine. The organic layer was dried and concentrated. The solid obtained was dissolved in AcOH (8.5 mL) and zinc dust (67.5 mg, 1.2 mmol) was added, the mixture was stirred at r.t. overnight under argon atmosphere. Methanol was added and the mixture filtered over Celite. The filtrate was concentrated and dissolved in ethyl acetate. The organic layer was washed with 2N NaOH, water and brine, then dried and concentrated. The oil obtained was purified following General Purification Method and the product thus obtained was redissolved in 4M HCI in dioxane and stirred at r.t. overnight. The precipitate was filtered and washed with diethyl ether to yield the final compound as hydrochloride salt (17%).
LRMS: m/z 406 (M+1 )+
Retention time: 10.58 min (Method C) 1H NMR (300 MHz, DMSO-d6) δ ppm 1.02 (s, 6 H) 1.59 (t, J=6.18 Hz, 2 H) 2.23 (s, 2 H) 2.43 (s, 6 H) 2.74 - 2.94 (m, 2 H) 2.93 - 3.08 (m, 5 H) 3.14 (t, J=5.63 Hz, 2 H) 7.74 (s, 2 H) 8.10 (br. s., 3 H) 8.58 (s, 1 H).
EXAMPLE 36
4-{3-[4-(2-aminoethoxy)-3,5-dimethylphenyl]-1,2,4-oxadiazol-5-yl}-N,7,7-trimethyl- 5,6,7, 8-tetrahydroisoquinolin-1-amine
Figure imgf000079_0001
Obtained (89% yield) from Preparation 81 following General Method 4. LRMS: m/z 422 (M+1 )+ Retention time: 10.45 min (Method C)
1H NMR (300 MHz, DMSO-d6) δ ppm 1.02 (s, 6 H) 1.59 (t, J=6.32 Hz, 2 H) 2.22 (s, 2 H) 2.37 (S, 6 H) 3.00 (s, 3 H) 3.13 (t, 2 H) 3.19 - 3.33 (m, 2 H) 4.01 (t, J=4.94 Hz, 2 H) 7.78 (s, 2 H) 8.21 (br. s., 3 H) 8.59 (s, 1 H).
EXAMPLE 37
3-(4-{5-[1-(dimethylamino)-7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl]-1,2,4- oxadiazol-3-yl}-2,6-dimethylphenyl)propane-1 ,2-diol
Figure imgf000079_0002
Obtained (30% yield) from Preparation 84 following the procedure described in Example 22.
LRMS: m/z 451 (M+1 )+
Retention time: 19.83 min (Method C)
PHARMACOLOGICAL ACTIVITY 35S-GTP-q binding assay:
The effect of the compounds was measured using a 35S-GTPyS binding assay. Briefly, membranes were incubated in a buffer containing 2OmM HEPES pH 7.4, 10OmM NaCI, 1OmM MgCI2, 10μM GDP, 50μg/mL saponin and 0.2% fatty acid-free BSA at various concentrations (0.1 nM-10μM) and 0.1 nM 35S-GTPyS. 10μM S1 P was used as 100% maximum efficacy. The assay was incubated for 90 min at room temperature with gentle mixing, and terminated by filtrating the reaction mixture through GF/C filter plates using the Manifold Filtration System. The filters were immediately washed with sodium phosphate pH 7.4 buffer. After drying the filter plates scintillant liquid were added to each well and 35S-GTPyS binding was measured on a Trilux Scintillation Counter.
The results are shown in Table 1.
Table 1
Figure imgf000080_0001
The tetrahidroisoquinolyl derivatives of the invention may also be combined with other active compounds in the treatment of diseases known to be susceptible to improvement by treatment with a sphingosine-1 -phosphate receptor agonist (S1 P1 ).
The combinations of the invention can optionally comprise one or more additional active substances which are known to be useful in the treatment of autoimmune diseases, chronic immune and inflammatory diseases, transplant rejection, malignant neoplastic diseases, angiogenic-related disorders, pain, neurological diseases.viral and infectious diseases, such as (a) beta interferons such as Betaseron, Avonex or Rebif, (b), immunomodulators such as glatiramer acetate, (c) inhibitors of DNA synthesis and repair, such as Mitoxantrone, (d) anti-alpha 4 integrin antibodies, such as Natalizumab (Tysabri), (e) alpha 4 integrin antagonists such as R-1295 , TBC-4746, CDP-323, ELND-002, Firategrast and TMC-2003, (f), dyhydrofolate reductase inhibitors, such as Methotrexate or CH-1504, (g) glucocorticoids such as prednisone or methylprednisolone, (h), DHODH inhibitors such as Teriflunomide, (i) fumaric acid esters, such as BG-12, (j) immunomodulators such as Laquinimod, (k) anti-CD20 monoclonal antibodies such as Rituximab, Ocrelizumab Ofatumumab or TRU-015, (I) anti-CD52 such as alemtuzumab, (m) anti-CD25 such as daclizumab, (n) anti-CD88, such as eculizumab or pexilizumab, (o) calcineurin inhibitors such as cyclosporine A or tacrolimus, (p) IMPDH inhibitors, such as mycophenolate mophetyl, (q) cannabinoid receptor agonists such as Sativex, (r) chemokine CCR1 antagonists such as MLN- 3897 or PS-031291 , (s) chemokine CCR2 antagonists such as INCB-8696, (t) interferon alpha such as Sumiferon MP, (u) NF-kappaB activation inhibitors such as FAE and MLN-0415, (v) JAK inhibitors such as CP-690550 or INCB018424, (W) Syk inhibitors, such as R-112, (x) PKC inhibitors, such as NVP-AEB071 , (y) phosphosdiesterase IV inhibitors such as GRC-4039, (z) P38 Inhibitors such as ARRY- 797, and (aa) MEK inhibitors, such as ARRY-142886 or ARRY-438162
The combinations of the invention may be used in the treatment of disorders which are susceptible to amelioration by sphingosine-1 -phosphate receptors agonists (S1 P1 ). Thus, the present application encompasses methods of treatment of these disorders, as well as the use of the combinations of the invention in the manufacture of a medicament for the treatment of these disorders.
Preferred examples of such disorders are multiple sclerosis, transplant rejection, systemic lupus erythematosus, asthma, psoriasis, rheumatoid arthritis, psoriatic arthritis and Crohn's disease, more preferably multiple sclerosis, transplant rejection, asthma and rheumatoid arthritis, and most preferably multiple sclerosis.
The active compounds in the combinations of the invention may be administered by any suitable route, depending on the nature of the disorder to be treated, e.g. orally (as syrups, tablets, capsules, lozenges, controlled-release preparations, fast-dissolving preparations, etc); topically (as creams, ointments, lotions, nasal sprays or aerosols, etc); by injection (subcutaneous, intradermic, intramuscular, intravenous, etc.) or by inhalation (as a dry powder, a solution, a dispersion, etc).
The active compounds in the combination, i.e. the sphingosine-1 -phosphate agonist of the invention, and the other optional active compounds may be administered together in the same pharmaceutical composition or in different compositions intended for separate, simultaneous, concomitant or sequential administration by the same or a different route. One execution of the present invention consists of a kit of parts comprising a sphingosine-1 -phosphate agonist of the invention together with instructions for simultaneous, concurrent, separate or sequential use in combination with another active compound useful in the treatment of multiple sclerosis, transplant rejection, systemic lupus erythematosus, asthma, psoriasis, rheumatoid arthritis, psoriatic arthritis and Crohn's disease,
Another execution of the present invention consists of a package comprising a sphingosine-1 -phosphate agonist of formula (I) and another active compound useful in the treatment of multiple sclerosis, transplant rejection, systemic lupus erythematosus, asthma, psoriasis, rheumatoid arthritis, psoriatic arthritis and Crohn's disease,
The pharmaceutical formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy.
Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil- in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary or paste.
A syrup formulation will generally consist of a suspension or solution of the compound or salt in a liquid carrier for example, ethanol, peanut oil, olive oil, glycerine or water with flavouring or colouring agent.
Where the composition is in the form of a tablet, any pharmaceutical carrier routinely used for preparing solid formulations may be used. Examples of such carriers include magnesium stearate, talc, gelatine, acacia, stearic acid, starch, lactose and sucrose.
A tablet may be made by compression or moulding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, lubricating, surface active or dispersing agent. Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein.
Where the composition is in the form of a capsule, any routine encapsulation is suitable, for example using the aforementioned carriers in a hard gelatine capsule. Where the composition is in the form of a soft gelatine capsule any pharmaceutical carrier routinely used for preparing dispersions or suspensions may be considered, for example aqueous gums, celluloses, silicates or oils, and are incorporated in a soft gelatine capsule.
Dry powder compositions for topical delivery to the lung by inhalation may, for example, be presented in capsules and cartridges of for example gelatine or blisters of for example laminated aluminium foil, for use in an inhaler or insufflator. Formulations generally contain a powder mix for inhalation of the compound of the invention and a suitable powder base (carrier substance) such as lactose or starch. Use of lactose is preferred. Each capsule or cartridge may generally contain between 2μg and 150 μg of each therapeutically active ingredient. Alternatively, the active ingredient (s) may be presented without excipients.
Packaging of the formulation for inhalation may be carried out by using suitable inhaler devices such as the NOVOLIZER ® SD2FL or GENUAIR ® which are described in the following patent applications: WO 97/000703, WO 03/000325 and WO 03/061742.
Typical compositions for nasal delivery include those mentioned above for inhalation and further include non-pressurized compositions in the form of a solution or suspension in an inert vehicle such as water optionally in combination with conventional excipients such as buffers, anti-microbials, tonicity modifying agents and viscosity modifying agents which may be administered by nasal pump.
Typical dermal and transdermal formulations comprise a conventional aqueous or nonaqueous vehicle, for example a cream, ointment, lotion or paste or are in the form of a medicated plaster, patch or membrane.
Preferably the composition is in unit dosage form, for example a tablet, capsule or metered aerosol dose, so that the patient may administer a single dose. The amount of each active which is required to achieve a therapeutic effect will, of course, vary with the particular active, the route of administration, the subject under treatment, and the particular disorder or disease being treated.
Effective doses are normally in the range of 2-2000 mg of active ingredient per day. Daily dosage may be administered in one or more treatments, preferably from 1 to 4 treatments, per day. Preferably, the active ingredients are administered once or twice a day.
When combinations of actives are used, it is contemplated that all active agents would be administered at the same time, or very close in time. Alternatively, one or two actives could be taken in the morning and the other (s) later in the day. Or in another scenario, one or two actives could be taken twice daily and the other (s) once daily, either at the same time as one of the twice-a-day dosing occurred, or separately. Preferably at least two, and more preferably all, of the actives would be taken together at the same time. Preferably, at least two, and more preferably all actives would be administered as an admixture.
The following preparations forms are cited as formulation examples:
COMPOSITION EXAMPLE 1
50,000 capsules, each containing 100 mg of 3-(4-(5-(1-ethyl-7,7-dimethyl-5,6,7,8- tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3-yl)-2,6-dimethylphenyl)propanamide
(active ingredient), were prepared according to the following formulation:
Figure imgf000084_0001
Procedure
The above ingredients were sieved through a 60 mesh sieve, and were loaded into a suitable mixer and filled into 50,000 gelatine capsules.
COMPOSITION EXAMPLE 2 50,000 tablets, each containing 50 mg of 3-(4-(5-(1-ethyl-7,7-dimethyl-5,6,7,8- tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3-yl)-2,6-dimethylphenyl)propanamide (active ingredient), were prepared from the following formulation:
Figure imgf000085_0001
Procedure
All the powders were passed through a screen with an aperture of 0.6 mm, then mixed in a suitable mixer for 20 minutes and compressed into 300 mg tablets using 9 mm disc and flat bevelled punches. The disintegration time of the tablets was about 3 minutes.

Claims

Claims
1. A compound of formula (I), or a pharmaceutically acceptable salt or N-oxide thereof,
Figure imgf000086_0001
wherein
A is selected from the group consisting of -N-, -O- and -S-;
B and C independently are selected from the group consisting of -N- and -O-, with the proviso that at least two of A, B and C are nitrogen atoms;
G1 is selected from the group consisting of nitrogen atoms and -CRC- groups, wherein Rc represents a hydrogen atom, a halogen atom, a Ci-4 alkyl group or a C1-4 alkoxy group;
R1 is selected from the group consisting of hydrogen atoms, Ci-4 alkyl groups, Ci-4 alkoxy groups, C3-4 cycloalkyl groups, and -NRdRe groups wherein Rd and Re are independently selected from hydrogen atoms and C1-4 alkyl groups;
R2 and R3 are independently selected from the group consisting of hydrogen atoms and C1-4 alkyl groups;
R4, R5 and R7 are independently selected from the group consisting of hydrogen atoms, halogen atoms, C1-4 alkyl groups, C1-4 alkoxy groups and Ci-4 haloalkyl groups;
R6 represents a C1-4 alkyl group or a C1-4 hydroxyalkyl group; or R6 is selected from the group consisting of -S(O)2-NR3R" groups, -(CRfR9)n-(CRhR')x-(CRJRk)y-NRaRb groups, -(CH2)n-NRaRb groups, -O-(CH2)n-NRaRb groups, -(CH2)n-COOH groups, -(CH2)n-NRa- CO-Rb' groups, -(CH2)n-NRa-(CH2)p-(NH)q-SO-CH3 groups and -(CH2Jn-CO-N RaRb groups, wherein n, p, x and y are each independently integers from 0 to 3,
q is O or 1 ,
Rf, R9, Rh, R', RJ and Rk independently represent hydrogen atoms or halogen atoms,
Rb is selected from the group consisting of methylsulphonyl groups, C1-4 alkyl groups, C1-4 hydroxyalkyl groups, C1-4 carboxyalkyl groups, and C1-4 haloalkyl groups;
Ra and Rb are independently selected from the group consisting of hydrogen atoms, methylsulphonyl groups, C1-4 alkyl groups, C1-4 hydroxyalkyl groups, C1^ carboxyalkyl groups, and C1-4 haloalkyl groups, or
Ra and Rb or Ra and Rbl together with the nitrogen atom to which they are attached form a 4 to 6 membered, saturated heterocyclic group, which contains, as heteroatoms, one or two nitrogen atoms and which is substituted by a carboxyl group or a C1-4 carboxyalkyl group; or
Rc together with R6 form a C5-8 carbocyclic ring optionally substituted by -NHR' wherein R' represents a hydrogen atom or a C1-4 carboxyalkyl group.
2. A compound according to claim 1 , wherein
R6 represents a C1-4 alkyl group, or a C1-4 hydroxyalkyl group, or
R6 is selected from the group consisting of -S(O)2-NRaRb groups, -(CH2)n-NRaRb groups, -(CH2)n-COOH groups, and -(CH2)n-CO-NRaRb groups, wherein,
n is an integer from 0 to 3,
Ra and Rb are independently selected from the group consisting of hydrogen atoms, methylsulphonyl groups and C1-4 carboxyalkyl groups, C1-4 alkyl groups and C1-4 haloalkyl groups, or
Ra and Rb together with the nitrogen atom to which they are attached form a 4 to 6 membered, saturated heterocyclic group, which contains, as heteroatoms, one or two nitrogen atoms and which is substituted by a carboxyl group or a C1-4 carboxyalkyl group; or
Rc together with R6 form a C5-8 carbocyclic ring optionally substituted by -NHR' wherein R' represents a hydrogen atom or a Ci-4 carboxyalkyl group.
3. A compound according to claim 1 or claim 2, wherein A is selected from the group consisting of -N- and -O-.
4. A compound according to any one of claims 1 to 3, wherein A represents -N-.
5. A compound according to any one of the preceding claims, wherein G1 represents a -CRC- group, wherein Rc represents a hydrogen atom, chlorine atom, fluorine atom or a C1-4 alkyl group.
6. A compound according to any one of claims 1 to 5, wherein R1 represents a hydrogen atom, a C1-4 alkyl group or a C3-4 cycloalkyl group.
7. A compound according to any one of the preceding claims, wherein R2 represents a C1-4 alkyl group.
8. A compound according to any one of the preceding claims, wherein R3 represents a C1-4 alkyl group.
9. A compound according to any one of claims 1 to 8, wherein R4 represents a hydrogen atom.
10. A compound according to any one of the preceding claims, wherein R7 represents a hydrogen atom.
11. A compound according to any one of the preceding claims, wherein R5 represents a hydrogen atom or a Ci-4 alkyl group.
12. A compound according to any one of claims 1 or 3 to 11 , wherein R6 represents a C1-4 alkyl group, or a C1-4 hydroxyalkyl group; or R6 is selected from the group consisting of -(CH2)n-NRaRb groups, -(CH2)n-COOH groups, -(CH2)n-NRa-(CH2)p- (NHJq-SO-CH3 groups and -(CH2)n-CO-NRaRb groups, wherein n and p are each independently integers from 0 to 3,
q is 0 or 1 ,
Ra and Rb are independently selected from the group consisting of hydrogen atoms, methylsulphonyl groups, C1-4 carboxyalkyl groups, C1-4 alkyl groups and C1-4 haloalkyl groups, or
Ra and Rb together with the nitrogen atom to which they are attached form a 4 to 6 membered, saturated heterocyclic group, which contains, as heteroatoms, one or two nitrogen atoms and which is substituted by a carboxyl group or a C1-4 carboxyalkyl group.
13. A compound according to claim 1 , wherein:
A represents -N-;
G1 represents a -CRC- group, wherein Rc represents a hydrogen atom or C1-4 alkyl group;
R2 and R3 independently represent C1-4 alkyl groups;
R4, R5 and R7 are independently selected from the group consisting of hydrogen atoms and C1-4 alkyl groups;
R6 represents a C1-4 alkyl group or a C1-4 hydroxyalkyl group, or R6 is selected from the group consisting of -S(O)2-NRaRb groups, -(CH2)n-NRaRb groups, -(CH2)n-COOH groups, -(CH2)n-NRa-(CH2)p-(NH)q-SO-CH3 groups and -(CH2)n-CO-NRaRb groups, wherein
n and p are each independently integers from 0 to 3,
q is 0 or 1 , Ra and Rb independently are selected from the group consisting of hydrogen atoms, methylsulphonyl groups, Ci-4 carboxyalkyl groups, C1-4 alkyl groups and C1^ haloalkyl groups, or
Ra and Rb together with the nitrogen atom to which they are attached form a 4 to 6 membered, saturated heterocyclic group, which contains, as heteroatoms, one or two nitrogen atoms and which is substituted by a carboxyl group or a C1-4 carboxyalkyl group; or
Rc together with R6 form a C5-8 carbocyclic ring optionally substituted by -NHR' wherein R' represents a hydrogen atom or a C1-4 carboxyalkyl group.
14. A compound according to claim one, which is a compound of formula (I1), or a pharmaceutically acceptable salt or N-oxide thereof,
Figure imgf000090_0001
Formula (I1) wherein
G1 is selected from the group consisting of nitrogen atoms and -CRC- groups, wherein Rc represents a hydrogen atom, a chlorine atom, or a C1-2 alkyl group;
R1 is selected from the group consisting of hydrogen atoms, C1-2 alkyl groups, cyclopropyl groups, -NH2 groups, -NHMe, and -NMe2 groups;
R4, R5 and R7 are independently selected from the group consisting of hydrogen atoms, chlorine atoms, C1-2 alkyl groups;
R6 represents a C1-2 alkyl group or a C1-4 hydroxyalkyl group; or R6 is selected from the group consisting of -S(O)2-NHR" groups, -(CH2)n-NHRb groups, -(CH2)n-COOH groups, -(CH2)n-CO-NHRb groups, and -O-(CH2)n-NHRb groups wherein
n is 2 or 3, Rb is selected from the group consisting of hydrogen atoms, methylsulphonyl groups, C1-2 carboxyalkyl groups, and C1-2 haloalkyl groups, or
Ra and Rb together with the nitrogen atom to which they are attached form an azetidine or piperazine group which groups are substituted by a carboxyl group or a C1-2 carboxyalkyl group; or
Rc together with R6 form a C6 carbocyclic ring substituted by -NHR' wherein R' represents a hydrogen atom or a C1-2 carboxyalkyl group.
15. A compound according to claim 1 wherein both A and B represent -N- and C represents -O-,
G1 represents a -CRC- group wherein Rc represents a C1-4 alkyl group, R1 represents a -NRdRe group, wherein Rd and Re are independently selected from hydrogen atom and C1-4 alkyl group,
Both R2 and R3 represent a methyl group,
Both R4 and R7 represent a hydrogen atom,
R5 represents a d^ alkyl group, and R6 represents a C1-4 hydroxyalkyl group, -O-(CH2)n-NRaRb or -(CH2)n-NRaRb, wherein Ra and Rb independently represent a hydrogen atom or a C1^ alkyl group.
16. A compound according to claim 1 which is one of: (4-(5-(1-ethyl-7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3- yl)phenyl)methanol
4-(5-(1-ethyl-7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3- yl)benzenesulfonamide
3-(4-(4-(5-(1-ethyl-7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-
3-yl)phenyl)piperazin-1 -yl)propanoic acid 3-(4-(5-(1 -ethyl-7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3- yl)phenylsulfonamido)propanoic acid
3-(4-(5-(1-ethyl-7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3- yl)-2,6-dimethylphenyl)propanoic acid
3-(4-(5-(1-ethyl-7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3- yl)-2,6-dimethylphenyl)propanamide
2-(4-(5-(1-ethyl-7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3- yl)-2,6-dimethylphenyl)ethanamine 3-(4-(5-(1-cyclopropyl-7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4- oxadiazol-3-yl)-2,6-dimethylphenyl)propanoic acid
3-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3-yl)-2,6- dimethylphenyl)propanoic acid 2-(4-(5-(1 -cyclopropyl^J-dimethyl-S.θy.δ-tetrahydroisoquinolin^-yO-i ,2,4- oxadiazol-3-yl)-2,6-dimethylphenyl)ethanamine
2-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3-yl)-2>6- dimethylphenyl)ethanamine
3-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3-yl)-3- methylphenyl)propanoic acid
2-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3-yl)-3- methylphenyl)ethanamine
2-(3-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3-yl)-2,6- dimethylphenyl)propanamido)ethanoic acid 3-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3- yl)phenyl)propanoic acid
4-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3- yl)phenyl)butanoic acid
2-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3- yl)phenyl)ethanamine
6-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2l4-oxadiazol-3-yl)-1 ,2,3,4- tetrahydronaphthalen-2-amine
3-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3-yl)-2,6- dimethylphenyl)propanamide 2-(6-(5-(7,7-dirriethyl-5,6l7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3-yl)-
1 ,2,3,4-tetrahydronaphthalen-2-ylamino)ethanoic acid
3-(4-(5-(7,7-dimethyl-5l6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3-yl)-2)6- dimethylphenyl)propan-1-amine
3-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3-yl)-2,6- dimethylphenyl)propane-1 ,2-diol
N-(3-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2l4-oxadiazol-3-yl)-
2,6-dimethylphenyl)propyl)methanesulfonamide
N-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3-yl)-2,6- dimethylphenethyl)-2,2-difluoroethanamine 1 -(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3-yl)-2,6- dimethylphenethyl)azetidine-3-carboxylic acid S-Cδ-CS-Cyj-dimethyl-S.θ.y.δ-tetrahyclroisoquinolin^-yO-i ^^-oxacliazol-S-yO-S- ethyl-6-methylpyridin-2-yl)propanoic acid
3-(2-chloro-4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3- yl)phenylsulfonamido)propanoic acid 3-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3- yl)phenylsulfonamido)propanoic acid
3-(4-(5-(1-amino-7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3- yl)-2,6-dimethylphenyl)propane-1 ,2-diol
4-(4-(5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3-yl)-2,6- dimethylphenyl)butanoic acid
1 -(4-(5-(1 -amino-7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3- yO^.Θ-dimethylphenethyOazetidine-S-carboxylic acid
N-(2-{4-[5-(7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl)-1 ,2,4-oxadiazol-3-yl]-
216-dimethylphenyl}ethyl)-2,2,2-trifluoroethanamine 3-(4-{5-[7,7-dimethyl-1 -(methylamino)-5,6,7,8-tetrahydroisoquinolin-4-yl]-1 ,2,4- oxadiazol-3-yl}-2,6-dimethylphenyl)propane-1 ,2-diol
4-[3-(3,5-dimethyl-4-{2-[(2,2,2-trifluoroethyl)amino]ethyl}phenyl)-1 ,2,4-oxadiazol-5- yl]-N,7,7-trimethyl-5,6,7,8-tetrahydroisoquinolin-1-amine
4-{3-[4-(2-aminoethyl)-3,5-dimethylphenyl]-1 ,2,4-oxadiazol-5-yl}-N,7,7-trimethyl- 5,6,7>8-tetrahydroisoquinolin-1 -amine
4-{3-[4-(2-aminoethoxy)-3,5-dimethylphenyl]-1 ,2,4-oxadiazol-5-yl}-N,7,7-trimethyl-
5,6,7,8-tetrahydroisoquinolin-1-amine
3-(4-{5-[1-(dimethylamino)-7,7-dimethyl-5,6,7,8-tetrahydroisoquinolin-4-yl]-1 ,2,4- oxadiazol-3-yl}-2,6-dimethylphenyl)propane-1 ,2-diol
and the pharmaceutically acceptable salts and N-oxides thereof.
17. A compound according to any one of claims 1 to 16 for use in the treatment of a pathological condition or disease susceptible to amelioration by sphingosine-1- phosphate receptors (S1 P1 ) agonists.
18. A compound according to claim 17, wherein the pathological condition or disease is selected from autoimmune diseases, chronic immune and inflammatory diseases, transplant rejection, malignant neoplastic diseases, angiogenic-related disorders, pain, neurological diseases, viral and infectious diseases.
19. A compound according to claim 17 or 18 wherein the pathological condition or disease is selected from multiple sclerosis, transplant rejection, systemic lupus erythematosus, asthma, psoriasis, rheumatoid arthritis, psoriatic arthritis and Crohn's disease.
20. A pharmaceutical composition comprising a compound as defined in any one of claims 1 to 16 in association with a pharmaceutically acceptable diluent or carrier.
21. Use of a compound as defined in any one of claims 1 to 16 for the manufacture of a medicament for the treatment of a pathological condition or disease as defined in any one of claims 17 to 19.
22. A method for treating a subject afflicted with a pathological condition or disease as defined in claims 17 to 19, which comprises administering to said subject a therapeutically effective amount of a compound as defined in any one of claims 1 to 15.
23. A combination product comprising (i) a compound according to any one of claims 1 to 15; and (ii) another compound selected from: a) Beta interferons such as Betaseron, Avonex or Rebif b) Immunomodulators such as glatiramer acetate c) Inhibitors of DNA synthesis and repair, such as Mitoxantrone d) Anti-alpha 4 integrin antibodies, such as Natalizumab (Tysabri) e) Alpha 4 integrin antagonists such as R-1295 , TBC-4746, CDP-323, ELND-002, Firategrast and TMC-2003 f) Dyhydrofolate reductase inhibitors, such as Methotrexate or CH-
1504 g) Glucocorticoids such as prednisone or methylprednisolone h) DHODH inhibitors such as teriflunomide i) Fumaric acid esters, such as BG-12 j) Immunomodulators such as Laquinimod k) Anti-CD20 monoclonal antibodies such as Rituximab, Ocrelizumab Ofatumumab or TRU-015
I) Anti-CD52 such as alemtuzumab m) Anti-CD25 such as daclizumab n) Anti-CD88, such as eculizumab or pexilizumab o) Calcineurin inhibitors such as cyclosporine A or tacrolimus p) IMPDH inhibitors, such as mycophenolate mophetyl q) Cannabinoid receptor agonists such as Sativex r) Chemokine CCR1 antagonists such as MLN-3897 or PS-031291 s) Chemokine CCR2 antagonists such as INCB-8696 t) Interferon alpha such as Sumiferon MP u) NF-kappaB activation inhibitors such as FAE and MLN-0415 v) JAK inhibitors such as CP-690550 or INCB018424 w) Syk inhibitors, such as R-112 x) PKC inhibitors, such as NVP-AEB071 y) Phosphosdiesterase IV inhibitors such as GRC-4039 z) P38 Inhibitors such as ARRY-797 aa) MEK inhibitors, such as ARRY-142886 or ARRY-438162
PCT/EP2010/000158 2009-01-19 2010-01-14 Oxadiazole derivatives as slpl receptor agonists WO2010081692A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
EP10700383A EP2387571A1 (en) 2009-01-19 2010-01-14 Oxadiazole derivatives as slpl receptor agonists
MX2011007455A MX2011007455A (en) 2009-01-19 2010-01-14 Oxadiazole derivatives as slpl receptor agonists.
AU2010205825A AU2010205825A1 (en) 2009-01-19 2010-01-14 Oxadiazole derivatives as SLPL receptor agonists
JP2011545678A JP2012515182A (en) 2009-01-19 2010-01-14 Oxadiazole derivatives as S1P1 receptor agonists
SG2011048329A SG172452A1 (en) 2009-01-19 2010-01-14 Oxadiazole derivatives as slpl receptor agonists
BRPI1005153A BRPI1005153A2 (en) 2009-01-19 2010-01-14 compound, pharmaceutical composition, use of a compound, method of treating an individual suffering from a pathological condition or disease and combination product
CA2748394A CA2748394A1 (en) 2009-01-19 2010-01-14 Oxadiazole derivatives as s1p1 receptor agonists
CN2010800049696A CN102282144A (en) 2009-01-19 2010-01-14 Oxadiazole derivatives as slpl receptor agonists
US13/144,377 US20110274657A1 (en) 2009-01-19 2010-01-14 Oxadiazole derivatives as s1p1 receptor antagonists
EA201101089A EA201101089A1 (en) 2009-01-19 2010-01-14 OXADIAZOLE DERIVATIVES AS AN AGONISTS OF S1P1 RECEPTOR
IL213630A IL213630A0 (en) 2009-01-19 2011-06-16 Oxadiazole derivatives as slpl receptor agonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09382004A EP2210890A1 (en) 2009-01-19 2009-01-19 Oxadiazole derivatives as S1P1 receptor agonists
EP09382004.1 2009-01-19

Publications (1)

Publication Number Publication Date
WO2010081692A1 true WO2010081692A1 (en) 2010-07-22

Family

ID=40568602

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/000158 WO2010081692A1 (en) 2009-01-19 2010-01-14 Oxadiazole derivatives as slpl receptor agonists

Country Status (17)

Country Link
US (1) US20110274657A1 (en)
EP (2) EP2210890A1 (en)
JP (1) JP2012515182A (en)
KR (1) KR20110110198A (en)
CN (1) CN102282144A (en)
AR (1) AR075022A1 (en)
AU (1) AU2010205825A1 (en)
BR (1) BRPI1005153A2 (en)
CA (1) CA2748394A1 (en)
EA (1) EA201101089A1 (en)
EC (1) ECSP11011200A (en)
IL (1) IL213630A0 (en)
MX (1) MX2011007455A (en)
SG (1) SG172452A1 (en)
TW (1) TW201028407A (en)
UY (1) UY32364A (en)
WO (1) WO2010081692A1 (en)

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012061459A1 (en) * 2010-11-03 2012-05-10 Bristol-Myers Squibb Company Heterocyclic compounds as s1p1 agonists for the treatment of autoimmune and vascular diseases
US8399451B2 (en) 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
US8415362B2 (en) 2005-12-13 2013-04-09 Incyte Corporation Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
WO2013113716A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113776A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113787A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113720A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113715A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113863A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113773A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
US8691807B2 (en) 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US8722693B2 (en) 2007-06-13 2014-05-13 Incyte Corporation Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US8933085B2 (en) 2010-11-19 2015-01-13 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
US8987443B2 (en) 2013-03-06 2015-03-24 Incyte Corporation Processes and intermediates for making a JAK inhibitor
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
US9115054B2 (en) 2013-02-21 2015-08-25 Bristol-Myers Squibb Company Tetrahydronaphthalenyl compounds useful as sipi agonists
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
US9216984B2 (en) 2009-05-22 2015-12-22 Incyte Corporation 3-[4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane—or heptane-nitrile as JAK inhibitors
US9249145B2 (en) 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US9334274B2 (en) 2009-05-22 2016-05-10 Incyte Holdings Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US9359358B2 (en) 2011-08-18 2016-06-07 Incyte Holdings Corporation Cyclohexyl azetidine derivatives as JAK inhibitors
US9358229B2 (en) 2011-08-10 2016-06-07 Novartis Pharma Ag JAK PI3K/mTOR combination therapy
US9464088B2 (en) 2010-03-10 2016-10-11 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
US9487521B2 (en) 2011-09-07 2016-11-08 Incyte Holdings Corporation Processes and intermediates for making a JAK inhibitor
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
US9522888B2 (en) 2014-08-20 2016-12-20 Bristol-Myers Squibb Company Substituted bicyclic compounds
US9655854B2 (en) 2013-08-07 2017-05-23 Incyte Corporation Sustained release dosage forms for a JAK1 inhibitor
US9993480B2 (en) 2011-02-18 2018-06-12 Novartis Pharma Ag mTOR/JAK inhibitor combination therapy
US10166191B2 (en) 2012-11-15 2019-01-01 Incyte Corporation Sustained-release dosage forms of ruxolitinib
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
US10758543B2 (en) 2010-05-21 2020-09-01 Incyte Corporation Topical formulation for a JAK inhibitor
US10899736B2 (en) 2018-01-30 2021-01-26 Incyte Corporation Processes and intermediates for making a JAK inhibitor
US11304949B2 (en) 2018-03-30 2022-04-19 Incyte Corporation Treatment of hidradenitis suppurativa using JAK inhibitors
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2455081A1 (en) * 2010-11-23 2012-05-23 Almirall, S.A. S1P1 receptor agonists for use in the treatment of crohn's disease
EP2455080A1 (en) * 2010-11-23 2012-05-23 Almirall, S.A. S1P1 receptor agonists for use in the treatment of multiple sclerosis
MA41139A (en) 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd PHARMACEUTICAL COMBINATION INCLUDING A SIP1 RECEPTOR SELECTIVE AGONIST
US11192886B2 (en) * 2016-07-22 2021-12-07 Medshine Discovery Inc. S1P1 agonist and application thereof
CA3158600A1 (en) * 2019-11-19 2021-05-27 Brian H. Heasley Compounds and methods of preparing compounds s1p1 modulators
KR20230154194A (en) * 2021-02-10 2023-11-07 이칸 스쿨 오브 메디슨 엣 마운트 시나이 Oxadiazolyl dihydropyrano[2,3-b]pyridine inhibitor of HIPK2 for the treatment of renal fibrosis
WO2024031041A2 (en) * 2022-08-05 2024-02-08 Icahn School Of Medicine At Mount Sinai Oxygen-containing heterocyclic compound and use thereof

Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994000943A1 (en) 1992-06-23 1994-01-06 Motorola, Inc. Multi-modulation scheme compatible radio
WO1997000703A1 (en) 1995-06-21 1997-01-09 Asta Medica Aktiengesellschaft Pharmaceutical powder cartridge with integrated metering device and inhaler for powdered medicaments
WO2003000325A1 (en) 2001-06-22 2003-01-03 Sofotec Gmbh & Co. Kg Powder formulation disintegrating system and method for dry powder
WO2003061742A2 (en) 2002-01-24 2003-07-31 Sofotec Gmbh & Co. Kg Humidity-tight cartridge for a powder inhaler
WO2003097028A1 (en) 2002-05-16 2003-11-27 Novartis Ag Use of edg receptor binding agents in cancer
WO2004010987A2 (en) 2002-07-24 2004-02-05 Novartis Ag Use of s1p receptor agonists in heart diseases
WO2004103279A2 (en) * 2003-05-15 2004-12-02 Merck & Co., Inc. 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
WO2004110421A1 (en) 2003-06-06 2004-12-23 Sanofi-Aventis Deutschland Gmbh Use of 2-amino-1-3-propanediol derivatives for the manufacture of a medicament for the treatment of various types of pain
WO2005025553A2 (en) 2003-09-12 2005-03-24 Neuronova Ab Treatment of disorders of nervous systemsystem with fty720
WO2005032465A2 (en) * 2003-10-01 2005-04-14 Merck & Co., Inc. 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
WO2005058295A2 (en) 2003-12-19 2005-06-30 Novartis Ag Use of sphingosine-1-phosphate (s1p) receptor agonists for the treatment of brain degenerative diseases
WO2005058848A1 (en) * 2003-12-17 2005-06-30 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists
WO2006131336A1 (en) * 2005-06-08 2006-12-14 Novartis Ag POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS
WO2007085451A2 (en) * 2006-01-27 2007-08-02 Novartis Ag 3,5-di (aryl or heteroaryl) isoxazoles and 1, 2, 4-oxadiazoles as s1p1 receptor agonists, immunosuppresssive and anti -inflammatory agents
WO2007089715A2 (en) 2006-01-27 2007-08-09 University Of Virginia Patent Foundation Method for treatment of neuropathic pain
WO2007091501A1 (en) 2006-02-06 2007-08-16 Kyorin Pharmaceutical Co., Ltd. Therapeutic agent for inflammatory bowel disease comprising 2-amino-1,3-propanaediol derivative as active ingredient, and method for treatment of inflammatory bowel disease
WO2007143081A2 (en) 2006-06-02 2007-12-13 The Ohio State University Research Foundation Therapeutic agents for the treatment of lymphoid malignancies
WO2008000419A1 (en) 2006-06-27 2008-01-03 Novartis Ag S1p receptor modulators for treating multiple sclerosis
WO2008021532A2 (en) 2006-08-17 2008-02-21 University Of Chicago Treatment of inflammatory diseases

Patent Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994000943A1 (en) 1992-06-23 1994-01-06 Motorola, Inc. Multi-modulation scheme compatible radio
WO1997000703A1 (en) 1995-06-21 1997-01-09 Asta Medica Aktiengesellschaft Pharmaceutical powder cartridge with integrated metering device and inhaler for powdered medicaments
WO2003000325A1 (en) 2001-06-22 2003-01-03 Sofotec Gmbh & Co. Kg Powder formulation disintegrating system and method for dry powder
WO2003061742A2 (en) 2002-01-24 2003-07-31 Sofotec Gmbh & Co. Kg Humidity-tight cartridge for a powder inhaler
WO2003097028A1 (en) 2002-05-16 2003-11-27 Novartis Ag Use of edg receptor binding agents in cancer
WO2004010987A2 (en) 2002-07-24 2004-02-05 Novartis Ag Use of s1p receptor agonists in heart diseases
WO2004103279A2 (en) * 2003-05-15 2004-12-02 Merck & Co., Inc. 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
WO2004110421A1 (en) 2003-06-06 2004-12-23 Sanofi-Aventis Deutschland Gmbh Use of 2-amino-1-3-propanediol derivatives for the manufacture of a medicament for the treatment of various types of pain
WO2005025553A2 (en) 2003-09-12 2005-03-24 Neuronova Ab Treatment of disorders of nervous systemsystem with fty720
WO2005032465A2 (en) * 2003-10-01 2005-04-14 Merck & Co., Inc. 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
WO2005058848A1 (en) * 2003-12-17 2005-06-30 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists
WO2005058295A2 (en) 2003-12-19 2005-06-30 Novartis Ag Use of sphingosine-1-phosphate (s1p) receptor agonists for the treatment of brain degenerative diseases
WO2006131336A1 (en) * 2005-06-08 2006-12-14 Novartis Ag POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS
WO2007085451A2 (en) * 2006-01-27 2007-08-02 Novartis Ag 3,5-di (aryl or heteroaryl) isoxazoles and 1, 2, 4-oxadiazoles as s1p1 receptor agonists, immunosuppresssive and anti -inflammatory agents
WO2007089715A2 (en) 2006-01-27 2007-08-09 University Of Virginia Patent Foundation Method for treatment of neuropathic pain
WO2007091501A1 (en) 2006-02-06 2007-08-16 Kyorin Pharmaceutical Co., Ltd. Therapeutic agent for inflammatory bowel disease comprising 2-amino-1,3-propanaediol derivative as active ingredient, and method for treatment of inflammatory bowel disease
WO2007143081A2 (en) 2006-06-02 2007-12-13 The Ohio State University Research Foundation Therapeutic agents for the treatment of lymphoid malignancies
WO2008000419A1 (en) 2006-06-27 2008-01-03 Novartis Ag S1p receptor modulators for treating multiple sclerosis
WO2008021532A2 (en) 2006-08-17 2008-02-21 University Of Chicago Treatment of inflammatory diseases

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BAUMRUKER ET AL., EXP. OPIN. INVEST. DRUGS, vol. 16, no. 3, 2007, pages 283 - 289
BRINKMANN, PHARMACOLOGY & THERAPEUTICS, vol. 115, 2007, pages 84 - 105
T.W. GREENE; P. G. M. WUTS: "Protective Groups in Organic Synthesis", 1991, WILEY
YAN LIN ET AL: "SAR studies of 3-arylpropionic acids as potent and selective agonists of sphingosine-1-phosphate receptor-1 (S1P1) with enhanced pharmacokinetic properties", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 17, no. 3, 1 February 2007 (2007-02-01), pages 828 - 831, XP002515921, ISSN: 0960-894X *

Cited By (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933086B2 (en) 2005-12-13 2015-01-13 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-B]pyridines and pyrrolo[2,3-B]pyrimidines as Janus kinase inhibitors
US9662335B2 (en) 2005-12-13 2017-05-30 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors
US8415362B2 (en) 2005-12-13 2013-04-09 Incyte Corporation Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US11744832B2 (en) 2005-12-13 2023-09-05 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US9814722B2 (en) 2005-12-13 2017-11-14 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors
US9974790B2 (en) 2005-12-13 2018-05-22 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors
US11331320B2 (en) 2005-12-13 2022-05-17 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US9206187B2 (en) 2005-12-13 2015-12-08 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase
US9079912B2 (en) 2005-12-13 2015-07-14 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors
US10398699B2 (en) 2005-12-13 2019-09-03 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
US10639310B2 (en) 2005-12-13 2020-05-05 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US8946245B2 (en) 2005-12-13 2015-02-03 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US8829013B1 (en) 2007-06-13 2014-09-09 Incyte Corporation Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US10610530B2 (en) 2007-06-13 2020-04-07 Incyte Corporation Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US9376439B2 (en) 2007-06-13 2016-06-28 Incyte Corporation Salts of the janus kinase inhibitor (R)-3(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US10016429B2 (en) 2007-06-13 2018-07-10 Incyte Corporation Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US8722693B2 (en) 2007-06-13 2014-05-13 Incyte Corporation Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US8822481B1 (en) 2007-06-13 2014-09-02 Incyte Corporation Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US11213528B2 (en) 2007-06-13 2022-01-04 Incyte Holdings Corporation Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US9623029B2 (en) 2009-05-22 2017-04-18 Incyte Holdings Corporation 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane- or heptane-nitrile as JAK inhibitors
US9334274B2 (en) 2009-05-22 2016-05-10 Incyte Holdings Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US9216984B2 (en) 2009-05-22 2015-12-22 Incyte Corporation 3-[4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane—or heptane-nitrile as JAK inhibitors
US8399451B2 (en) 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
US9249145B2 (en) 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US11285140B2 (en) 2010-03-10 2022-03-29 Incyte Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
US9464088B2 (en) 2010-03-10 2016-10-11 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
US10695337B2 (en) 2010-03-10 2020-06-30 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
US9999619B2 (en) 2010-03-10 2018-06-19 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
US11219624B2 (en) 2010-05-21 2022-01-11 Incyte Holdings Corporation Topical formulation for a JAK inhibitor
US11571425B2 (en) 2010-05-21 2023-02-07 Incyte Corporation Topical formulation for a JAK inhibitor
US10869870B2 (en) 2010-05-21 2020-12-22 Incyte Corporation Topical formulation for a JAK inhibitor
US10758543B2 (en) 2010-05-21 2020-09-01 Incyte Corporation Topical formulation for a JAK inhibitor
US11590136B2 (en) 2010-05-21 2023-02-28 Incyte Corporation Topical formulation for a JAK inhibitor
JP2013544811A (en) * 2010-11-03 2013-12-19 ブリストル−マイヤーズ スクイブ カンパニー Heterocyclic compounds as S1P1 agonists for the treatment of autoimmune and vascular diseases
WO2012061459A1 (en) * 2010-11-03 2012-05-10 Bristol-Myers Squibb Company Heterocyclic compounds as s1p1 agonists for the treatment of autoimmune and vascular diseases
CN103298807A (en) * 2010-11-03 2013-09-11 百时美施贵宝公司 Heterocyclic compounds as S1P1 agonists for the treatment of autoimmune and vascular diseases
US8629282B2 (en) 2010-11-03 2014-01-14 Bristol-Myers Squibb Company Heterocyclic compounds as S1P1 agonists for the treatment of autoimmune and vascular diseases
US10640506B2 (en) 2010-11-19 2020-05-05 Incyte Holdings Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidines derivatives as JAK inhibitors
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
US8933085B2 (en) 2010-11-19 2015-01-13 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
US9993480B2 (en) 2011-02-18 2018-06-12 Novartis Pharma Ag mTOR/JAK inhibitor combination therapy
US8691807B2 (en) 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US9023840B2 (en) 2011-06-20 2015-05-05 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US11214573B2 (en) 2011-06-20 2022-01-04 Incyte Holdings Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US10513522B2 (en) 2011-06-20 2019-12-24 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US9611269B2 (en) 2011-06-20 2017-04-04 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US9358229B2 (en) 2011-08-10 2016-06-07 Novartis Pharma Ag JAK PI3K/mTOR combination therapy
US9359358B2 (en) 2011-08-18 2016-06-07 Incyte Holdings Corporation Cyclohexyl azetidine derivatives as JAK inhibitors
US9718834B2 (en) 2011-09-07 2017-08-01 Incyte Corporation Processes and intermediates for making a JAK inhibitor
US9487521B2 (en) 2011-09-07 2016-11-08 Incyte Holdings Corporation Processes and intermediates for making a JAK inhibitor
WO2013113788A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113773A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113863A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113791A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113776A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113787A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113715A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113720A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113716A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
US11337927B2 (en) 2012-11-15 2022-05-24 Incyte Holdings Corporation Sustained-release dosage forms of ruxolitinib
US10166191B2 (en) 2012-11-15 2019-01-01 Incyte Corporation Sustained-release dosage forms of ruxolitinib
US11576864B2 (en) 2012-11-15 2023-02-14 Incyte Corporation Sustained-release dosage forms of ruxolitinib
US11576865B2 (en) 2012-11-15 2023-02-14 Incyte Corporation Sustained-release dosage forms of ruxolitinib
US10874616B2 (en) 2012-11-15 2020-12-29 Incyte Corporation Sustained-release dosage forms of ruxolitinib
US11896717B2 (en) 2012-11-15 2024-02-13 Incyte Holdings Corporation Sustained-release dosage forms of ruxolitinib
US9115054B2 (en) 2013-02-21 2015-08-25 Bristol-Myers Squibb Company Tetrahydronaphthalenyl compounds useful as sipi agonists
US9487481B2 (en) 2013-02-21 2016-11-08 Bristol-Myers Squibb Company Bicyclic compounds
US9359286B2 (en) 2013-02-21 2016-06-07 Bristol-Myers Squibb Company Bicyclic compounds
US9221845B2 (en) 2013-03-06 2015-12-29 Incyte Holdings Corporation Processes and intermediates for making a JAK inhibitor
US8987443B2 (en) 2013-03-06 2015-03-24 Incyte Corporation Processes and intermediates for making a JAK inhibitor
US9714233B2 (en) 2013-03-06 2017-07-25 Incyte Corporation Processes and intermediates for making a JAK inhibitor
US9655854B2 (en) 2013-08-07 2017-05-23 Incyte Corporation Sustained release dosage forms for a JAK1 inhibitor
US10561616B2 (en) 2013-08-07 2020-02-18 Incyte Corporation Sustained release dosage forms for a JAK1 inhibitor
US11045421B2 (en) 2013-08-07 2021-06-29 Incyte Corporation Sustained release dosage forms for a JAK1 inhibitor
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
US11058696B2 (en) 2014-08-20 2021-07-13 Bristol-Myers Squibb Company Substituted bicyclic compounds
US10166249B2 (en) 2014-08-20 2019-01-01 Bristol-Myers Squibb Company Substituted bicyclic compounds
US9770459B2 (en) 2014-08-20 2017-09-26 Bristol-Myers Squibb Company Substituted bicyclic compounds
US10709719B2 (en) 2014-08-20 2020-07-14 Bristol-Myers Squibb Company Substituted bicyclic compounds
US11701373B2 (en) 2014-08-20 2023-07-18 Bristol-Myers Squibb Company Substituted bicyclic compounds
US9522888B2 (en) 2014-08-20 2016-12-20 Bristol-Myers Squibb Company Substituted bicyclic compounds
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
US11278541B2 (en) 2017-12-08 2022-03-22 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
US10899736B2 (en) 2018-01-30 2021-01-26 Incyte Corporation Processes and intermediates for making a JAK inhibitor
US11304949B2 (en) 2018-03-30 2022-04-19 Incyte Corporation Treatment of hidradenitis suppurativa using JAK inhibitors
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Also Published As

Publication number Publication date
AU2010205825A1 (en) 2011-07-07
MX2011007455A (en) 2011-08-03
CN102282144A (en) 2011-12-14
EA201101089A1 (en) 2012-02-28
KR20110110198A (en) 2011-10-06
CA2748394A1 (en) 2010-07-22
TW201028407A (en) 2010-08-01
EP2387571A1 (en) 2011-11-23
IL213630A0 (en) 2011-07-31
BRPI1005153A2 (en) 2019-09-24
UY32364A (en) 2010-02-26
EP2210890A1 (en) 2010-07-28
SG172452A1 (en) 2011-07-28
JP2012515182A (en) 2012-07-05
ECSP11011200A (en) 2011-08-31
AR075022A1 (en) 2011-03-02
US20110274657A1 (en) 2011-11-10

Similar Documents

Publication Publication Date Title
WO2010081692A1 (en) Oxadiazole derivatives as slpl receptor agonists
KR101721716B1 (en) Selective sphingosine 1 phosphate receptor modulators and methods of chiral systhesis
WO2011144338A1 (en) Pyrazole derivatives as s1p1 agonists
TWI410421B (en) Pyridin-4-yl derivatives
JP2012513958A (en) 1,2,4-oxadiazole derivatives and their therapeutic use
KR101781233B1 (en) Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
CA2524867A1 (en) 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
TW201113277A (en) New thiadiazole derivatives
ES2548258T3 (en) Oxadiazole compounds substituted and their use as S1P1 agonists
CA2818470C (en) 2-methoxy-pyridin-4-yl derivatives
TW201120019A (en) New 2-aminothiadiazole derivatives
WO2011113578A1 (en) New oxadiazole derivatives
US20220194908A1 (en) Sphingosine 1 phosphate receptor modulators

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080004969.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10700383

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 593414

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2010205825

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2748394

Country of ref document: CA

Ref document number: 001290-2011

Country of ref document: PE

WWE Wipo information: entry into national phase

Ref document number: 5051/DELNP/2011

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2010205825

Country of ref document: AU

Date of ref document: 20100114

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12011501394

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: MX/A/2011/007455

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2011545678

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2011001724

Country of ref document: CL

Ref document number: 11088758

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 20117016785

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: a201109935

Country of ref document: UA

WWE Wipo information: entry into national phase

Ref document number: 2010700383

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 201101089

Country of ref document: EA

ENP Entry into the national phase

Ref document number: PI1005153

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110719